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Abstract 
This abstract is for the thesis entitled ‘The functional characterisation of a novel 
microtubule-actin interacting protein, GAS2-like 3’ submitted for the Degree of Doctor of 
Philosophy to the Faculty of Life Sciences, University of Manchester by Matthew Stroud 
in 2010. 
The microtubule (MT) and actin cytoskeletons are fundamental to cell integrity, as they 
control a host of cellular activities. Until recently, studies have investigated these 
cytoskeletal components as separate entities, however, it has become increasingly clear 
that the MT and actin cytoskeletons function in an interdependent way. Elucidating how 
the two components interact will be key to our further understanding of fundamental 
cellular processes such as cell division, growth, polarisation and migration. 
This study focused on a newly identified and highly conserved protein, named GAS2-like 
3, which contains a putative actin binding calponin homology (CH) domain and a 
putative MT binding GAS2-related (GAR) domain. GAS2-like 3 predominantly localised 
to both MT and actin cytoskeletons. By using a series of truncation mutants, the 
fundamental regions of GAS2-like 3 involved in mediating these interactions were 
dissected, both in cells and in vitro. Data from sedimentation assays revealed the CH 
domain binds directly to F-actin, and the C-terminus binds directly to MTs, whereas the 
GAR domain does not interact directly with MTs. In order to assess the dynamics of 
GAS2-like 3 and its mutants in cells, Fluorescence Recovery After Photobleaching 
experiments were performed to reveal that the GAR domain of GAS2-like 3 modulates 
the binding strength of GAS2-like 3 to MTs and actin. GAS2-like 3 localisation is 
dependent on both MT and actin cytoskeletons, although MTs have a greater influence 
on GAS2-like 3 localisation. Interestingly, tubulin acetylation enhanced GAS2-like 3 
localisation to MTs.  
This study also uncovered two binding motifs for the MT plus-end binding protein 1 
(EB1). EB1 was characterised as a new interaction partner of GAS2-like 3, which 
directly interacted with the C-terminus of GAS2-like 3 in vitro. Furthermore, a molecular 
mechanism in which GAS2-like 3 was recruited to MTs via EB1 in cells was revealed. 
Interestingly, the interaction between EB1 and GAS2-like 3 required the complete C-
terminus, rather than the specific EB1-binding motifs themselves. 
Taken together, this study provides insights into the new protein, GAS2-like 3, which has 
the capacity to crosslink MTs and actin and provides a mechanistic insight into how 
GAS2-like 3 localisation is regulated in cells.  
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Lay abstract 
Human beings are made up of many living cells. Living cells are comprised of 
many different molecules, which all must work together in order to maintain a 
healthy individual. One important group of these molecules, are called proteins. 
There are thousands of different proteins that can be found in cells, and they are 
often specific for a certain cell type, however, there are a number of proteins that 
are found in all cells. These include the proteins that make up a cellular scaffold, 
known as the cytoskeleton. The cytoskeleton is made up of two important 
components; the actin cytoskeleton, which governs cell shape, and the 
microtubule cytoskeleton, which controls cell division. It is crucial for these two 
cytoskeletons to communicate with one another in order to keep both the cell 
and the individual healthy. Defects in proteins that manage the communication 
between the cytoskeletons result in various diseases including 
neurodegeneration, severe skin blistering and cancer. Thus, it is essential for us 
to understand the underlying regulatory mechanisms behind these medical 
conditions. 
Here, we have discovered a new protein, named GAS2-like 3, which mediates 
the communication between the two cytoskeletons. By conducting a series of 
experiments, we have demonstrated the association of GAS2-like 3 with both the 
actin cytoskeleton and the microtubule cytoskeleton. We also revealed that 
GAS2-like 3 interacts with another protein, called EB1, which governs where 
GAS2-like 3 is found in the cell. This interaction could dictate the role of GAS2-
like 3 in cells. In addition, we discovered that when GAS2-like 3 was expressed 
in cells, it resulted in cell death. Many cancers arise as a result of cells being 
unable to kill themselves, possibly indicating that cells lacking GAS2-like 3 are 
more susceptible to cancer. Intriguingly, we found GAS2-like 3 on mitochondria, 
which are specific regions of the cell that instigate cell death. Thus, GAS2-like 3 
is likely to perform the cross-communication between actin, microtubules and 
mitochondria. GAS2-like 3 could therefore be a key therapeutic target to alleviate 
medical disorders, which arise as a result of defective proteins that control the 
cytoskeleton. 
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1) Introduction 
 
The cytoskeleton is fundamental to cellular integrity, providing a molecular 
framework for both mechanical support and the intracellular transport 
infrastructure. All eukaryotes contain actin filaments and microtubules (MTs), 
whereas only some contain intermediate filaments (Figure 1.1). It has become 
increasingly clear that the actin and MT cytoskeletons are organised and function 
in an interdependent way (Karakesisoglou et al., 2000; Leung et al., 2002; 
Subramanian et al., 2003). 
Cytoskeletal proteins are linked to many human pathological conditions, such as 
cancer, infection, and various cardiovascular diseases. Some of the most well 
characterised proteins involved in linking actin filaments to MTs belong to the 
spectraplakin family, for example Microtubule-Actin Crosslinking Factor 1 
(MACF1) (Kodama et al., 2003; Lee and Kolodziej, 2002; Roper et al., 2002; Sun 
et al., 2001). 
Dissecting the mechanisms behind MT-actin crosslinking in greater detail will be 
essential to understand the underlying disorders that arise as a consequence of 
mutations in the respective proteins. 
 
1.1) The Microtubule and Actin Cytoskeletons  
1.1.1) Microtubule cytoskeleton  
 
MTs play key roles in processes that are fundamental to cell homeostasis, such 
as cell division and cell motility, thus they also have central roles in many 
physiological and disease processes. MTs provide polarised molecular tracks, 
which molecular motors move along, transporting a variety of cargo from the 
microtubule organising centre (MTOC) to the cell periphery and vice versa 
(Caviston and Holzbaur, 2006). 
MTs are composed of stable α/ β -tubulin heterodimers that are aligned in a 
polarised head to tail fashion which form protofilaments. These protofilaments 
are assembled to form a cylindrical and helical MT wall, typically comprising 13 
parallel protofilaments in vivo (Figure 1.2).  MTs can grow and shrink through 
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Figure 1.1: Localisation of microtubules (MTs) and actin cytoskeletons in NIH3T3 
fibroblasts.  
Above; NIH3T3 cells were fixed and stained for MTs using an antibody directed against α-tubulin, 
followed by a Cy5 conjugated secondary antibody. Actin was labelled using FITC-conjugated 
phalloidin. Below; merged image of MTs and actin. Scale bar = 10µm. 
 
polymerisation and depolymerisation, respectively which is driven by the binding, 
exchange and hydrolysis of a guanine nucleotide on the β -tubulin monomer 
(Kirschner and Mitchison, 1986). Polymerisation is initiated from a pool of GTP-
bound tubulin dimers, which are incorporated at the growing plus (+) end. Once 
incorporated into the MT lattice, GTP is hydrolysed and the inorganic phosphate 
is released. It has been postulated that GTP hydrolysis changes the 
conformation of the tubulin dimer from slightly curved to a profoundly curved 
conformation (Wang and Nogales, 2005). This nucleotide-dependent 
 20 
 
Figure 1.2: Microtubule structure and dynamic instability. 
Adapted from (Akhmanova and Steinmetz, 2008). A: The stable α /β tubulin dimer with either 
GDP or GTP bound and assembled into protofilaments. B: The organisation of cylindrical and 
helical MT wall consists of 13 parallel protofilaments in vivo. C: The polymerisation/ 
depolymerisation cycle of MTs; MT polymerisation is driven from a pool of GTP-loaded tubulin. 
Once added to the growing MT end, the GTP is hydrolysed to release inorganic phosphate 
causing a conformational change in the tubulin dimer. This is thought to straighten the tubulin 
dimer once it is incorporated into the MT wall. Closure of the growing end results in a metastable 
intermediate MT, which may pause, grow (polymerisation) or shrink (depolymerisation) in a 
phenomenon known as ‘dynamic instability’. 
 
conformation change suggests that the curved tubulin-GDP is forced to remain 
straight once incorporated into the MT wall. The growing + end is thought to 
maintain a ‘cap’ of GTP-bound tubulin subunits to stabilise the straight tubulin 
conformation within the MT lattice. Closure of the MT end generates a 
metastable-intermediate structure, which can either pause, grow (termed rescue) 
or undergo depolymerisation (termed catastrophe). MTs undergoing catastrophe 
are characterised by a fountain-like array of ring and spiral protofilaments 
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structures (Figure 1.2). This is presumably directed by a conformational change 
in GDP-tubulin, resulting in the destabilisation of lateral contacts between 
adjacent protofilaments. The depolymerisation-polymerisation cycle is completed 
by the exchange of GDP for GTP on the β-tubulin subunit. 
Whereas the β -tubulin subunit can exchange its GDP for GTP, the α -tubulin 
subunit can also undergo post-translational (PT) modification in an enzymatic 
detyrosination/ tyrosination cycle. The enzyme tubulin Tyrosine 
carboxypeptidase (TTCP) is used to repeatedly cleave the Tyrosine (Tyr) residue 
of the conserved EEY/F sequence motif, whereas the ATP-dependent tubulin Tyr 
ligase (TTL) repeatedly adds back a Tyr residue. TTCP preferentially acts on 
MTs and TTL can only act on free tubulin monomers. This means that longer 
living, more stable MTs accumulate Glutamate (Glu)-tubulin, whereas freshly 
polymerised MTs contain larger amounts of Tyr-tubulin. This cycle provides an 
explanation as to why MTs containing high proportions of Glu-tubulin are 
hypothesised to be more stable. In fibroblasts, Glu-MTs reorientate themselves 
to the leading edge of cells undergoing migration, thus they are thought to be 
important in cell polarisation (Li and Gundersen, 2008). 
Another ubiquitous PT-modification of tubulin is the acetylation of α-tubulin on 
Lysine 40 (Edde et al., 1991). Similarly to detyrosination, acetylated MTs are 
also a hallmark of stabilised MTs. A prominent candidate to perform this role is 
histone deacetylase 6 (HDAC6), which belongs to the class II histone 
deacetylases (Boyault et al., 2007). HDAC6 can directly acetylate tubulin, and 
has been shown to regulate MT dynamics likely through an interaction with MT 
plus-end binding proteins or +TIPs (Zilberman et al., 2009). Whereas this 
evidence suggested that acetylation does not play a role in regulating MT 
dynamics, there is evidence to suggest tubulin acetylation does play a role in 
recruiting MT-associated proteins, such as the motor protein kinesin 1(Dompierre 
et al., 2007; Reed et al., 2006). 
There are various other PT-modifications of tubulin which are beyond the scope 
of this study, such as the removal of the Glu-Tyr dipeptide from the C-terminus of 
α-tubulin, polyglutamylation and polyglycination of α and β -tubulins, and 
phosphorylation of some tubulins, which all occur at the acidic C-terminus of 
tubulin molecules. 
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1.1.2) Actin cytoskeleton 
The actin cytoskeleton provides the cell with mechanical strength important for 
maintaining cellular integrity and for cell motility. Cellular actin comprises a pool 
of globular (G) actin monomers, which can polymerise to form filamentous (F) 
actin. In a similar fashion to MTs, F-actin fibres are polarised with the 
polymerising end (+ end equivalent) denoted as the ‘barbed’ end and the 
depolymerising end denoted as the ‘pointed’ end. G-actin in the cytoplasm is 
able to exchange ADP for ATP, which enables polymerisation to form F-actin. 
Once integrated at the barbed end, F-actin is able to hydrolyse ATP to ADP + Pi 
to form ADP-bound F-actin which eventually dissociates and returns to the ADP-
bound G-actin state (Figure 1.3). In the steady state, actin is simultaneously 
undergoing both polymerisation and depolymerisation in a process known as 
‘treadmilling’. This enables the actin filament to move forward whilst remaining 
the same length, as well as generating a protruding force essential for many 
processes including cell migration.  
Treadmilling of pure actin is often too slow for cell migration, hence various other 
proteins are used to regulate actin dynamics and nucleation. The respective 
proteins can bind to either the barbed or pointed ends of F-actin and prevent or 
promote the association and/ or dissociation of G- actin. Capping proteins bind to 
barbed ends with high affinity, preventing the addition of actin monomers, 
thereby increasing the local concentration of G-actin to enable rapid growth of 
adjacent noncapped filaments in a process called funnelling. The heterodimeric 
capping protein and gelsolin are implicated in cellular functions such as 
lamellipodium protrusion and cell migration, respectively (Le and Carlier, 2008). 
Profilin also localises at the barbed ends, where it binds to G-actin and alters the 
conformation of G-actin to promote ATP/ADP exchange, which increases 
polymerisation. Cofilin localises throughout the lamellipodium and binds to the 
pointed ends of actin filaments to promote dissociation of G-actin, it can also 
inhibit ATP/ADP exchange to prevent actin polymerisation. Phosphorylation of 
cofilin results in dissociation from G-actin, this subsequently promotes ATP/ADP 
exchange and actin polymerisation.  
As well as proteins which solely prevent or accelerate actin treadmilling, there 
are three major classes of proteins which are used to nucleate actin. The first of 
which is the Arp2/3 complex, which mediates simultaneous actin nucleation and 
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Figure 1.3: Regulation of actin treadmilling  
Adapted from (Le and Carlier, 2008). 1) Cofilin (ADF) binds to ADP-actin filaments and promotes 
pointed end depolymerisation to increase the concentration of G-actin at steady state. 2) Profilin 
binds to the barbed end and promotes ATP/ADP exchange, to promote recycling of actin 
monomers. 3) Capping proteins at the barbed ends abrogate polymerisation of the actin filament 
by preventing the addition of G-actin. This enables ‘funnelling’ of G-actin to the noncapped 
filaments which accelerates their growth. 
 
branching of F-actin at the pointed end and is important in lamellipodium 
formation (Arp2/3 complex) (Lai et al., 2008). Secondly, spire proteins nucleate 
actin to assemble unbranched filaments, and also bind to the pointed ends of F-
actin. The third actin nucleation mechanism relies on the formin family of 
proteins, which nucleate parallel actin bundles such as those found in stress 
fibres (Romero et al., 2004). Generally, formins bind to the barbed ends and 
remain bound, adding G-actin to the growing end in a processive manner. The 
constant presence of formins at the barbed ends prevents capping proteins from 
binding, which aids filament growth. As well as their actin nucleating activity, 
formins are also able to stabilise MTs, which will be discussed later as they are 
potential MT- actin crosslinkers (see section 1.2.3) (Bartolini et al., 2008; Ishizaki 
et al., 2001; Palazzo et al., 2001). 
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1.2) Evidence of microtubules linking to the actin cytoskeleton  
Several lines of evidence implicate the actin cytoskeleton in stabilising and 
guiding MTs from the MTOC to the cell periphery (Goode et al., 2000; Salmon et 
al., 2002; Schaefer et al., 2002). Dual-wavelength, fluorescent speckle 
microscopy reveals growth of MTs along F-actin bundles in epithelial cells 
(Salmon et al., 2002) and MTs in neuronal growth cones cease to grow in 
regions where the underlying actin network is perturbed (Schaefer et al., 2002). 
Further evidence comes from studies of cell migration, during which cells must 
polarise, using their actin cytoskeleton to enable cell protrusion at the front and 
retraction at the rear of the cell (Vasiliev, 1991). In order to polarise, co-operation 
between the actin and MT cytoskeletons is required, as it is impaired or lost 
when MTs are disrupted (Ballestrem et al., 2000; Vasiliev et al., 1970). There is 
some evidence that the stability of MTs and/ or their coordinated movements 
with F-actin rely upon direct physical linkages of the two cytoskeletons (Kodama 
et al., 2003). The actin cytoskeleton is thought to provide a robust stabilising 
platform for MT capture, growth and/or guidance of MTs (Basu and Chang, 2007; 
Goode et al., 2000; Kaverina et al., 2002; Small and Kaverina, 2003; Wu et al., 
2008). The molecular events regulating these processes are still unclear, 
although one can speculate that these events may use a combination of MT 
plus-end tracking proteins (+TIPS), spectraplakins, formins, and potentially the 
GAS2 family, amongst other proteins which are yet to be fully characterised. 
 
1.2.1) Microtubule plus-end tracking proteins  
MT dynamics are mostly regulated by tubulin-interacting proteins which can 
stabilise and maintain linear growth of MTs, promote instability, or capture MTs 
at specific cellular locations (Galjart and Perez, 2003). A collective group of 
proteins that mediate these roles are known as the +TIPS. These proteins bind 
to the distal ends of MTs and are thought to guide the MT +ends to the cell 
cortex, where the small Rho GTPases reside (Figure 1.4). Rho GTPases are 
molecular switches which play key roles in regulating the actin cytoskeleton, 
resulting in changes in cell polarity and microtubule dynamics amongst many 
others (Etienne-Manneville and Hall, 2003). For example, the Rho GTPase 
Cdc42 activates distinct MT tethering sites by promoting localised actin 
polymerisation (Etienne-Manneville and Hall, 2003). IQGAP1, which is an 
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Figure 1.4: Localisation of EB1 to the plus-ends of MTs. 
NIH 3T3 cells were transfected with EB1-GFP, fixed and stained using an antibody directed 
against α-tubulin followed by a Cy5-conjugated secondary antibody. 
 
effector of Cdc42 and fellow Rho GTPases Rac1, has been shown to bind the 
+TIP CLIP-170 directly, providing a link between a polarised MT cytoskeleton 
and cell polarisation (see Figure 1.5). Several other links between activated 
Cdc42 binding proteins and +TIPS have been described (Etienne-Manneville and 
Hall, 2001; Fukata et al., 2002). Figure 1.5 shows the array of proteins which can 
bind to the +ends of MTs, and potential interacting proteins which could link MTs 
and F-actin. In addition to +TIP interactions with Rho family GTPases, there is 
also evidence suggesting that they interact with spectraplakins (as described in 
Section 1.2.2) (Applewhite et al., 2010; Wu et al., 2008). 
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Figure 1.5: Organisation of MTs, F-actin bundles and various cytoskeleton associated 
proteins at the cell membrane. 
Adapted from (Lansbergen and Akhmanova, 2006).The plus-ends of microtubules can bind to a 
variety of +TIP proteins, including APC, EB1 and CLIP-170. There are putative links between the 
MTs and actin bundles via the Rho effector, IQGAP and CLIP-170. Furthermore, the 
spectraplakin ACF7 can bind to both MT and actin cytoskeletons, implying it maybe involved in 
crosslinking the two. 
 
In spite of recent advances, a lack of knockout mutations in most of these genes 
raises questions about their functional significance in multicellular organisms.  
Are any of these links sufficient to tether and polarise MTs at activated cortical 
sites? Are additional proteins involved, if so, what are they and how are they 
involved? Most data suggest that cell polarisation is likely to involve coordinated 
integration of actin-MT dynamics, however little is known about the molecular 
integrators involved. 
 
1.2.2) Spectraplakins 
Other prominent candidate proteins for the role of microtubule guiding along F-
actin belong to the spectraplakin family (Jefferson et al., 2004). Members of this 
family all have binding sites for both F-actin via their calponin homology (CH) 
domains and for MTs via the GAS2-related (GAR) domain and/ or GSR repeats 
as shown in Figure 1.6. The first members of this family were classified 
separately from the plakin  
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Figure 1.6: The domain organisation of the plakin family and the mammalian and 
invertebrate plakin isoforms. 
Adapted from (Jefferson et al., 2004). All family members contain an actin binding domain (ABD) 
at their N-termini, which is conferred by tandem CH domains, and a MT binding domain (MTBD) 
at their C-termini conferred by the GAS2 domain and/ or GSR repeats. 
 
superfamily (which connect adhesion receptors to intermediate filaments) and 
the spectrin superfamily (which bind and crosslink actin filaments and attach 
these to membrane receptors), as they can play these roles individually (Roper 
et al., 2002). Short-stop (Shot) in Drosophila and the dystonin/BPAG1 and 
MACF1 proteins in mammals were the first spectraplakins identified. More 
recently VAB-10 was identified in C. Elegans (Figure 1.6) (Bosher et al., 2003). 
The fact that their amino acid sequence is conserved and they are also found in 
lower organisms implies they have an important functional role. 
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Recent evidence regarding the mammalian spectraplakin MACF1 (Microtubule 
Actin Crosslinking Factor 1) uncovers roles for spectraplakins in MT dynamics, 
guidance, cortical tethering, stability and cellular polarisation (Kodama et al., 
2003). It has been shown that the ablation of MACF1 in endodermal cells leads 
to the uncoupling of MT from microfilaments and a change in MT dynamics. 
Interestingly, MACF1 has also been shown to interact with the +TIP end-binding 
protein 1 (EB1) (Honnappa et al., 2009), implying that spectraplakins can also 
bind to the +ends of MTs, as well as to the MT lattice and F-actin.  
In Drosophila S2 cells, the interaction with EB1 is hypothesised to be important 
when Shot is in its inactive form in the cell interior and the MT +ends are 
undergoing a ‘search and capture’ mechanism for an activation signal to engage 
with actin. Upon activation, Shot undergoes a conformational change to release 
EB1 and to engage with F-actin via its CH domains, and the MT lattice via its 
GAR domain. When engaged with both cytoskeletons, Shot stabilises MTs 
against lateral movements driven by motor proteins, and guides them along F-
actin in the cell periphery (Applewhite et al., 2010). This study suggests that Shot 
only binds EB1 in the cell interior, however, another study suggests that the 
interaction between the mammalian spectraplakin, MACF1 and EB1 occurs 
throughout the cytoplasm from the cell interior to peripheral focal adhesions 
(FAs), and is necessary for the MT-actin crosslinking (Wu et al., 2008). In the 
latter study, an actin-dependent ATPase activity was identified in MACF1 and 
was found to be essential to recover defects in cell migration in MACF1 null cells. 
The ATPase activity of MACF1 is thought to be essential to target MTs to FAs for 
remodelling, which is fundamental for effective cell migration.  
Mutations in spectraplakin genes result in the degeneration of cells that express 
them, and despite the large size of spectraplakins (>500kDa), rescue 
experiments using the actin and MT binding domains suggest that these 
domains are both necessary and sufficient to rescue defects in neurogenesis 
and cell polarisation (Kodama et al., 2003; Lee and Kolodziej, 2002).  
Various medical conditions and developmental defects arise as a result of 
mutated spectraplakins, (Giorda et al., 2004; Leung et al., 2002; Sjoblom et al., 
2006; Sonnenberg and Liem, 2007). The severe phenotypes observed illustrates 
the importance of proteins that link the actin and MT cytoskeletons. Further 
characterisation of these proteins will progress the understanding and 
importantly the alleviation of spectraplakin-associated pathological conditions. 
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1.2.3) Formins 
Formins are a conserved family of proteins, containing a formin homology 2 
(FH2) domain, which assembles unbranched actin filaments from the barbed end 
(Faix and Grosse, 2006). The diaphanous-related formins (DRFs) are a 
subfamily of formins characterised by domains that regulate their activation by 
the Rho family of small GTPases and their subcellular localisation. Binding of 
Rho-GTP to the GTPase Binding Domain (GBD) relieves the autoinhibitory 
conformation between the N-terminal diaphanous inhibitory domain (DID) and a 
short segment C-terminal to the FH2 domain termed the diaphanous 
autoregulatory domain (DAD) (Figure 1.7).  
In terms of crosslinking MTs to F-actin, there is evidence to suggest that the MTs 
co-align with F-actin when a constitutively active version of mDia1 is expressed 
(Ishizaki et al., 2001). Ishizaki and colleagues propose that the FH2 domain is 
fundamental in this role, implying that other formins may also play a role in 
crosslinking the two cytoskeletons. To augment this data, similar observations 
were made using a constitutively active version of mDia2. However, from the 
mDia1 study no inferences were made as to the stability of MTs (as the 
orientation of stable MTs towards the leading edge is indicative of cell 
polarisation). When the stability of MTs was probed in a study on mDia2 
(Palazzo et al., 2001), it was found that the MTs which co-aligned with F-actin 
were dynamic MTs, which are not indicative of cell polarisation as suggested by 
the mDia1 study. Palazzo and colleagues argue from this observation that 
mDia’s ability to induce the formation and orientation of stable MTs is 
independent of its ability to co-align the MT and actin cytoskeletons. 
Nevertheless it is possible that dynamic MTs also crosslink with actin 
cytoskeletons, although crosslinking may decrease the dynamic instability of 
MTs. 
For both the DRFs, murine Diaphenous1 (mDia1) and mDia2, the integrity of the 
FH1 and FH2 domains is vital for actin nucleation activity and MT stabilisation 
(Ishizaki et al., 2001;Palazzo et al., 2001;Bartolini et al., 2008). 
A recent study using mDia2 implies that this protein can stabilise microtubules 
independently of its actin nucleation activity, as mutants defective at actin 
polymerisation were still able to stabilise MTs (Bartolini et al., 2008). Bartolini 
and coworkers conclude that the MT stabilisation effect could be via an  
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Figure 1.7: Schematic representation of the domain organisation of diaphanous-related 
formins (DRFs).  
Adapted from (Faix and Grosse, 2006). The GTPase binding domain (GBD) enables partial 
activation of DRFs by Rho GTPase to relieve the autoinhibited hairpin conformation of the 
Diaphanous inhibitory domain (DID) interaction with the Diaphanous autoregulatory domain 
(DAD). Additional signals are required to fully activate DRFs. 
 
interaction with the +TIPs, EB1 or APC. Interestingly, a ‘knotted’ MT phenotype, 
in which the stable MTs localised in a perinuclear distribution rather than a 
regular peripheral distribution was observed when the actin polymerisation 
defective mutants were expressed in cells. From this observation it is apparent 
that the actin nucleation driven by mDia2 plays a role in MT stabilisation albeit 
one that is not fundamental. 
It remains unclear whether the FH2 domain plays a role in crosslinking MTs to 
actin in order to stabilise the MTs, or whether MT stabilisation by FH2 occurs 
independently of actin crosslinking. The FH1 domain has been implicated in 
playing a role in actin polymerisation, as it can bind to profilin (Ishizaki et al., 
2001). It would be interesting to see whether mutations in this domain to 
abrogate actin binding affect MT co-alignment with actin. 
It has been shown that the formation of stable MTs by mDia1 requires the +TIPS 
adenomatous polyposis coli (APC) and EB1, enabling capture at the cell cortex 
(Wen et al., 2004). From this study, it was concluded that EB1/ APC/ mDia1 may 
form a complex with EB1/ APC acting downstream of mDia1. Another link 
between MTs and F-actin could plausibly be formed between MT plus-end 
tracking proteins (+TIPS) and the small Rho GTPases. 
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1.3) Potential roles of members of the GAS2 family in MT-actin 
crosslinking 
1.3.1) GAS2 family  
Similar to the spectraplakins, members of the GAS2 family all contain a CH 
domain, a GAR domain and a non-conserved C-terminal domain, which varies in 
length between family members (Figure 1.8). The GAS2 protein family is little 
characterised and conserved among species ranging from C. elegans to H. 
sapiens, which implies an important functional role. Its constituent members are 
much smaller than the spectraplakins and currently include GAS2, GAR22 
(GAS2-like 1), GAR17 (GAS2-like 2) (Brancolini et al., 1992; Goriounov et al., 
2003; Schneider et al., 1988; Zucman-Rossi et al., 1996), and the new protein 
GAS2-like 3 (G2L3) (Stroud et al., 2010). 
The first member of the GAS2 family was GAS2, which is shorter in length than 
GAS2-like proteins. GAS2 was described to be involved in growth arrest, 
apoptosis and may play a tumour suppressor role (Brancolini et al., 1995; 
Brancolini and Schneider, 1994; Lee et al., 1999). GAS2 is cleaved by caspases 
in cultured cells undergoing apoptosis, to produce an N-terminal fragment which 
contains the CH domain and dramatically reorganises the F-actin network of the 
cells collapsing it around the nucleus (Brancolini et al., 1995). This caspase-
mediated cleavage of GAS2 is hypothesised to be necessary for the 
morphological changes observed in the cell during apoptosis. Further evidence 
of GAS2 playing a role in apoptosis is that GAS2 expression and cleavage are 
induced in interdigital tissues of mouse embryos between days 13.5 and 15.5, 
which are developmental stages characterised by extensive apoptosis (Lee et 
al., 1999). Nevertheless, it should be noted that GAS2 was undetectable in other 
regions, which are known to undergo extensive apoptosis, such as the heart. 
Whereas the literature supports the argument that GAS2 is involved in apoptosis, 
there is no evidence to suggest this for its related family members (Goriounov et 
al., 2003). For example, the cleaved form of GAS2-like1 was not found in a 
variety of cell lines treated with apoptotic signals. Full length GAS2-like1 
isoforms or versions encoding the N-terminus which were transfected into COS7 
cells resulted in no change in cell morphology, as was observed with the 
equivalent GAS2 construct. Similarly to GAS2, GAS2-like 1 expression increased 
during growth arrest, however, GAS2-like 1 is highly phosphorylated on serine  
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Figure 1.8: The constituent members of the GAS2 family and their domain organisations. 
All members contain a Calponin Homology (CH) and GAS2-Related domain (GAR), GAS2 
contains a short C-terminal extension (C-term) in comparison to the GAS2-like proteins. GAS2-
like 1 and GAS2-like 2 can be alternatively spliced to produce proteins 337 or 681 aas in length 
and 213 or 880 aas in length respectively (as indicated in the figure). 
 
and threonine residues in quiescent cells. This is in contrast to GAS2, which is 
specifically phosphorylated on serine residues in cells undergoing the transition 
from quiescence (G0 phase) to the G1 phase (Brancolini and Schneider, 1994). 
Active GAS2 is thought to inhibit the G0 to G1 transition, and phosphorylation is 
thought to downegulate GAS2 activity, thus allowing cells to reenter the cell 
cycle. These results imply that GAS2 has different in vivo functions to its related 
family members. Indeed there is some evidence to suggest that GAS2-like 1 and 
GAS2-like 2 are able to crosslink F-actin and MTs in cells (Goriounov et al., 
2003) through their CH and GAR domains, respectively (Sun et al., 2001). This 
finding suggests that their physiological functions may involve the integration of 
these two components of the cytoskeleton. Despite the apparent differences in 
function, it is likely that the GAS2 family members play tissue specific roles. For 
example, GAS2 is predominantly found in lung tissue, GAS2-like 1 in brain and 
testis, and GAS2-like 2 in skeletal muscle.  
 
1.3.2) GAS2 Family Domains 
1.3.2.1) Calponin Homology Domain 
The CH domain was first identified at the N-terminus of calponin, which binds 
actin and plays a key role in regulating muscle contraction (Gimona et al., 
2002;Korenbaum and Rivero, 2002). CH domains are found in a variety of 
proteins such as IQGAP, which is involved in signalling, and the spectraplakins, 
which bind actin filaments. They are categorised by sequence similarity into 
three classes; CH1, CH2 and CH3 (Gimona et al., 2002). CH1 and CH2 domains 
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are able to combine and form actin-binding domains (ABDs) with CH3 domains 
often found alone at the N-terminus. GAS2 family members contain a CH3 class 
domain, which is a putative ABD. It appears that the avidity of a protein for actin 
increases with the number of CH domains. The CH3 domain found in calponin 
appears not to bind to F-actin (Fu et al., 2000;Gimona and Mital, 1998), however 
there is well-founded evidence that the CH3 domain found in the GAS2 family 
appears to bind both in vivo and in vitro to F-actin (Goriounov et al., 
2003;Brancolini et al., 1995;Brancolini et al., 1992). CH domain-containing 
proteins can also bind to MTs, for example it is speculated that EB1 can bind to 
tubulin (Gimona et al., 2002). 
 
1.3.2.2) GAS2-Related Domain 
The GAS2-Related (GAR) domain was originally identified in GAS2 and is a 
putative MTBD that is highly conserved during evolution (Sun et al., 2001). 
Sequence analysis revealed that the GAR domain also exists in spectraplakins, 
where, in concert with the C-terminus, it binds to MTs and partially stabilises 
them from the MT-depolymerising agent, nocodazole. The GAR domains 
contained in the GAS2 family members GAS2-like 1 and GAS2-like 2, weakly 
bind to the MTs, and shows some evidence of colocalisation to them (Goriounov 
et al., 2003). 
 
1.3.2.3) C-terminus 
The GAS2-like members of the GAS2 family contain extended C-termini, in 
which we have identified putative EB1 binding sites, also referred to as MT-tip 
localisation signals (MtLSs) (Honnappa et al., 2009). GAS2 itself contains only a 
short C-terminus of 40 amino acids (AAs), without any MtLSs, whereas its fellow 
family members have C-termini ranging from 60 to 600 AAs. GAS2-like1 and 
GAS2-like3 both contain two MtLSs, whereas GAS2-like2 contains four MtLSs. 
The lack of an extended C-terminus may explain the slightly different proposed 
functions of GAS2. 
The CH and GAS2 domains make up only 30-40% of the total amino acid 
sequence of GAS2 proteins, raising the question of the possible functions of the 
remaining regions. It is likely that the uncharacterised regions of the GAS2 family 
play a role in the recruitment of proteins which regulate actin and MT dynamics. 
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Indeed preliminary evidence suggests that the +TIP protein EB1 may recruit 
GAS2-like 3 to microtubules (unpublished observation M. Stroud). This 
interaction alone could potentially create a plethora of interactions and further 
analysis of the C-terminus should enable identification of other important binding 
domains. 
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1.4) Aims and Objectives 
The MT and actin cytoskeletons are fundamental to cell integrity, as they control 
a host of cellular activities including cell division, growth, polarisation and 
migration. 
We have identified a new protein, called GAS2-like 3, which is a new member of 
the GAS2 family and has the potential to interact with both MT and actin 
cytoskeletons. The GAS2 family comprises the proteins GAS2, GAS2-like 1, 
GAS2-like 2 and GAS2-like 3. Currently, there are only a handful of papers 
describing the functions of the GAS2 family members, which include roles in 
apoptosis and in mediating the communication between MTs and actin. Despite 
these functions, very little is known about the molecular mechanisms underlying 
them. Thus, the overall aim of this study is to functionally characterise GAS2-like 
3, and to gain insights into the molecular mechanisms underlying its function. 
 
1.4.1) Elucidating the cell and tissue distribution of GAS2-like 3 
Fellow members of the GAS2 family are expressed in various different tissues, 
suggesting they may play tissue-specific roles. As GAS2-like 3 is a new protein, 
nothing is currently known about its tissue and cell distribution. Without an 
antibody directed against GAS2-like 3 to detect it at the protein level, PCRs will 
be performed on cDNA libraries generated from different human tissues and cell 
lines. This analysis will reveal where GAS2-like 3 is expressed at the mRNA 
level and give an indication as to where the protein is expressed.  
 
1.4.2) Determining the sub-cellular localisation and binding strengths of 
GAS2-like 3 to the MT and actin cytoskeletons 
To gain insights into the function of GAS2-like 3, and the molecular mechanisms 
underlying this role, its sub-cellular localisation will be determined. 
GAS2-like 3 contains a putative actin-binding CH domain, and a putative MT-
binding GAR domain, suggesting it may localise to both MT and actin 
cytoskeletons. In order to establish where the full-length protein localises, 
fluorescent proteins will be conjugated to GAS2-like 3, and expressed in cells.  
The roles of each domain in the potential localisation and binding to the 
cytoskeletons will be characterised by generating a series of truncation mutants. 
The localisation and binding to the cytoskeletons of the mutants will be 
 36 
determined using both immunofluorescence and biochemistry-based 
approaches, respectively. This will provide insight into the function of the 
domains of GAS2-like 3, and whether they are able to recruit GAS2-like 3 to 
different places in the cell where it may exert its various functions. 
To gain estimates of the binding strength of the various domains of GAS2-like 3 
involved in linking GAS2-like 3 to the cytoskeleton or to other structures, live-cell 
imaging combined with Fluorescence Recovery After Photobleaching (FRAP) will 
be used. This will provide new information on the dynamics of GAS2-like 3 in live 
cells and will be used to confirm the fixed-cell imaging and biochemical 
sedimentation assays.  
 
1.4.3) Identifying potential regulatory mechanisms which affect GAS2-like 3 
localisation 
Various post-translational modifications of tubulin are known to change MT 
dynamics, MT stability and the ability of MTs to recruit other proteins 
(Westermann and Weber, 2003). For example, acetylated and detyrosinated 
MTs are able to recruit MT-interacting proteins, such as the motor protein 
kinesin-1 and the MT-end binding protein, CLIP-170, respectively (Dompierre et 
al., 2007; Mishima et al., 2007). The question I aim to address is whether certain 
modifications of tubulin affect GAS2-like 3 localisation, and thus function. 
Given the potential for GAS2-like 3 to interact with MTs, various drugs will be 
used to assess whether modifying the stability of MTs or whether post-
translational modifications of tubulin affect GAS2-like 3 localisation. 
 
1.4.4) Categorising the preliminary binding partners of GAS2-like 3 
Insights into GAS2-like 3 function may be gained by identifying potential binding 
partners. 
Preliminary sequence analysis has revealed that GAS2-like 3 contains two 
putative EB1-binding MtLSs at its C-terminus. There is also evidence to suggest 
that related sequences are used by EB1 to bind spectraplakins (Applewhite et 
al., 2010; Honnappa et al., 2009; Wu et al., 2008). In order to establish whether 
GAS2-like 3 interacts with EB1 in vitro, a combination of biochemical assays will 
be performed. Following which, full-length GAS2-like 3 and its C-terminus will be 
co-expressed with EB1 to determine whether their localisation is effected. If EB1 
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does bind GAS2-like 3 in vitro and affects GAS2-like 3 localisation in cells, a 
series of mutants of the GAS2-like 3 C-terminus will be created to dissect the key 
residues necessary for this interaction. By elucidating the key residues for GAS2-
like 3 to bind to EB1, it may enable the prediction of fellow EB1 binding proteins 
in the GAS2 family and provide insight into the molecular mechanism underlying 
their function. 
 
1.4.6) Functional characterisation of GAS2-like 3 
As mentioned previously in this chapter, GAS2 has been implicated in apoptosis 
and growth arrest (Benetti et al., 2005; Benetti et al., 2001; Brancolini et al., 
1995; Lee et al., 1999). There is a lack of knowledge as to how GAS2 induces 
apoptosis, and whether it can link to the key apoptotic machinery. There is little 
evidence to suggest the GAS2-like members of the GAS2 family play any role in 
apoptosis (Goriounov et al., 2003). Thus, it is unclear as to whether the GAS2 
family plays a role in apoptosis. One of the main aims of this study is to 
characterise the function of GAS2-like 3 and increase the understanding of the 
GAS2 family. 
By taking into consideration that GAS2-like 3 shares the highest degree of amino 
acid identity to GAS2, it is likely to play a similar, albeit separate function. Using 
immunofluorescence, the role of GAS2-like 3 will be assessed in cells by 
investigating whether it can instigate apoptosis. If GAS2-like 3 expression results 
in apoptosis, its localisation in cells will be further probed to investigate if there is 
evidence of localisation to mitochondria, which host the apoptotic machinery 
(Karbowski and Youle, 2003; Taylor et al., 2008).  
The GAS2 family is related to the spectraplakins, which are implicated in 
diseases such as neurodegeneration and cancer (Giorda et al., 2004; Leung et 
al., 2002; Sjoblom et al., 2006; Sonnenberg and Liem, 2007). However, the 
precise cellular role of spectraplakins in these diseases is unclear. 
Neurodegeneration is often one of the consequences of defects in proteins that 
mediate mitochondrial dynamics (Lin and Beal, 2006), thus GAS2-like 3 is a 
potential candidate that links apoptosis and mitochondrial dynamics to cancer 
and neurodegeneration, respectively. 
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2) Materials and Methods 
 
2.1) Materials 
See Appendix 2 
2.1.1) Vector Maps 
See Appendix 3 
2.1.2) Bacterial Strains 
JM109 and JM109 (DE3) cells purchased from Novagen, UK. 
BL21 CodonPlus (DE3) cells were purchased from Stratagene, UK 
2.2) Methods 
2.2.1) Cell Culture 
All mammalian cells were grown in DMEM (Sigma Aldrich, Dorset, UK) 
supplemented with 10% FBS, 1% penicillin/ streptomycin, and 1% glutamine in a 
5% CO2 in a humidified incubator, and passaged in a 1:10 dilution every 3 days.  
2.2.2) Transfections 
For transfections, cells were plated in 6-well dishes (for immunofluorescence) or 
10cm petri dishes (for large scale) a day before transfections. For small and 
large-scale transient transfections, 1-1.5µg or 8µg of DNA respectively, was 
transfected into cells using Lipofectamine Plus (Invitrogen, Paisley, UK) in 
accordance with manufacturer’s instructions. For immunofluorescence, cells 
were replated after 3-4 hours in glass-bottomed dishes (MatTek Corporation, 
Ashland, USA) coated with 10 µg/mL bovine fibronectin (pFN; Sigma). For drug 
treatment, cells were incubated for 30 mins with either nocodazole (10µM), 
cytochalasin D (2µM), trichostatin A (5µM), or paclitaxel (taxol, 10µM) (all from 
Sigma). For pulldown experiments, cells were washed thrice in PBS, and once in 
complete DMEM (as above), and left overnight before lysis the following day. 
2.2.3) Fixed immunofluorescence Imaging 
Cells were fixed and permeabilised with 3% paraformaldehyde (Sigma) 
containing 0.25% Triton X-100 (Sigma) and 0.05% glutaraldehyde (Sigma) for 15 
mins, before being washed in PBS (Lonza, Verviers, Belgium). Autofluorescence 
from reactive amine groups was quenched using 0.01% sodium tetrahydroborate 
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(Sigma) in PBS for 15 mins before being washed in PBS. Subsequently cells 
were incubated for 45 mins with anti-α tubulin (DM1A) or anti-acetylated tubulin 
(6-11B-1) antibody, both at 1:500 dilution (both from Sigma), followed by three 
washes with PBS. Secondary antibodies conjugated to either Cy2, 3 or 5 
(Jackson ImmunoResearch Laboratories, Suffolk, UK) were then applied for 30 
mins. In the case of colabelling for actin, Texas Red or FITC-labelled phalloidin 
(Invitrogen) was added together with the secondary antibody). Cells were then 
washed three times in PBS before being imaged using an oil-immersed 100X 
objective, with 1.35 numerical aperture on an inverted microscope (IX71; 
Olympus) controlled by a Deltavision system (Applied Precision, Washington, 
USA). Images were captured using a Coolsnap HQ CCD camera (Princeton 
Instruments, Lurgan, UK).  
 
2.2.4) Live-cell Imaging 
Cells were washed thrice in PBS, and DMEM was replaced with pre-warmed 
Ham’s F12 medium supplemented with 25mM HEPES, 1% L-glutamine, 1% 
penicillin/ streptomycin and the pH was adjusted to 7.3 with NaOH. Ham’s F12 is 
preferred to DMEM for live imaging as it contains a very low amount of riboflavin, 
which exhibits a high autofluorescence in the excitation range of 450-490 nm and 
emssion range of 500-560 nm. Cells were placed in a pre-warmed microscope 
chamber at least an hour prior to the experiment and then imaged using an oil-
immersed 100X objective, with 1.35 numerical aperture (NA) on an inverted 
microscope (IX71; Olympus) controlled by a Deltavision system (Applied 
Precision, Washington, USA). Movies were captured using a Coolsnap HQ CCD 
camera (Princeton Instruments, Lurgan, UK). For longer-term and real-time drug 
treatments, cells were imaged using an oil-immersed 100X objective, with 1.49 
NA on an inverted microscope (Nikon TE2000E) with laser-based perfect focus 
system. Movies were captured using a Roper Cascade II EM CCD camera 
(Photometrics, AZ, USA), controlled by MetaMorph image acquisition software 
(Molecular Devices, PA, USA). For drug treatments, cells were incubated with 
2µm cytochalasin D or 10µm nocodazole for 10 minutes, followed by washout 
using three washes in pre-warmed Ham’s F12 media. 
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Antibody Generated In 
Directed 
Against IF WB SPBA 
DM1A (Sigma) Mouse α tubulin 1:500 1:5000 - 
FITC-conjugated 
DM1A 
(Sigma) 
Mouse α tubulin 1:500 - - 
6-11B-1 (Sigma) Mouse Acetylated tubulin 1:500 - - 
GST 
(GE Healthcare) Mouse 
Glutathione-S 
Transferase - 1:200 1:200 
GFP 
(Roche) Mouse 
Green 
Fluorescent 
Protein 
- 1:1000 - 
Cy2, Cy3, Cy5 
conjugated anti-
mouse (Jackson 
Immunoresearch) 
Goat Mouse IgG 1:500 - - 
Cy2, Cy3, 
conjugated anti-
rabbit (Jackson 
Immunoresearch) 
Goat Rabbit IgG 1:500 - - 
HRP-conjugated 
anti-mouse 
(Jackson 
Immunoresearch) 
Goat Mouse IgG - 1:5000 1:5000 
HRP-conjugated 
anti-rabbit 
(Jackson 
Immunoresearch) 
Goat Rabbit IgG - 1:5000 - 
Table 2.1: List of antibodies used for immunofluorescence (IF), Western Blotting (WB) and 
Solid Phase Binding Assays (SPBA).  
Primary antibodies are in red, secondary antibodies are in blue. 
 
2.2.5) Image Processing 
Images were processed using ImageJ version 1.38X. For colocalisation studies 
and calculation of the ratio of G2L3 (or variation) / MTs, images were 
background subtracted using a 2D-bandpass filter, and overlay images were 
created. From these a threshold was set to restrict analyses to MTs, and the 
outline of the cell was drawn followed by measuring the percentage area of 
positive pixels (see Figure 2.1). This was repeated for full-length G2L3, its C-
terminus, and for G2L3 after drug treatment and divided by the value given for 
MTs to give a ratio theoretically between zero and one. Adobe Photoshop CS4™ 
was used in the preparation of figures for this manuscript. 
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Figure 2.1: Image processing applied to cells.  
Initially, images were taken and were background subtracted using a 2D bandpass filter. A 
threshold was set to restrict analysis to MTs, and an outline drawn around the cell. Following 
which, the percentage area of positive pixels were taken and the ratio of % G2L3: % MTs was 
calculated. 
 
2.2.6) Statistical methods 
Using the ratios obtained from the image processing, a Student’s t-test was 
performed using Microsoft Excel to compare the ratios of GAS2-like 3 expressing 
control cells, taxol treated GAS2-like 3 expressing cells, and EB1 with GAS2-like 
3 coexpressing cells. Student’s t-test was also performed before and after drug 
treatments to determine if there was a significant shift of localisation. 
It was also used to compare the % area of MTs for each condition.  
 
2.2.7) Glutathione S-Transferase pull-down assay from cell lysates 
Following overnight expression in 100mm petri dishes, COS cells were washed 
with PBS and trypsinised. They were subsequently centrifuged and lysed in 
500µL ice cold lysis buffer (1% NP40, 50mM Tris pH7.4, 120mM NaCl, 2.5mM 
EGTA pH 7.4, 10mM MgCl, supplemented with 2X protease inhibitor cocktail 
solution). Lysates were passed 10X through a 27G needle, and centrifuged in a 
precooled centrifuge at 4°C for 15mins at 800g in order to remove the insoluble 
fraction. An aliquot of the supernatant was taken and placed in SDS-loading 
buffer as the total cell lysate, the remaining supernatant was precleared with 
Glutathione-coated Sepharose beads (GE Healthcare) for one hour at 4°C, 
followed by centrifugation at 2000g and aspiration of the supernatant. During 
preclearing, washed Glutathione-coated Sepharose beads were incubated with 
either Glutathione S-Transferase (GST) conjugated-EB1 or GST alone (control) 
in order to attach the bait protein to the bead. After preclearing, the EB1-GST or 
GST coated beads were washed thrice in PBS containing 0.01% Tween 20 
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(PBS-T), and were resuspended in the precleared lysate, and rotated for an hour 
at 4°C. The samples were centrifuged at 2000g, and an aliquot of the unbound 
fraction was taken. The beads were subsequently washed 4 times in PBS-T and 
the bound proteins were eluted from the beads in 2X SDS-loading buffer at 
100°C for 10 mins. The individual fractions were then separated by SDS-PAGE 
and analysed by immunoblotting, using an anti-GFP antibody (See Table 2.1) 
2.2.8) Glutathione S-Transferase pull-down assay using recombinant 
proteins 
The C-terminus of G2L3 was incubated in a 1.5X molar excess with human EB1-
GST for an hour at 4ºC in PBS containing 40mM EDTA. Before resuspending the 
beads, a fraction of the incubation mixture was taken for the prebound fraction. 
An excess of Glutathione-coated Sepharose beads (GE Healthcare) were 
washed five times in PBS before being resuspended with PBS containing EB1-
GST, C-terminus or their respective combination. These were incubated on a 
rotator for an hour at 4ºC, after which an unbound fraction was taken. The beads 
were washed five times in PBS, with aliquots of supernatant aspirated after each 
wash (wash fractions). After the final wash, an aliquot of beads (resin fraction) 
was taken and boiled in 2X SDS-loading buffer for 10 mins along with the 
previously collected fractions. These were then analysed on a 15% SDS-PAGE 
gel. 
2.2.9) Solid Phase Binding Assay 
Wells of Costar high binding microtitre plates (Corning Costar, UK) were coated 
with 100µL aliquots of purified Thioredoxin-6X-His Tag- C-terminus G2L3 at 
10µg/mL diluted in PBS overnight at 4ºC. Wells were blocked for 2-3 hours at 
room temperature with 200µL of blocking buffer [5% BSA (w/v) in PBS], followed 
by 3 washes with 200 µL washing buffer [0.1% BSA (w/v) in PBS]. Wells were 
incubated at the indicated concentrations of EB1-GST or GST (control) in a total 
of 100µL wash buffer for 2-3hrs, 37 ºC and washed 3X with 200 µL washing 
buffer. Mouse-α-GST antibodies (500ng/mL) were added to wells in 50µL wash 
buffer for 1 hour at 37 ºC followed by 3 further washes using 200 µL washing 
buffer. GST-binding proteins were detected using horseradish peroxidase (HRP)-
conjugated anti-mouse antibody diluted 1:5000 in wash buffer incubated for 
30mins at 37 ºC. Wells were washed 4 times with 200µL before the addition of 
100µL ABTS substrate [0.55mg/mL 2,2’-azino-bis(3-ethylbenzthiazoline-6-
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sulfonic acid), 0.0026% (v/v) H2O2 , 0.1M sodium acetate and 50mM NaH2PO4, 
pH5.0] at room temperature. Absorbance readings at 405nm were measured 
using a Powerwave 340 multiscan plate reader (Biotek, USA). Each 
experimental condition was assayed in at least three replicate wells and 
background attachment to BSA-blocked wells subtracted from all measurements. 
Means and standard error of the means were calculated for each experimental 
condition using Microsoft Excel 2003 (Microsoft, USA). 
 
2.2.10) Molecular Biology Methods 
2.2.10.1) Polymerase chain reaction (PCR) 
 
2.2.10.1a) cDNA panels 
To identify expression levels in tissues, a “master mix” containing forward and 
reverse primers, dNTPs, reaction buffer and Taq polymerase was made for 
Clontech cDNA panels as indicated in Table 2.2. PCR primers were designed to 
span exons 2-6 of GAS2-like 3, to avoid amplifying genomic DNA. A “master 
mix” was also made to identify expression in the following cell lines: HeLa, 
Human Foreskin Fibroblast (HFFs), HT1080, Human Embryonic Kidney 293T 
and murine NIH 3T3. The total reaction volume for each reaction was 25µL, they 
were incubated at 94ºC for 1 minute, followed by 35 cycles of 30 seconds at 94 
ºC (denaturation), 30 seconds at 55 ºC (annealing) and 60 seconds at 72 ºC 
(extension). The reaction products were subsequently run on a 1% agarose (w/v) 
gel for an hour at 120V. 
 
2.2.10.1b) Sub-cloning 
G2L3 truncation products were produced as indicated in Figure 2.2, using the 
primers listed in Table 2.3. All reaction mixtures were made up to 50µL with 
ddH2O, except from the production of the G2L3-ΔGAR construct, which was 
made up to 100µL. They were incubated at 94ºC for 1 minute, followed by 35 
cycles of 30 seconds at 94 ºC (denaturation), 30 seconds at 50 ºC (annealing) 
and 2 minutes at 72 ºC (extension). The reaction products were subsequently 
run on a 1% agarose gel containing 0.005% (v/v) ethidium bromide (Sigma, 
Poole, UK), excised and purified using a QIAquick Gel Extraction kit (Qiagen, 
Crawley, UK). 
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“Master mix” Component 
Volumes for 
Clontech 
Panel (µL) 
Cell line 
cDNA library 
(µL) 
cDNA 3 5 
10X PCR buffer 28 44 
dNTPs (2.5mM) 28 35 
5’ primer (10pmol/µL) 
5’ CACGGACCAGGATTGGCTAATG 3’ 
9 5 
3’ primer (10pmol/µL) 
5’ TGTAGCTCTTCATGCCGACAGC 3’ 
9 5 
ddH2O 180 330 
Taq polymerase 1 1 
Table 2.2: Showing the reaction volumes used to screen cDNA panels or cDNA libraries 
from different cell lines. 
 
 
 
  
 
Figure 2.2: Showing the various constructs used for this study.  
The truncations were cloned into eGFP-N1, mCherry-N1 or eGFP-C1 vectors for 
immunofluorescence. For recombinant expression, G2L3-CH and G2L3-C-term were cloned into 
pHisTrx and G2L3-GAR was cloned into pHisNusA. 
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Reaction  
Product Primers Used Template 
dNTPs  
(uL) 
PCR  
buffer 
 (uL) 
Taq  
G2L3-
ΔCH for 
 eGFP-N1 
or 
 mCherry-
N1 
Forward: 5' 
CTGGTCGCTAGCATGGGGCCT 
GAAGATTCCATCAG -3' (586- 
606bp) 
 
Reverse: 5'- 
CTGGTCAAGCTTTTTTCTAGG 
TTTCTTACTTCCAG -3' (2061-
2094bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5 U 
G2L3-ΔC-
term 
for 
 eGFP-N1 
or 
 mCherry-
N1 
Forward: 5'-  
CTGGTCGCTAGCATGCAGCCT 
GCAATTCAAGTATG -3' (1-
26bp) 
 
Reverse: 5'- 
CTGGTCAAGCTTTCGACAGG 
GGTCATATTTAAGC -3' (821-
843bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5 U 
G2L3-C-
term 
for 
 eGFP-N1 
or 
 mCherry-
N1 
Forward: 5'- 
CTGGTCGCTAGCATGCGAATA 
TTACAGTTTGCCACAC -3' 
(841-863bp) 
 
Reverse: 5'-
CTGGTCAAGCTTTTTTCTAGG 
TTTCTTACTTCCAG -3' (2061-
2094bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5 U 
G2L3-CH 
for 
 eGFP-N1 
or 
 mCherry-
N1 
Forward: 5'-  
CTGGTCGCTAGCATGCAGCCT 
GCAATTCAAGTATG -3' (1-
26bp) 
 
Reverse: 5’- 
CTGGTCAAGCTTTTTTCTAG 
GTTTCTTACTTCCAG -3’ (565-
588bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3-
GAR for 
 eGFP-N1 
or 
 mCherry-
N1 
Forward: 5’- 
CTGGTCGCTAGCATGGAGCTA 
CATGAAGCTGTTAAAC -3’ 
(634-656bp) 
 
Reverse: 5'- 
CTGGTCAAGCTTTCGACAGG 
GGTCATATTTAAGC -3' (821-
843bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
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G2L3-
ΔGAR for 
 eGFP-N1 
or 
 mCherry-
N1 
 
Forward: 5'-  
CTGGTCGCTAGCATGCAGCCT 
GCAATTCAAGTATG -3' (1-
26bp)   
+ 
5’- 
GCTGTCGGCATGAACGAAT 
ATTACAGTTTGCCACAC -3’ 
(597-633bp) 
 
Reverse: 5'- 
CTGGTCAAGCTTTTTTCTAGG 
TTTCTTACTTCCAG -3' (2061-
2094bp) + 
5’- CTGTAATATTCGTTCATG 
CCGACAGCATGATTTTG -3’ 
(841-860bp) 
 
300ng 
mCherryN1- 
G2L3 
8 10 2.5U 
G2L3-CH 
for 
pHisTrx 
Forward: 5’ CTGGTCGGATCC 
ATGCAGCCT 
GCAATTCAAGTATG -3' (1-
26bp) 
 
Reverse: 5’- 
CTGGTCGAATTCTTTTCTAG 
GTTTCTTACTTCCAG -3’ (565-
588bp) 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3-
GAR for 
pHisNusA 
and for 
pEGFP-
C1 
Forward: 5’ 
CTGGTCGAATTCGAGCTA 
CATGAAGCTGTTAAAC -3’ 
 
Reverse: 5’  
CTGGTCGGATCCTCGACAGG
GGTCATATTTAAGC -3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
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G2L3-C-
term for 
pHisTrx 
Forward: 5’ 
CTGGTCGGATCCCGAATA 
TTACAGTTTGCCACAC -3’ 
(841-863bp) 
 
Reverse: 5’- 
CTGGTCGGATCCTTTTCT 
AGGTTTCTTACTTCCAG -3’ 
(2061-2094bp) 
 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3 for 
pEGFP-
C1 
Forward: 5’  
CTCGTCTCCGGAATGCAGCCT
GCAATTCAAGTATG -3’ 
 
Reverse: 5’  
CTCGTCGGATCCTTATTTTCTA
GGTTTCTTACTTCC -3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3-C-
term for 
pEGFP-
C1 
Forward: 5’  
CTCGTCGGATCCCGAATATTA
CAGTTTGCCACAC 
  -3’ 
 
Reverse: 5’  
CTCGTCGGATCCTTATTTTCTA
GGTTTCTTACTTCCAG 
  -3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3-
myc-GAR 
for 
pEGFP-
C1 
Forward: 5’ 
CTGGTCGAATTCATGGAGCAG
AAACTCATCTCTGAAGAGGAT
CTG  
CGGCATGAAGAGCTACATGA
AG-3’ 
Reverse: 5’ 
CTGGTCTTATTAGCGGCCGCT
TGTTCTAGTGTGGCAAACTG-
3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
G2L3-CT1 
for 
pEGFP-
C1 
Forward: 5’ 
CTCGTCTCCGGACGAATATTA
CAGTTTGCCACAC -3’ 
Reverse: 5’ 
CTCGTCGGATCCTTAAGCTAA
GTGAGATACTGCATTATC -3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
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Table 2.3: Primers used in PCRs for this study.  
Blue= ATG start codon. Red = Incorporated restriction enzyme sites. Bold = DNA sequence 
corresponding to the published human G2L3 sequence. Green = Overlapping regions to produce 
ΔGAR construct. Brackets = Corresponding DNA base pair region of human G2L3 chain 
fragments. 
 
Construct Restriction endonucleases used 
G2L3-CH, G2L3-ΔCH, G2L3-GAR, 
G2L3-ΔGAR, G2L3-C-term, G2L3-ΔC-
term in pEGFP-N1 or pmCherry-N1 
NheI and HindIII 
G2L3-CH in pHisTrx BamHI and EcoRI 
G2L3-C-term in pHisTrx BamHI 
G2L3-GAR in pHisNusA BamHI and EcoRI 
G2L3 in pEGFP-C1 BspE1 and BamHI 
G2L3-C-term in pEGFP-C1 BamHI 
G2L3-myc-GAR in pEGFP-N1 BamHI and NotI 
G2L3-CT1 and CT2 in pEGFP-C1 BspEI and BamHI 
Table 2.4: List of restriction endonucleases used to prepare the G2L3 constructs. 
 
 
 
 
 
G2L3-CT2 
for 
pEGFP-
C1 
Forward: 5’ 
CTCGTCTCCGGAGCACATTCA
AATTCATCCTCAAAA -3’ 
Reverse: 5’ 
CTCGTCGGATCCTTATTTTCTA
GGTTTCTTACTTCCAG 
  -3’ 
300ng 
mCherryN1- 
G2L3 
4 5 2.5U 
Primers 
to screen 
cDNA 
libraries 
Forward: 5’  
CACGGACCAGGATTGGCTAA
TG -3’ 
Reverse: 5’  
TGTAGCTCTTCATGCCGACAG
C -3’ 
cDNA 
libraries 2 2.5 
1.25
U 
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2.2.10.2) Restriction Endonuclease Digestion, Cloning and Ligations 
The pEGFP-N1, pmCherry-N1, and pEGFP-C1 vectors (Clontech) and pHisTrx 
and pHisNusA vectors as well as the reaction products designed for these 
vectors were restricted at 37ºC for 3 hours using the restriction enzymes listed in 
Table 2.4. They were subsequently run on a 1% agarose gel containing 0.005% 
(v/v) ethidium bromide, excised and purified using a QIAquick Gel Extraction kit.  
For ligations, a 4:1 molar ratio of insert : plasmid, together with 2 µL 5X Ligate IT 
buffer (USB), 0.5 µL T4 DNA ligase (Roche) and ddH2O were used to make up 
the reaction mixture to 10 µL. The ligation mixture was incubated at room 
temperature for 15 minutes, followed by a 1 hour incubation on ice with the E. 
coli strain JM109. After which cells were heat shocked at 42ºC for 45s 
(kanamycin vector) or 90s (ampicillin vector) and immediately cooled on ice for 
2min, before being grown in 400µL LB broth [0.17M NaCl, 0.8% (w/v) tryptone, 
1% (w/v) yeast extract] for an hour at 37ºC. They were subsequently plated and 
grown on LB agar plates containing 40 µg/mL kanamycin for eGFP-N1 and 
mCherry-N1 vectors or 50 µg/mL ampicillin for pHisTrx. 
Three colonies were picked from each plate and then incubated overnight at  
37ºC in 5mL LB media containing either 30 µg/mL kanamycin or 50 µg/mL 
ampicillin depending on the resistance conferred by the vector. 
The insert sequences of each construct were confirmed by DNA sequencing with 
an ABI 377 automated sequencer (PE Applied Biosystems). 
 
2.2.10.3) cDNA synthesis from Cell Lines 
cDNA libraries were synthesised from various cell lines using the ‘Absolutely 
RNA Microprep Kit’ followed by the Stratascript QPCR cDNA Synthesis Kit 
(Stratagene, Stockport, UK). Briefly, cell pellets from 10cm petri dishes were 
snap frozen in liquid nitrogen. They were subsequently thawed and resuspended 
in lysis buffer (Absolutely RNA Microprep Kit, Stratagene), containing a strong 
protein denaturant guanidium thiocyanate to prevent ribonuclease degradation of 
the RNA. The lysate was treated with DNase I to degrade DNA, washed to 
remove contaminants and eluted into 30µL. 7µL of this eluate containing RNA, 
was added to 10 µL cDNA synthesis master mix (2X), with either 2 µL of random 
or oligo (dT) primers and 1 µL of StrataScript RT-RNase Block enzyme mixture. 
This was incubated at 25ºC for 5 minutes (annealing), followed by 42 ºC for 90 
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minutes (cDNA synthesis) and 95 ºC for 5 minutes to terminate the cDNA 
synthesis reaction. 
 
2.2.11) Protein expression, purification and analysis 
2.2.11.1) Protein Expression 
300ng of DNA for each construct was used to transform the E. coli strain JM109 
(DE3) using the same protocol as for the JM109 strain. Colonies were picked 
and grown over the day in 5ml LB containing 100µg/mL ampicillin. The cultures 
were then transferred to 500mL conical flasks containing 495mL auto-induction 
media (as prepared in (Studier, 2005), and incubated overnight at 37 ºC, with 
shaking at 225rpm. 
 
2.2.11.2) Sonication and Metal Chelation Chromatography 
Cells were spun down and pellets resuspended in 30mL 1X binding [40mM 
Imidazole (Sigma), 4M NaCl, 160mM Tris, pH7.9] and sonicated 6 times for 30 
seconds at 20% amplitude. Cellular debris was pelleted by centrifugation at 
18,000rpm for 20 minutes at 4ºC, and the crude cell lysate was retained on ice. A 
further 20mL 1X binding buffer was added to the pellet, sonicated and 
centrifuged as described above. The resulting supernatant was pooled with the 
original lysate. The protein was purified by exploiting the N-terminal 6X histidine 
tag, using a Chelating Sepharose Fast-Flow Column (GE Healthcare, Bucks, 
UK) charged with nickel ions, according to the manufacturer’s protocol. All 
fractions were collected, with the protein content of each fraction analysed on a 
15% SDS-PAGE gel. The cleanest collection fraction was dialysed at least twice 
into thrombin cleavage buffer (20mM TRIS, 150mM NaCl, 2M urea, pH 8.4) in 
preparation for thrombin cleavage. 
 
2.2.11.3) Removal of 6x His tag 
For test digestions, reaction mixtures were made up to 100µL with 0.1U thrombin 
(high activity thrombin from human plasma (Calbiochem, Beeston, UK) and 
2.5mM CaCl2. 20 µL aliquots were removed during the time course, and 
analysed using a 15% SDS-PAGE gel. From this, the optimal digestion 
conditions were determined and scaled up to digest the remainder of the eluates. 
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The digested protein was loaded onto the Chelating Sepharose Fast-Flow 
Column (GE Healthcare) purified as described earlier. Each fraction was 
collected and analysed using a Tricine-SDS-PAGE gel. Appropriate fractions that 
contained the digested target protein were pooled and dialysed into PBS. 
Determination of protein concentration was achieved by analysis of tryptophan 
and tyrosine residues at 280nm. 
 
2.2.11.4) SDS-Polyacrylamide (SDS-PAGE) gels 
Samples were boiled at 95ºC in 2X SDS sample buffer (30% glycerol, 4% SDS, 
0.125M Tris, 5% β  mercaptoethanol, dH2O, bromophenol blue at pH 6.8) and 
separated on 15% SDS-PAGE gels, run at 150V for 80 minutes. Gels were 
stained using either Instant Blue (Novexin, Cambridge, UK) or stained with 
Coomassie stain (0.25% Coomassie BB, 7.5% CH3COOH, 50% methanol), and 
destained with destaining solution (45% methanol, 50% dH2O, 5% CH3COOH). 
Images were captured using an HP Scanjet 4600, with HP Photo and Imaging 
Gallery Version 1.1 (HP, Bracknell, UK). 
 
2.2.11.5) Immunoblotting 
Following SDS-PAGE, gels were transferred to PVDF membrane by creating a 
sandwich comprising of Whatman Paper, SDS-PAGE Gel, and PVDF 
membrane, which had been presoaked in methanol. The transfer was performed 
in Transfer Buffer (10mM Sodium Tetraborate) for 1hr at 250mA, followed by 
blocking in PBS-T supplemented with 5% Milk Powder (Marvel, London, UK) for 
an hour at room temperature or overnight at 4°C, to minimise cross-reactivity of 
primary antibodies. Primary antibodies were either incubated with membranes 
for an hour at room temperature or overnight at 4°C in PBS-T containing 2% 
milk. The membrane was washed thrice in PBS-T to remove unbound primary 
antibody and incubated with the appropriate HRP-conjugated secondary 
antibody (Jackson Laboratories) for 30mins at room temperature. The membrane 
was washed again 3X and incubated with ECL reagent (Cheshire Sciences, 
Cheshire, UK). The membrane was then exposed to Kodak MR photographic 
film (Sigma). 
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2.2.11.6) Tricine-SDS-PAGE gels 
Samples were prepared as for SDS-PAGE gels. The gel contained a 1-70kDa 
separating gel (16.5% T/ 3%C), spacer gel (10% T / 3% C) and stacking gel (4% 
T / 3% C), and was run at 15mA overnight. 	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Summary 
This chapter describes the use of microscope-based Fluorescence Recovery 
After Photobleaching. To qualify the dynamics of proteins within a subcellular 
compartment, we first outline the general aspects of FRAP experiments and then 
provide a detailed protocol of how to measure and analyse the most important 
parameters of FRAP experiments such as mobile fraction and half-time of 
recovery.  
 
Keywords 
Fluorescence Recovery After Photobleaching; fluorescence microscopy; green 
fluorescent protein; half-time of recovery; mobile fraction; diffusion; binding 
reaction kinetics; focal adhesions. 
 
1. Introduction 
1.1. Principles of FRAP 
Fluorescence Recovery After Photobleaching (FRAP) is a powerful, microscopy 
based methodology for investigating molecular dynamics within living cells. 
Whereas traditional fluorescence microscopy yields information in a qualitative 
‘yes or no’ manner as to the localisation of molecules in cells, FRAP allows us to 
elucidate the dynamics of the protein of interest. In order to perform FRAP, this 
protein of interest must be tagged to a fluorophore. Green fluorescent protein 
(GFP) is a well-characterised fusion tag widely used for protein labelling in live 
cells. It was originally discovered in the jellyfish, Aequorea victoria, and has been 
subsequently modified to produce brighter and more photostable variants (Tsien, 
1998). In FRAP, fluorescent molecules that localise to a region of interest (ROI) 
are irreversibly bleached using a high power laser illumination (see Figure 1A). 
The fluorescence recovery over time within the ROI provides details about the 
dynamics of the protein of interest (Axelrod et al., 1976) (see Figures 1A and 
1B). The rate of fluorescence recovery is governed by two major events 
(Sprague and McNally, 2005). The first is the diffusion of the fluorescently tagged 
protein within the localised environment, a fast process occurring over a few 
milliseconds. The second event is the binding between the fluorescently tagged 
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protein and potential binding partners within the ROI. Most proteins in a cell 
undergo continuous turnover within complexes allowing bleached fluorescent 
proteins to be replaced by newly recruited fluorescent proteins, thus leading to 
the recovery of fluorescence (see Figure 1A). Such recovery can be quantified 
by plotting the intensity of the fluorescence over time within the defined ROI, 
before, during and after the bleaching event (see Figure 1B). Further 
mathematical analysis including curve fitting then allows a detailed assessment 
of the behaviour of a fluorescently tagged protein within live cells. 
This protocol will focus on FRAP as a method to assess the mobility of 
fluorescently labelled proteins within focal adhesions of a live cell (see Figure 
1C). We describe here the acquisition of time-lapse images, the bleaching and 
recovery of fluorescence with an emphasis on the compulsory controls, and 
cover some aspects of data processing. A complete methodology detailing the 
processing of raw data from FRAP experiments is described in (Sprague et al., 
2006; Sprague et al., 2004). 
 
1.2. Readouts of FRAP experiments 
Analysis of the FRAP experiments yields information about the mobility of the 
fluorescently tagged protein. Two main parameters can be readily assessed, 
namely the mobile fraction and the half time of recovery. 
The mobile fraction (FM) is the proportion of bleached proteins that are replaced 
by unbleached proteins during the monitoring of the recovery event. Thus, 
mobile fraction can be determined by calculating the ratio of fluorescence 
intensity between the end of the time-lapse recordings (F∞) and the initial 
intensity before the bleaching event (Finitial) corrected by the experimental bleach 
value (F0) (Axelrod et al., 1976) (see Figure 1B). This ratio results in values 
between 0 and 1, or when expressed as a percentage, between 0 % and 100 %. 
Due to binding reactions within the ROI, the theoretical value of 100 % of 
recovery is rarely achieved in practice. Therefore, the recovery reaches a 
plateau below this value by the end of the time-lapse (see Figure 1A). Moreover, 
unintentional bleaching and dynamics of the overall structure during recovery 
limit the length of the time lapse recording. In general, proteins that bind strongly 
to fixed components will have lower mobile fractions than those that interact 
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weakly. Proteins that can freely diffuse show a maximal mobile fraction of 100 % 
as they don’t interact with any partner. 
The second parameter, the half-time of recovery, is the time it takes for the 
fluorescence to reach half of its maximal recovery intensity (termed t1/2) (see 
Figure 1B). The rate of the recovery depends on the size of the complexes and 
the stability of the interaction with large or fixed proteins (Lippincott-Schwartz et 
al., 2001). Under some circumstances, the recovery may exceed 100% of the 
initial fluorescence value. This observation indicates that the bleached structure 
undergoes a formation or growth phase during the timeframe of the experiment.  
The precise determination of FM and t1/2 is only possible in biological systems 
that have reached equilibrium before photobleaching, so that the total amounts 
of both fluorescent protein and its binding sites remain constant over the course 
of the experiment. In this case, the only parameter changing after 
photobleaching is the equilibrium between the bleached and the unbleached 
molecules and the return to equilibrium provides the readout of the recovery 
curve. Finally, reliable measurements will only be obtained for proteins that are 
part of an immobile complex during the length of the monitored recovery. 
 
1.3. Requirements of the fluorescent label 
To study the dynamics of a protein in FRAP experiments, the protein of interest 
must be fused to a fluorophore suitable for expression and monitoring in live 
cells. To avoid artefacts this fluorophore should have the following 
characteristics: 
1. It should be bright enough to obtain a high signal-to-noise ratio. 
2. It should be photostable to prevent excessive bleaching during time-lapse 
recordings however, it should not resist bleaching with the high power laser. 
3. It should not be prone to photoreversible bleaching, an event whereby a 
proportion of the fluorophore is able to revert back to its original fluorescent state 
(see Note 1). Such an event can be tested to a certain extent by performing 
FRAP on fixed cells (see section 3.2). 
4. It should be monomeric to avoid any irrelevant association between the 
tagged proteins. 
 
The monomeric enhanced GFP (mEGFP) is usually a good choice, since it has 
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all these properties, to a greater extent than the original GFP and many other 
GFP derivatives. In addition, most confocal microscopes will be equipped with an 
argon laser line at 488 nm, which enables high power photobleaching and low 
power monitoring. The use of dyes emitting in the red spectrum is not preferred, 
as bleaching is less efficient with these lasers (see Note 2). 
Independently of the chosen tag, the fused protein should carry out the same 
function as the endogenous protein. It is therefore crucial to choose wisely where 
the fluorescent tag is placed in order to avoid artefactual readouts (see Note 3). 
 
1.4. Use of the correct microscope 
FRAP experiments can be carried out on both confocal and wide-field 
microscopes equipped with the necessary laser, but one should be aware of the 
strengths and weaknesses of the respective systems. 
Because of their design, wide-field microscopes capture the light emitted by the 
fluorescent molecules within a thicker optical section of the sample. On one hand 
this allows the measurement of low fluorescent intensities that would otherwise 
be below the threshold for a confocal microscope. Such systems can be fitted 
with electron multiplying-charge-coupled device (EM-CCD) cameras that have a 
higher sensitivity, a larger dynamic range and a faster acquisition rate than most 
conventional confocal scanning heads. On the other hand, FRAP experiments 
should be performed on the assumption that the movement of fluorescently 
labelled proteins is restricted to a two-dimensional plane (Sprague et al., 2006; 
Sprague et al., 2004). To a certain extent, it is possible to overcome this problem 
on a wide-field system by the use of background subtraction methods. However, 
since confocal microscopes monitor a precise optical section of a defined 
thickness, in many cases this type of microscope can deliver more accurate 
results. 
In our hands, results of FRAP experiments on adherent cells expressing vinculin-
mEGFP (see Figure 1C) are not significantly different when performed on a 
Leica SP5 confocal microscope or on a DeltaVision QLM wide-field microscope 
using the integrated analysis software. 
 
 
 
 58 
1.5. Validation of measurements and data fitting 
When performing FRAP experiments on proteins expressed transiently, the 
variability of the expression levels of the fluorescent protein can lead to 
misinterpretation of the results. The level of expression dictates the proportion 
between the pool of proteins interacting with other molecules and the pool of 
freely diffusing proteins in the immediate environment. Thus, it is important to 
determine whether there is a dependence between the FRAP coefficients and 
the protein expression levels. FRAP coefficients over a wide range of expression 
levels must be calculated and plotted against the overall cell fluorescence 
intensity; the slope of the regression line through the data points should not be 
statistically different from 0, with 95 % confidence (see Section 3.3.3). 
Correct data fitting is essential for the interpretation of the results. There are 
many software packages available but we recommend using MATLAB in order to 
process large amounts of data. MATLAB allows easy automation of the analysis 
by fitting the recovery curve and extracting the FRAP coefficients such as FM and 
t1/2. 
The fitting parameters depend on several factors, which have been outlined in 
great detail in (Sprague et al., 2004). Two major processes can influence the 
kinetics of the recovery: the diffusion of the fluorescent protein and the binding to 
its partners. Most of the FRAP protocols used by biologists assume that the 
binding reaction is dominant in their system, however this should be determined 
empirically on a protein-by-protein basis. To test whether the binding reaction is 
dominant, it is important to compare the different fluorescence recovery curves 
obtained by changing diameter of the region bleached by the FRAP laser. If the 
fluorescence recovery curves are similar and give the same rates of recovery 
independently of the diameter of the bleached spot, then diffusion is negligible. 
This is referred to as a ‘reaction dominant model’ (Sprague et al., 2004) in which 
diffusion occurs a lot faster than the binding reaction. Therefore, the recovery of 
fluorescence is driven by the following binding equation: 
€ 
F + S
kon⎯ → ⎯ 
koff← ⎯ ⎯ 
FS  
 
Where F represents free proteins, S represents unoccupied binding sites for the 
tagged protein and FS represents the bound complex. In this case of a single 
binding state, the predicted FRAP recovery curve is the inverse of an exponential 
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decay. The FRAP data can then be fitted with the following equation to obtain the 
off-rate constant of binding (koff): 
F(t) = 1 - A e-koff t 
The parameter A can be used to calculate the association rate (kon), using: 
A = kon / (kon + koff) 
The mobile fraction is given directly by: 
FM = F∞ – F0 / Finitial – F0 
The half-time of recovery can be determined from the curve fitting equation with 
F(t1/2)=(F∞ – F0) / 2: 
t1/2 = ln 2 / koff 
 
2. Materials 
 
2.1. Cell culture and transfection: equipment and reagents 
1. Laminar flow, tissue culture cabinet. 
2. Temperature-regulated, humidified incubator set at 37°C and 5 % CO2 gas for 
the maintenance of mammalian cells. 
3. Cell culture medium (Dulbecco’s modified Eagle’s medium, DMEM) 
supplemented with 10% foetal calf serum (FCS), glutamine, and antibiotics. 
4. Trypsin–ethylene diamine tetraacetic acid (EDTA) dissociation solution. 
5. Sterile phosphate-buffered saline (PBS-) without Mg2+ and Ca2+. 
6. Cultured adherent cells (e.g. NIH 3T3 mouse fibroblasts) expressing the 
protein of interest as a fusion protein with mEGFP (see Note 4). 
7. Flasks or Petri dishes treated for cell culture. 
8. Six-well tissue culture plates. 
9. Transfection kit suitable for the cell type used. We use Lipofectamine Plus 
reagent (Invitrogen Corporation). 
10. mEGFP expression vectors (Clontech). 
 
2.2. Microscope setup and reagents for imaging 
The microscope setup described here is currently used in our laboratory; 
however, any laser scanning confocal microscope with an equivalent setup is 
suitable. 
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1. Leica TCS SP5 AOBS inverted laser scanning confocal microscope (Leica 
microsystems) (see Notes 5 and 6). 
2. Leica HCX PL Apo 63x (lambda blue and NA iris corrected) objective 
(NA = 1.4) or another high numerical aperture oil immersion objective. 
3. An argon 488 nm laser line (see Note 6). 
4. Leica LAS AF software for image acquisition and FRAP procedure (supplied 
with the microscope) or another image acquisition software package. 
5. Heated chamber enclosing the microscope stage (see Note 7). 
6. Glass-bottom sterile culture containers (e.g., glass bottom dishes from MatTek 
or CellView from Greiner BioOne) for live imaging of cells (see Note 8). 
7. Fibronectin from bovine plasma (see Note 9). 
8. Ham’s F12 medium supplemented with a final concentration of 25 mM HEPES 
and pH adjusted to 7.3 using a 1 M NaOH solution. After sterile filtration, 
supplement with glutamine and antibiotics (see Notes 7 and 10). 
9. 4% paraformaldehyde (PFA) solution in PBS (w/v) (see Note 11) 
 
2.3. Software for analysis 
1. Software to extract the fluorescence measurements from the time-lapse 
images generated by the microscope system. Many software suites controlling 
microscopes are more or less suitable to perform the complete analysis through 
simplified wizards (e.g. Leica LAS AF software from Leica Microsystems, 
softWoRx Suite from Applied Precision). For a better controlled and a more 
accurate analysis, we prefer to use an open-source image-processing program 
such as ImageJ (NIH, freely available at http://rsbweb.nih.gov/ij/). 
2. Software to perform the data analysis. Any basic spreadsheet software is 
suitable, however, we recommend the use of a more advanced software 
package such as MATLAB (The MathWorks), enabling rapid automation in the 
analysis of large datasets (see Note 12). 
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3. Methods 
 
3.1. Transfection and preparation of cells 
This protocol is based on conditions optimised for our measurements of FRAP 
coefficients of focal adhesion plaque and cytoskeleton associated proteins. 
 
1. Prepare the mEGFP fusion proteins using standard molecular biology 
techniques. 
2. Transfect cells with either the construct encoding the fusion protein in a 6 well 
plate using Lipofectamine Plus reagent according to the manufacturer’s 
instructions (see Note 2). 
3. Coat the glass-bottom dishes for 1 h at room temperature with 10 µg/mL of 
fibronectin (see Note 10). 
4. After 4 hours of incubation, wash the cells twice with sterile PBS-. 
5. Trypsinise the cells and wash them twice in DMEM supplemented with FCS 
and plate 5x104 cells per 35-mm glass bottom dish (see Note 9). 
6. Incubate the cells for 12 to 48 hours in an incubator until the expression of the 
transfected plasmid reaches its maximum (see Note 13). 
7. Replace the DMEM with pre-warmed Ham’s F12 medium (see Note 11). 
8. Place the dish in the pre-warmed microscope chamber at least 1 hour prior to 
the FRAP experiment to allow the medium to equilibrate (see Notes 8 and 14). 
 
3.2. Data acquisition 
3.2.1. Protocol 
Three separate phases of the experiment can be distinguished. Firstly, the ROI 
must be defined and the fluorescence intensity of the GFP fusion protein within 
this ROI monitored using low-power laser settings. Secondly, a high intensity 
laser pulse is emitted to irradiate the ROI and eliminate the fluorescence within 
this region. Thirdly, immediately after bleaching, the sample is monitored using 
the same low-intensity imaging settings as before the bleach. Images are 
collected at regular time intervals until the intensity in the bleached ROI reaches 
a plateau (see Note 15). To facilitate the acquisition of in-focus images over a 
long time period, the microscope can be fitted with a real-time autofocusing 
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system (see Note 16). 
 
1. Select cells expressing a reasonable level of fluorescent protein in the 
appropriate cellular compartment using the eyepiece of the microscope (see 
Note 5). 
2. Set the parameters following the guidelines provided for monitoring the 
fluorescence. The individual parameters must be adjusted empirically to obtain 
high quality data while achieving three objectives: [1] obtaining an almost 
complete bleach in the specified ROI, [2] monitoring over a sufficient period of 
time until the fluorescence recovery becomes stable, and [3] keeping the 
photobleaching and phototoxicity to a minimum (see Note 17). Additionally, the 
intensity measured must always be confined to the dynamic range of the scan 
head (see Note 18). 
The settings we use on the confocal microscope are: 
• Confocal scan head settings: scan rate of 400 Hz for an intermediate size 
image of 512x512 pixels, using bi-directional scanning (see Note 19). 
• Laser power of the 488 nm argon laser line is set to 20 % and the 
transmission of the AOBS to 20 % during the monitoring. For the 
bleaching pulse, the AOBS setting is increased to 100 % (see Note 6). 
• Pinhole setting: 1 Airy Unit (see Note 20). 
• Zoom factor: set between 1.6 and 2 to fit the ROI for the bleaching event 
only. 
• Gain adjustment: 900 V (see Note 21). 
• Offset value: -1 (as close to zero as possible until a few zero intensity 
pixels appears on screen). 
• Beam size (or ROI radius): set to 0.5 mm of radius (see Note 22). 
• Iterations: 3-5 iterations to achieve full bleach (see Note 17). 
• Time lapse (see Notes 15, 17 and 22): 
o 1 frame every 10 seconds for 3 frames before bleach. 
o 1 frame every 10 seconds for 10 minutes after bleach, starting 
straight after the bleaching event. 
3. Adjust precisely the focus and select your desired ROI (see Note 24). 
4. Start your time-lapse. 
5. Proceed with another cell. Acquire multiple cells showing a broad range of 
expression levels, as this will give useful information for the analysis (see 
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Section 1.5 and 3.3.3). 
 
3.2.2. Controls 
Using this detailed protocol and the same settings as for the biological samples, 
several controls must be performed at the same time to accurately interpret the 
results of a FRAP experiment: 
1. Carry out initial experiments to optimise the ideal time course and image 
acquisition number to ensure that the recovery of fluorescence is complete and 
photoreversible bleaching is minimised. 
2. Bleach several ROI with different spot sizes to test whether diffusion has a 
major role in the fluorescence recovery. This will allow the user to apply the 
appropriate mathematical model for determining the protein dynamics according 
to (Sprague et al., 2004). 
3. Ensure that the overall fluorescence intensity of the entire cell is not 
significantly different before and after photobleaching. Bleached spots must 
comprise a relatively small proportion of the cellular pool of fluorescent proteins. 
To do this, one should perform several FRAP experiments with increasing size 
and/or number of bleached ROI to determine the limit for the bleach area. Slower 
recovery curves in experiments with a larger bleach spot size indicate that 
recovery of fluorescence is affected by a depletion of the pool of fluorescently 
labelled proteins. 
 
3.3. FRAP data analysis 
3.3.1. Intensity measurements 
1. Collect a complete set of FRAP experiments (20 to 30 cells per condition) and 
transfer the images to the analysis workstation. 
2. Correct any noticeable stage drift by realigning the individual images, e.g. 
ImageJ plug-in StackReg (Thevenaz et al., 1998) (see Note 25). 
3. Redraw the boundaries of the bleached ROI using the circular selection tool 
(see Note 22). The ROI position and diameter are likely to be found in the 
metadata recorded by the microscope software during acquisition. 
4. Extract the fluorescence intensity values for: 
• The bleached ROI 
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• Unbleached areas representative of the background fluorescence 
• Unbleached structures similar to the bleached target (see Note 26). 
5. Label the data in a fully comprehensive manner and store them in a backed-
up text file or spreadsheet. 
 
3.3.2. Normalisation and curve fitting 
 
Several calculations must be carried out to allow the comparison of the FRAP 
readouts between different biological samples or FRAP experiments. 
 
1. Plot all the raw data from each ROI separately to validate the integrity of the 
measurements (see Figure 2A and Note 27).  
2. Obtain the background value (Fbgd[t]) by averaging the fluorescence intensity 
from unbleached areas representative of the background and subtract this 
background value from each measurement of a photobleached ROI (Fbleach[t]): 
 
F[t] = (Fbleach[t] − Fbgd[t]) 
 
4. Obtain the control value (Fctr[t]) by averaging the fluorescence intensity from 
several unbleached structures similar to the bleached target (see Note 26) in 
order to compensate for the overall loss of fluorescence. 
5. Correct each measurement with the background subtracted control value from 
an unbleached ROI to obtain the experimental recovery (Rnorm[t]) as follows: 
 
Rnorm[t] = F[t] / (Fctr[t] − Fbgd[t]) 
 
6. Correct the experimental recovery with the first postbleach fluorescence 
intensity set to zero (F0) to obtain the fractional recovery measurement (Rfrac[t]): 
 
Rfrac[t] = (Rnorm[t] − F0) / (1 − F0) 
 
7. Average the multiple Rfrac[t] obtained within the same cell and over the same 
time course. 
8. Plot the average fractional fluorescence recovery curve (Rfrac[t]) obtained (see 
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Figure 2B). 
9. Superimpose multiple fractional fluorescence recovery curves obtained from 
different cells and use them to calculate the standard deviation (see Figure 2C). 
10. The mobile fraction and the half-time of recovery can already be estimated 
from this curve but a more accurate approach requires curve fitting. 
11. Export the data to MATLAB. 
12. Fit the plotted data using the following equation with the ezyfit toolbox for 
MATLAB (see Note 28): 
F(t) = 1 - A e-koff t 
 
13. Obtain the FRAP coefficients. 
 
3.3.3. Evaluation of the relationship between expression level and FRAP 
coefficients 
 
To assess any relationship between the expression level of the fluorescently 
tagged protein and the FRAP coefficients which could invalidate the results, a 
correlation study must be performed: 
1. With the help of the selection tool in ImageJ, measure the intensity of the 
fluorescence in the cell before the bleaching event. 
2. Plot the overall intensity value against its estimated mobile fraction in a scatter 
plot (see Figure 2D); in a second figure, plot the same value against the 
estimated half-time of recovery. 
3. Calculate the slope of the regression line through the data points. It must not 
be statistically different from 0 with 95 % confidence. 
 
4. Notes 
 
1. Photoreversible bleaching can pose a problem during the quantitative 
analysis of FRAP data and lead to an artefactual measurement of protein 
dynamics. Furthermore, different fluorescent proteins show different rates of 
photoreversible bleaching; therefore comparisons between GFP variants 
within an experiment may give misleading results. Photoreversible bleaching 
can occur in the GFP species on a millisecond time scale (Dickson et al., 
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1997). It is known that YFP species also exhibit photoreversible bleaching, 
which occurs in the timescale of seconds and is dependent on complex 
protonation reactions (McAnaney et al., 2005). The longer time scale 
associated with YFP may become apparent in experiments with short time 
intervals, therefore GFP is usually the preferred option. 
2. Being able to completely bleach the fluorescence emitted by the tagged 
protein is crucial. Theoretically, bleaching using a high-power laser beam can 
be achieved on any fluorescent protein, depending on the availability of the 
appropriate laser line on the microscope system; this should match the 
excitation peak of the targeted molecule. For example, the red fluorescent 
protein (RFP) or its derivative, mCherry (Shaner et al., 2004) may also be 
used for FRAP, however the fluorescence quantum yield is significantly lower 
than that of EGFP and suitable lasers (like the Helium-Neon Orange 594 nm) 
are known to be weak and may not achieve full bleach, therefore the GFP 
variant is preferred. 
3. Ideally, the fluorescent tag should be inserted in at least two different 
positions, for example on the N- and C-termini of the protein separately. The 
localisation of the overexpressed construct should be similar to that of the 
endogenous protein, and concerns about a potential perturbation of the 
function must rise if the FRAP coefficients obtained are significantly different 
between the constructs. Such control experiments can be easily done on 
paraformaldehyde-fixed cells (see Note 11). 
4. In most cases, either transient or stable expression of the fusion protein in 
cells can be performed. Using a stable cell line for FRAP ensures that the 
measurements are more consistent by reducing the variability of expression 
levels (see also 3.3.3). 
5. The Acousto-Optical Beam Splitter (AOBS) is a common feature on more 
recent confocal microscopes, allowing the physical separation of emission 
and excitation light paths with high transmission efficiency. An Acousto-
Optical Tunable Filter (AOTF) allows the rapid alternation between switching 
the laser on and off, and the adjustment of laser lines and their respective 
intensities by modifying the transmission coefficient, as opposed to changing 
the power of the laser emission itself. This component is essential to perform 
automated monitoring and bleaching of the sample over time. 
6. The use of laser-based microscopes is restricted to persons who have been 
 67 
adequately trained and are familiar with the local safety regulations. 
7. We use a temperature and CO2 controlled chamber to provide the optimal 
conditions for live imaging. It is possible to avoid the need for CO2 by using a 
CO2 independent buffered system such as HEPES instead of bicarbonate 
buffer. 
8. Plastic culture dishes and plates are poorly suited for fluorescence studies as 
they exhibit non-stable auto fluorescence (Piruska et al., 2005), therefore 
cells must be transferred to a glass-bottomed dish after transfection. 
9. Other extracellular matrix proteins such as laminin, vitronectin or collagen 
may be required to ensure the spreading of some cell lines. 
10. In order to reduce background fluorescence due to the medium, Ham’s F12 
medium is preferred to DMEM for live imaging as it contains low amount of 
riboflavin and less phenol red. Riboflavin exhibits high autofluorescence in 
the excitation range of 450-490 nm and emission range of 500-560 nm. 
Phenol red has a maximum excitation peak around 555 nm. To further 
minimise the autofluorescence, FRAP experiments are preferably performed 
in low serum or serum-free medium. 
11. Paraformaldehyde (PFA) is a toxic powder that must be handled with care 
using gloves and a respiratory mask in an isolated environment. A 4 % PFA 
solution in PBS (w/v) will dissolve overnight with constant stirring at 50°C. 
The stock solution can be aliquoted and stored at -80°C for a year. Thawed 
aliquots must be kept at 4°C and used within a week. Fixation of cells is 
performed at room temperature for 15 minutes followed by 3 washes in PBS. 
12. MATLAB can be linked to ImageJ through an additional Java package 
created by Daniel Sage and Dimiter Prodanov (Biomedical Imaging Group, 
Swiss Federal Institute of Technology, Lausanne, Switzerland, 
http://bigwww.epfl.ch/sage/soft/mij/) 
13. The expression of the construct in a suitable cell line for the study must be 
monitored by fixing the cells in PFA (see Note 4) at various time points after 
transfection as the expression level and maturation speed of the fluorescently 
tagged protein vary considerably depending on the tag and the cell line. 
Moreover, the delivery of the overexpressed protein in the appropriate cellular 
compartment is another feature that varies, as it is dependant on the renewal 
rate of the endogenous protein. 
14. To equilibrate the sample with the experimental conditions, it should be 
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placed on the microscope stage an hour before the beginning of the 
experiment. 
15. The duration of the recorded recovery should be continued until the intensity 
of fluorescence within the ROI reaches a plateau value. 
16. Real-time autofocus systems can help to compensate for focus drifts due to 
temperature variations for example. 
17. Despite the fact that the parameters will be used to monitor living cells, it is 
more convenient to use a fixed sample (see Note 4) maintained in the same 
conditions as for the live cells. The laser settings for the bleaching event 
should be set to achieve a sufficient decrease in fluorescence within the ROI. 
As a guideline, we consider that the first reading after bleach should be less 
than 20 % of the measurement before the bleaching event. Although, this 
value is subject to discussion as the bleaching illumination must be kept as 
low as possible for two reasons: firstly, to avoid excessive phototoxicity and 
secondly, because the beginning of fluorescence recovery must not overlap 
with the last bleaching iteration. Indeed, the bleaching duration must be 
confined to a limited space (i.e. the ROI) and time (ideally instantaneous) to 
allow accurate measurement. Unfortunately, there is no general rule and it is 
more a case of a trial and error for the user to get the optimal bleaching and 
imaging parameters. 
18. It is crucial to adjust the acquisition parameters of the photomultiplier tube 
(PMT) in order to remain in the dynamic range of intensity acquisition. 
Saturation of fluorescence intensity during the time-lapse will result in 
inaccurate measurements of FRAP coefficients. 
19. On the majority of line scanning confocal microscopes, an option is available 
for bi-directional scanning. This allows the scan head to image the sample in 
both directions along the x-axis and inevitably increases the acquisition rate. 
Additionally, the frame averaging function should be avoided while doing live 
measurements as it leads to a loss of time resolution. 
20. The pinhole value, determined by the numerical aperture of the objective and 
the light wavelength, should ideally be adjustable. For live cell work, the 
pinhole should be opened wide enough to get adequate signal intensity, while 
keeping the laser intensity low to minimise photobleaching and phototoxicity. 
Meanwhile, opening the pinhole affects the resolution by increasing the 
thickness of the optical section. 
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21. The PMT gain value should be around 900-1000 V. A value below 600 V 
means that the laser line intensity can be lowered; conversely it needs to be 
increased if the gain setting is above 1100 V. 
22. If these experiments will be analysed according to the method detailed by 
Sprague et al. (Sprague et al., 2004), the ROI must be circular. 
23. It is necessary to record 3 to 5 frames before the bleaching step to get the 
value of the initial maximum intensity within the ROI. 
24. It is recommended to bleach multiple ROI of identical size for each time 
lapse. Recovery curves obtained from multiple ROI within the same cell 
should be averaged after normalisation to obtain smooth data (see Section 
3.3.2 and Figure 2C). Pooling data is acceptable under these circumstances 
as the level of expressed fusion proteins (i.e. both fractions of bound and free 
molecules) is the same between the different ROI. 
25. Plug-in created by Philippe Thévenaz (Biomedical Imaging Group, Swiss 
Federal Institute of Technology, Lausanne, Switzerland, 
http://bigwww.epfl.ch/thevenaz/stackreg/) 
26. The data have to be corrected for unintentional bleaching that occurs during 
the monitoring phases. Two techniques can be used: the first consists of 
recording the fluorescence intensity within several unbleached regions to the 
one displayed in the bleached ROI. The second technique involves the 
recording of the averaged intensity of the cell. 
27. Discard any sets of data that exhibit any of the following defects: inconsistent 
background fluorescence intensities, unstable prebleach intensities and 
recovery curve that does not exhibit a plateau. 
28. Ezyfit toolbox for MATLAB created by Frederic Moisy, Laboratory FAST, 
University Paris Sud, Paris, France, http://www.fast.u-psud.fr/ezyfit/). 
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7. Figure Legends 
 
Figure 1: Principle of FRAP experiment and example. 
A. Scheme depicting the photobleaching and fluorescence recovery of a region 
of interest (ROI) within a focal adhesion (FA) in a cell; Before the bleach event, 
the fluorescent proteins are uniformly distributed within the structure and are in 
dynamic equilibrium, immediately after photobleaching the equilibrium is lost and 
the fluorescence intensity recovers as fluorescent proteins move back into the 
ROI. This model represents a reaction-dominant recovery, in which diffusion is 
negligible. B. Fluorescence intensity is recorded as a function of time; this 
enables the half-time of recovery (t1/2), and the mobile and immobile fractions (FM 
and FI respectively) to be measured. The fluorescence intensities before and 
immediately after bleaching, are indicated (Finitial and F0 respectively) as well as 
the intensity after recovery (F∞). C. Example of a FRAP experiment on a focal 
adhesion plaque component; FRAP was performed on NIH 3T3 cells transiently 
expressing vinculin-mEGFP. Panels represent still frames taken at the indicated 
timepoints (in seconds), throughout the course of the experiment. Dashed circles 
indicate the bleach ROI, scale bar = 5µm. 
 
Figure 2: Workflow of analysis of FRAP data 
A. Fluorescence intensities extracted from the time-lapse images are individually 
plotted over time to visualise any abnormal behaviour. The intensity recorded 
within several bleached ROI are termed FRAP1, FRAP2 and FRAP3. The 
background readings are termed bgd1, bgd2 and bgd3; and finally, the recording 
for the unintentional bleaching are labelled as ctrl1 and ctrl2. B. After background 
subtraction and correction for the postbleach intensity, the fractional 
fluorescence recovery of the three bleached ROI are plotted over time. The 
intensity of the monitored fluorescence now varies between 1 (prebleached 
value) and 0 (immediatly after the bleach event). C. Multiple fractional 
fluorescence recovery curves acquired in the same cell are averaged and plotted 
with their standard deviation of the mean. The curve is the best fit obtained from 
the experimental data. The main parameters discussed in the text have been 
extracted for these data (see legend). D. A scatter plot is shown here to illustrate 
the absence of correlation between the intensity of fluorescence in the cell, e.g. 
the expression level of the tagged protein, and the mobile fraction over a 4.5 fold 
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range. A similar graph should be plotted with the half-time of recovery and the 
overall fluorescence intensity (see Section 3.3.3). 
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Abstract 
The microtubule (MT) and actin cytoskeletons are fundamental to cell integrity, 
as they control a host of cellular activities. Until recently, studies have 
investigated these cytoskeletal components as separate entities, however, it has 
become increasingly clear that the MT and actin cytoskeletons function in an 
interdependent way. Elucidating how the two components interact will be key to 
our further understanding of fundamental cellular processes such as cell division, 
growth, polarisation and migration. Proteins involved in mediating the crosstalk 
between MT and actin cytoskeletons are fundamental to many cellular processes 
and play important physiological roles. 
Here we describe a new member of the spectraplakin superfamily, GAS2-like 3. 
We show that GAS2-like 3 is widely conserved throughout evolution and is 
ubiquitously expressed in human tissues. GAS2-like 3 interacts with filamentous 
(F) actin and MTs via its single calponin homology type 3 (CH3) domain and C-
terminus, respectively. Interestingly, the role of the putative MT-binding GAS2-
related (GAR) domain is to modulate the binding of GAS2-like 3 to F-actin and 
MTs. This is in contrast to GAR domains found in related proteins, where it 
functions as a MT-binding domain. We find that both MTs and F-actin influence 
GAS2-like 3 localisation, although MTs have a greater influence on this 
localisation. Furthermore, we describe that GAS2-like 3 localisation to MTs can 
be enhanced by tubulin acetylation. 
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Introduction 
The cytoskeleton is fundamental to cellular integrity, providing a molecular 
framework for both mechanical support and an intracellular transport 
infrastructure (Li and Gundersen, 2008). Until recently, the microtubule (MT) and 
actin cytoskeletons have been investigated as separate entities, however, it has 
become clear that the MT and actin cytoskeletons function in an interdependent 
way (Goriounov et al., 2003; Kodama et al., 2003). For example, there is 
evidence to suggest MTs use filamentous actin (F-actin) to guide them from the 
cell interior to focal adhesions at the cell periphery (Wu et al., 2008). 
Understanding how the two components interact will therefore be key to our 
further understanding of fundamental cellular processes, such as cell division, 
growth, polarisation and migration. 
The spectraplakins are a well characterised example of a protein family which 
can crosslink MT and actin cytoskeletons (Jefferson et al., 2004). There are two 
members expressed in mammals, microtubule-actin crosslinking factor 1 
(MACF1 or ACF7) and bullous pemphigoid antigen 1 (BPAG1), both of which are 
huge, multi-domain containing proteins (>500kDa in mass) with binding sites for 
both F-actin via their calponin homology (CH) domains and MTs via their GAS2-
related (GAR) domain and/ or GSR repeats. Ablation of the ACF7 gene in mice 
results in embryonic lethality. However, ACF7 -/- cells can be derived from the 
embryo and display defects in MT dynamics, guidance, cortical tethering, stability 
and cellular polarisation (Kodama et al., 2003). Interestingly, the expression of a 
mini-version of ACF7 consisting of the CH and GAR domains is necessary and 
sufficient to rescue these perturbations in function, implying these are the key 
functional domains of spectraplakins. Accordingly, various medical conditions 
and developmental defects arise as a result of mutations in genes encoding 
spectraplakins, including mental retardation, cancer and chronic skin blistering 
(Sonnenberg and Liem, 2007), which shows the importance of proteins which 
link the actin and MT cytoskeletons. 
Whereas the role of spectraplakins in crosslinking the MT and actin 
cytoskeletons is well established (Kodama et al., 2003; Sun et al., 2001; Wu et 
al., 2008), the functions of the related GAS2 family remain to be determined. 
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The GAS2 family can be thought of as mini-versions of spectraplakins, as they 
too contain a putative actin-binding CH domain and a putative MT-binding GAR 
domain. The first identified member of the GAS2 crosslinking family, termed 
GAS2, was originally identified in a screen looking for genes induced by growth 
arrest (Schneider et al., 1988). GAS2 localises along stress fibers (Brancolini et 
al., 1992) and it may also be involved in apoptosis and tumour suppression 
(Brancolini et al., 1995; Brancolini and Schneider, 1994; Lee et al., 1999). Two 
related family members were identified either in a search for putative tumour 
suppressors (human Gas2-related gene on chromosome 22 (hGAR22) or GAS2-
like 1 (G2L1)) or by sequence similarity to hGAR22 (human Gas2-related gene 
on chromosome 17 (hGAR17) or GAS2-like 2 (G2L2)) (Goriounov et al., 2003; 
Zucman-Rossi et al., 1996). Both transcripts which code for the respective 
proteins are subject to alternative splicing, which result in proteins with different 
localisation and binding properties. The shorter isoforms termed, hG2L1α and 
hG2L2α, predominantly localise to the actin cytoskeleton, and interact with F-
actin in vitro. Conversely, both of the longer isoforms, termed hG2L1β and 
hG2L2β,  localise and bind to both F-actin and MTs (Goriounov et al., 2003), 
suggesting that they may play a role in mediating crosstalk between the 
cytoskeletal systems.  
In the present study, we describe the characterisation of a new family member, 
GAS2-like 3 (G2L3), which has the potential to communicate between MTs and 
actin. G2L3 is widely conserved through evolution, and it is abundant in most 
human tissues, and the majority of cell lines we tested. Full-length G2L3 interacts 
with both F-actin and MTs in cells and in vitro via its CH domain and C-terminus, 
respectively. A third domain, termed the GAR domain, does not directly bind to 
F-actin or MTs, however is involved in modulating the binding strength of G2L3 
to each cytoskeletal system. Interestingly, we found that acetylation of α-tubulin 
contributes to the recruitment of G2L3 to MTs. 
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Results 
GAS2-like 3 is highly conserved amongst species and is widely expressed 
in human tissues 
In order to identify potential actin and MT binding proteins, we performed a 
TBLASTN search for genes containing both CH and GAR domains using GAS2 
as a template. As a proof of principle, we identified GAS2, G2L1, G2L2, MACF1, 
BPAG1, but also an uncharacterised gene, G2L3 (GenBank/ EMBL/DDJB 
accession No. AC_000144). It  has an open reading frame of 2229 base pairs, 
spanning eight exons and encodes a putative protein of 694 amino acids with a 
deduced molecular mass of 75.2 kDa (Figure 1A). The protein sequence consists 
of a single CH3-class, CH domain comprising 122 amino acids at the amino 
terminus, with 24% amino acid identity to the CH domain identified in calponin. 
To the carboxy terminus of the CH domain is an 82 amino acid-long GAR 
domain, which is abutted to a stretch of 404 amino acids that is predicted to have 
little secondary structure. The domain organisation of G2L3 is the same as 
GAS2, G2L1 and G2L2, therefore classifying it as a new member of the GAS2 
protein family. 
We next examined how closely related the members of the human GAS2 family 
were. We discovered G2L3 shared the highest identity to GAS2 (60%), and the 
lowest identities with G2L1 and G2L2 at 30% and 36%, respectively (Figures 1B 
and 1C).  In terms of domain sequence conservation, the CH and GAR domains 
of G2L3 are compared to the other members in Figure 1C.  
In addition to comparing human GAS2 members, we investigated whether G2L3 
homologues are conserved across different species. We found G2L3 
homologues are present in all vertebrates; For example, there is 65% identity 
between the conserved CH and GAR domains belonging to the human G2L3 and 
the zebrafish G2L3 (see Supplementary Table 1). There is also evidence for the 
existence of genes with the same domain architectures in fruit flies, where it has 
been named ‘picked eggs’ (Pigs) (Accession number: NM_132103) (Pines et al., 
2010). A similar protein is expressed in Caenorhabditis elegans, except the CH 
domain has been duplicated (Accession number: NM_069025). Taken together, 
we have discovered a new member of the GAS2 family by searching for genes 
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related to GAS2 that is highly conserved through evolution, which implies it plays 
an important function.  
After confirming G2L3 is widely conserved amongst species, we next sought to 
determine the expression of G2L3 in human tissues and cell lines. Using cDNA 
libraries generated from different human tissues and cell lines, we performed 
PCRs to investigate the respective levels of G2L3 mRNA, and used this as an 
indication of G2L3 protein levels. G2L3 mRNA was widely expressed within the 
body, and was most prominently found in the pancreas, heart, skeletal muscle, 
liver, kidney, placenta and lung, whereas it was expressed at low levels in the 
brain (Figure 2A). As tissues contain many different cell types, we investigated 
whether G2L3 expression was confined to a particular one. We discovered G2L3 
in a wide variety of cell lines, including HeLa, Human Foreskin Fibroblasts, 
Human Embryonic Kidney 293 cells, and we found the murine homologue in 
NIH3T3 cells. Conversely, it was not expressed in HT1080 cells, which are a 
highly transformed cell line (Figure 2B). These data suggest that G2L3 is 
abundantly expressed in many tissues and cell lines. Notably, it is absent in 
HT1080 cells, which may indicate a role in tumour suppression. 
 
The calponin homology domain mediates localisation to actin stress fibres 
and the C-terminus recruits GAS2-like 3 to microtubules 
In order to determine the subcellular localisation of G2L3 and to study the roles 
of its domains in this localisation, we expressed fluorophore-tagged versions of 
G2L3 and a series of G2L3 mutants in NIH3T3 cells. We found that full-length 
G2L3 localised to overlapping MTs and actin stress fibers in 70% of all tested 
cells and G2L3 localised only to MTs in the remaining 25% of cells (Figure 3A, 
Supplementary Movie 1). The localisation to actin was mediated by the CH 
domain, since expression of this domain alone (referred to as G2L3-CH) 
decorated actin stress fibers in all cells (Figures 3B and 3D). In contrast, a 
construct missing the CH domain (G2L3-∆CH) localised predominantly to MTs, 
suggesting that the remaining sequence contained a MT binding site (Figures 3B 
and 3C). The localisation to MTs was mediated by the C-terminus, since 
expression of this domain (G2L3-C-term) localised exclusively to MTs (Figure 
3C). Notably, the MTs appeared to be bundled in 82% of cells expressing G2L3-
C-term. To investigate whether the GAR domain, a domain which has been 
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frequently implicated in MT binding in other proteins (Sun et al., 2001), played a 
role in localising G2L3 to either cytoskeleton, we generated mutants including 
and excluding this domain (G2L3-GAR and G2L3-∆GAR, respectively). We found 
that G2L3-GAR localised diffusely in the cytoplasm in most cells and G2L3-
∆GAR localised along the MT lattice, implying that the GAR domain does not 
regulate G2L3 localisation to MTs or actin (Figure 3C). Interestingly, G2L3-∆C-
term, which lacks the C-terminus but contains both the CH and GAR domains 
localised predominantly to the actin cytoskeleton, albeit to different actin 
structures than G2L3-CH. Specifically, G2L3-∆C-term localised to both 
lamellipodia and filopodia (Figure 3D and Supplementary Movie 2).  
Taken together, these data indicate that the CH domain controls the localisation 
of G2L3 to actin and the C-terminus regulates its localisation to MTs. The GAR 
domain is not essential for localisation to MTs and the bundling of MTs by the C-
terminus may imply that it has the ability to crosslink MTs. 
 
GAS2-like 3 interacts directly with microtubules and filamentous actin 
To determine whether the localisation of the individual domains of G2L3 is 
mediated by direct interactions with the different cytoskeletal systems, we 
performed in vitro co-sedimentation assays using recombinant purified domains. 
We found that purified G2L3-CH co-sedimented with F-actin after high-speed 
centrifugation, indicating they directly interact (Figure 3E). Conversely, G2L3-C-
term remained in the supernatant, implying it fails to directly interact with actin 
(Figure 3E). As controls, the proteins were centrifuged in the absence of 
polymerised actin and both were found in the supernatant, showing they fail to 
sediment alone. A similar assay was performed with MTs, to reveal that G2L3-C-
term interacts directly with MTs (Figure 3F). In contrast, neither G2L3-CH nor 
G2L3-GAR were found in the pellet fraction with MTs, implying neither interact 
directly with MTs (Figure 3F). 
Overall, these data are consistent with the IF data, confirming that the CH 
domain binds to actin, and the C-terminus binds to MTs. These data suggest that 
the GAR domain does not interact with MTs directly in vitro. 
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The individual domains of GAS2-like 3 influence the binding strength to 
microtubules and F-actin 
To study the influence of the different domains of G2L3 on its binding strength to 
F-actin or MTs, we performed Fluorescence Recovery After Photobleaching 
(FRAP) experiments on cells expressing different mutants (Figures 4A and 4B). 
In these experiments we determined the half-time (t1/2) of recovery of the 
different mutants, and used it as an indicator of protein mobility (Humphries et 
al., 2007; Stroud et al., 2011). In comparison to the subpopulation of G2L3 which 
localised to actin, we observed a twofold increase in the t1/2 of recovery of 28.5s 
for G2L3-CH, indicating that the turnover of the CH domain is slower than full-
length G2L3 (Figure 4B). Conversely, G2L3-ΔC-term showed a sixfold decrease 
in t1/2 of recovery of 2.5s compared to G2L3, implying the turnover of G2L3-ΔC-
term is faster and has a weaker interaction with actin than G2L3. These data 
indicate that the removal of the GAR domain and C-terminus amplifies the 
binding strength of the CH domain for actin. Interestingly, the presence of the 
GAR domain alone is sufficient to destabilise the interaction of the CH domain 
with actin. We subsequently analysed the mobility of the various constructs 
which localised to MTs. We discovered that full-length G2L3 and the construct 
lacking the CH domain (G2L3-ΔCH) had the slowest turnovers with t1/2s of 
recovery of 14.9s and 15.3s, respectively. In contrast, the t1/2 of recovery of 
G2L3-C-term was reduced almost fourfold (3.9s) and the t1/2 of recovery of 
G2L3-ΔGAR was more than halved (6s). These data indicate that the CH domain 
does not affect the interaction of G2L3 with MTs, conversely the simultaneous 
removal of both the CH and GAR domains destabilises the interaction of the C-
terminus with MTs. 
These data suggest a critical role for the GAR domain in modulating the binding 
to the different cytoskeletal systems, i.e. it strengthens the interaction with MTs, 
however weakens the interaction with F-actin. 
GAS2-like 3 localisation is dependent on both microtubule and actin 
cytoskeletons 
The presence of both MT and actin binding sites on G2L3 raises the question as 
to whether the binding of G2L3 to one of the cytoskeletons influences the binding 
to the other. To elucidate this, we analysed the localisation of G2L3 in the 
absence of either F-actin or MTs. In 70% of control cells, G2L3 localised to both 
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MTs and F-actin and in 25% of cells it localised exclusively to MTs. Disruption of 
the actin cytoskeleton using cytochalasin D resulted in G2L3 localising more to 
MTs (74% compared to 25% in untreated control cells) (Figures 5A and B). 
These data suggest that F-actin is not required for G2L3 localisation to MTs. 
After treatment of cells with nocodazole to ablate MTs, G2L3 localised diffusely 
in the cytoplasm (36% compared to 5% in control cells). More importantly, G2L3 
localised to the actin cytoskeleton in a small percentage of cells treated with 
nocodazole (4%). Notably, G2L3 localisation was enhanced to nocodazole 
resistant MTs, in a subset of cells. These data imply that MTs aid G2L3 
localisation to F-actin, however they are not fundamental for it. 
In summary, these data suggest that G2L3 is able to localise to both F-actin and 
MTs irrespectively of one another, however the presence of MTs aids G2L3 
localisation to F-actin. 
Post-translational acetylation of tubulin enhances GAS2-like 3 localisation 
to MTs 
The enhancement of localisation of G2L3 to remnant MTs after nocodazole 
treatment, suggests that G2L3 preferentially binds to stable MTs. One way MTs 
can be stabilised against nocodazole is through post-translational (PT) 
modifications of tubulin, such as acetylation (Gundersen et al., 1994). To 
examine this possibility, we treated G2L3-GFP expressing cells with the histone 
deacetylase 6 (HDAC6) inhibitor trichostatin A (TSA), which dramatically 
increases the amount of acetylated α-tubulin. This increase in tubulin acetylation 
lead to a significant 9% increase in G2L3 recruitment to MTs in comparison to 
DMSO treated control cells (Figures 6A and 6C). This increase was not due to 
the possible stabilisation of MTs by the inhibitor per se, since MTs stabilised by 
taxol were not found to increase G2L3 localisation (data not shown). 
In summary, these data suggest that G2L3 localisation may be regulated by 
molecular mechanisms that lead to MT acetylation. 
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Discussion 
Here, we have characterised a new member of the GAS2 family, G2L3, which is 
highly conserved and expressed in many tissues. G2L3 binds to both F-actin and 
MTs via its single CH domain and unstructured C-terminus, respectively. 
Moreover we have shown that the GAR domain can modulate the interaction 
strength of G2L3 with both actin and MTs, and that tubulin acetylation enhances 
G2L3 localisation to MTs. 
A single type 3-calponin homology domain mediates actin binding 
Actin-binding of many prominent proteins such as MACF1 and α-actinin is 
mediated very efficiently by tandem type 1 (CH1) and type 2 (CH2) CH domain 
repeats (Gimona et al., 2002; Roper et al., 2002). The importance of the tandem 
repeat has been highlighted, as the removal of the CH1 domain in MACF1, 
ablates its actin binding ability, despite the remaining CH2 domain (Lee and 
Kolodziej, 2002). 
In contrast to the tandem CH1 and CH2 domain repeats, single CH3 domains 
such as the ones found in calponin and MT-end-binding proteins are considered 
to be inefficient actin binding domains (ABDs) (Gimona et al., 2002; Gimona and 
Mital, 1998). It is hypothesised that CH3 domains serve to locate canonical 
ABDs, for example the CH3 domain on calponin is thought to interact with the 
CH1 domain on α -actinin and bring it in proximity to actin (Galkin et al., 2006; 
Leinweber et al., 1999). Despite this evidence for other CH3 domains, we found 
that the single CH3 domain in G2L3 does indeed function as an ABD, an 
observation which is supported by the other GAS2 family members (Goriounov et 
al., 2003). Interestingly, full-length G2L3 only localises to actin stress fibers in a 
subset of cells, implying that the mechanism of CH3 domain binding to actin, in 
the context of the full-length protein, is tightly regulated. In support of this, our 
FRAP experiments show lower binding strength to actin when the CH domain is 
coupled with the GAR domain and may suggest that the latter domain contains a 
motif that can modulate actin binding. This is further substantiated by F-actin 
sedimentation assays of G2L2, in which actin was less able to sediment G2L2β, 
than the truncated splice-mutant encoding the single CH domain (G2L2α) 
(Goriounov et al., 2003). 
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The C-terminus is essential for efficient microtubule binding 
We discovered that the C-terminus in G2L3 is fundamental for binding to the MT 
cytoskeleton. Given the high degree of similarity between the GAR domain in 
G2L3 and the published MT-binding GAR domains in GAS2 (63% identity) and 
MACF1 (38%), we predicted that the G2L3-GAR domain would interact with 
MTs. Conversely to our hypothesis, we found that the GAR domain in G2L3 
localises very weakly to MTs in cells and is unable to bind to them in vitro. Our 
observations are similar to those described for G2L1 and G2L2 (Goriounov et al., 
2003). This raises an important question as to how the other GAR domains 
mediate this interaction? Initial sequence analyses revealed that the other GAR 
domains have overall positive charges, ranging from +2 to +6, whereas the 
G2L3-GAR has a net charge of zero. As MTs have an overall negative charge, 
one likely possibility is that the GAR domains of other proteins interact 
electrostatically, as has been shown for cationic peptides (Wolff, 1998). Further 
examination of the other GAR domains used to characterise MT binding exposed 
a weakness in construct design. For example, the GAR domain in GAS2 appears 
to be missing a final methionine residue, which is predicted to form part of the 
ultimate alpha helix (Sun et al., 2001). Also, the GAR domain used in a recent 
study on the Drosophila spectraplakin, Shot (Applewhite et al., 2010), lacks the 
first four residues which form part of the initial alpha helix. This study showed 
that the GAR domain localised to MTs very strongly. Both of these published 
GAR domains are likely to fold incorrectly and may act similarly to the positively 
charged and unfolded C-terminus of G2L3. In spite of these observations, it 
appears that the G2L3-GAR domain contributes slightly to MT binding strength 
since our FRAP data suggest that the presence of the GAR domain increases 
the binding strength of G2L3 to MTs. We speculate that the GAR domain in 
G2L3, and indeed in other proteins, interact with MT-associated proteins, which 
modulate binding to the microtubular network.  
Acetylation contributes to GAS2-like 3 recruitment to microtubules 
It has been reported previously that detyrosination and acetylation of α -tubulin 
are hallmarks of MT stabilisation (Gundersen and Bulinski, 1988; Webster and 
Borisy, 1989). We discovered that G2L3 localisation to MTs is enhanced to 
acetylated MTs, which is similar to other MT-interacting proteins such as the 
motor protein, kinesin-1 (Dompierre et al., 2007; Reed et al., 2006). Although the 
 86 
function of this regulation is unclear, parallels can be drawn to the function of 
tubulin detyrosination. Recently it has been shown that detyrosination of α-
tubulin effects the recruitment of proteins which contain a cytoskeleton-
associated protein glycine-rich (CAP-GLY) domain (Mishima et al., 2007). 
Proteins containing these domains include the MT plus-end binding proteins, 
CLIP-170 and p150glued, which can regulate MT dynamics and targeting. Thus, it 
is possible that localised tubulin acetylation can drive recruitment of G2L3 to 
specific loci within the cell, where it then exerts its function. 
The similarity to spectraplakins 
Members of the GAS2 family and the spectraplakins have a similar domain 
organisation, they equally bind to MTs and actin, they both localise similarly in 
cells and they exhibit similar behaviour in response to cytoskeleton-disrupting 
drugs (Karakesisoglou et al., 2000). These findings strongly suggest they may 
have similar functions. ACF7 regulates MT growth as well as the dynamics of 
focal adhesions associated with F-actin (Wu et al., 2008). Targeting of focal 
adhesions by MTs is essential for focal adhesion turnover (Kaverina et al., 1999), 
and disrupting MTs leads to inhibition of cell migration (Ballestrem et al., 2000). 
MTs grow along F-actin and can thus be guided to adhesion sites ((Rodriguez et 
al., 2003); and our observation). In the absence of ACF7, MT growth is unlinked 
from F-actin in epidermal cells, leading to a diminished turnover rate of focal 
adhesions and proteins therein (Wu et al., 2008). Given the potential exciting 
roles the GAS2 family may play in cell motility, future experiments will be 
necessary to clarify whether G2L3 or other members of the GAS2 family exert a 
similar function. With the potential role of stable MTs in migration (Gundersen 
and Bulinski, 1988), one possible avenue of investigation will be into the role of 
tubulin acetylation, and the proteins which mediate this, as they may govern 
G2L3 function. 
 
 
 87 
Materials and Methods 
Cell Culture and Transfections 
All cells were grown in DMEM (Sigma Aldrich, Dorset, UK) supplemented with 
10% FBS, and 1% glutamine in a 5% CO2 in a humidified incubator, and 
passaged in a 1:10 dilution every 3 days. For transfections, cells were plated in 
6-well dishes a day before transfections. For transient transfections, 1-1.5µg of 
DNA in total was transfected into cells using Lipofectamine Plus (Invitrogen, 
Paisley, UK) in accordance with manufacturer’s instructions. Cells were replated 
after 3 hours in glass-bottomed dishes (MatTek Corporation, Ashland, USA) 
coated with 10 µg/mL bovine fibronectin (pFN; Sigma). For drug treatments, cells 
were incubated for 30mins with either nocodazole (10µM), cytochalasin D (2µM), 
or trichostatin A (TSA)  (5µM), (all from Sigma). 
Immunofluorescence Imaging 
Cells were fixed and permeabilised with 3% paraformaldehyde (Sigma) 
containing 0.25% Triton X-100 (Sigma) and 0.05% glutaraldehyde (Sigma) for 15 
mins, before being washed in PBS (Lonza, Verviers, Belgium). Autofluorescence 
from reactive amine groups was quenched using 0.01% sodium tetrahydroborate 
(Sigma) in PBS for 15 mins before being washed in PBS. Subsequently cells 
were incubated for 45 mins with anti-tubulin or anti-acetylated tubulin antibodies 
at 1:500 dilution (DM1A and 6-11B-1, respectively Sigma), followed by three 
washes with PBS. Secondary antibodies conjugated to either Cy2, 3 or 5 
(Jackson ImmunoResearch Laboratories, Suffolk, UK) were then applied for 30 
mins. In the case of colabelling for actin, Texas Red or FITC-labelled phalloidin 
(Invitrogen) was added together with the secondary antibody). Cells were then 
washed three more times in PBS before being imaged using an oil-immersed 
100X objective, with 1.35 numerical aperture on an inverted microscope (IX71; 
Olympus) controlled by a Deltavision system (Applied Precision, Washington, 
USA). Images were captured using a Coolsnap HQ CCD camera (Princeton 
Instruments, Lurgan, UK). 
Fluorescence Recovery After Photobleaching (FRAP) 
An inverted microscope (IX70) equipped with a 488-nm laser lines (Olympus) 
under the control of software (DeltaVisionRT) were used for FRAP experiments. 
Cells plated on glass-bottom dishes and expressing indicated GFP-tagged 
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constructs were imaged at 37°C in Ham’s F12 medium. 1.5-µm-diam regions of 
interest were selected. Half-times of recovery were calculated using softWoRx 
FRAP analysis software (see application notes at 
http://www.api.com/lifescience/dv-pubsandapps.html#appnotes). 
Image Processing 
Images were processed using ImageJ version 1.43R. For colocalisation studies 
and calculation of the ratio of GAS2-like 3  / MTs for TSA analysis, images were 
background subtracted using a 2D-bandpass filter, overlay images were created. 
From these a threshold was set to restrict analyses to MTs, and the outline of the 
cell was drawn followed by measuring the percentage area of positive pixels. 
This was repeated for GAS2-like 3 and divided by the value given for MTs to give 
a ratio theoretically between zero and one. Adobe Photoshop CS4 was used in 
the preparation of figures for this manuscript. 
cDNA panels 
To identify human tissue expression, a “master mix” containing forward and 
reverse primers, dNTPs, reaction buffer and Taq polymerase was made for 
cDNA panels (Clontech, CA, USA). cDNA libraries from various cell lines were 
made using the ‘Absolutely RNA Microprep Kit’ followed by the Stratascript 
QPCR cDNA Synthesis Kit (Stratagene, Cheshire, UK) according to the 
manufacturer’s recommendations  A “master mix” was also made to identify 
expression in the cell lines; HeLa, Human Foreskin Fibroblast (HFFs), HT1080, 
Human Embryonic Kidney 293T and murine NIH 3T3. The total reaction volume 
for each reaction was 25µL, they were incubated at 94ºC for 1 minute,  followed 
by 35 cycles of  30 seconds at 94 ºC (denaturation), 30 seconds at 55 ºC 
(annealing) and 60 seconds at 72 ºC (extension). The reaction products were 
subsequently run on a 1% agarose (w/v) gel for an hour at 120V. 
Sub-cloning 
For immunofluorescence, the CH domain, ΔC-term, ΔGAR, and ΔCH constructs 
were cloned into pEGFP-N1 or mCherry-N1 vectors (Clontech) using the 
restriction endonucleases NheI and HindIII at the amino acids indicated in Figure 
1A. The other constructs were all cloned into the pEGFP-C1 vector (Clontech) 
using the restriction endonucleases BspEI and BamH1 for GAS2-like 3, EcoR1 
and BamHI for the GAR domain, and BamH1 for the C-terminus.  
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For recombinant expression in E. coli, the CH domain and C-terminus were 
cloned into the pHisTrx vector (Kammerer et al., 1998) using either the restriction 
endonucleases BamHI and EcoRI or BamHI, respectively. The GAR domain was 
cloned into pHisNusA vector using the same restriction sites as for 
immunofluorescence. All recombinant insert DNA was verified by DNA 
sequencing. 
Protein expression and purification 
The recombinant GAS2-like 3 constructs were expressed in E. coli JM109 (DE3) 
host strain (Merck Biosciences, Nottingham, UK) as previously described 
(Kammerer et al., 1995) using an autoinduction protocol (as described by 
(Studier, 2005)). The 6xHis-tagged proteins were purified by immobilised metal 
affinity chromatography on Ni2+-Sepharose (GE Healthcare, Bucks, UK). 
Purification was performed under denaturing condition using 8 M urea as 
described in the pET system manual (Merck Biosciences). Removal of the 6xHis 
tags by thrombin from the CH domain and C-terminus was performed as 
previously described (Kammerer et al., 1995). Determination of protein 
concentration was achieved by the absorbance of tryptophan and tyrosine 
residues at 280 nm (Edelhoch, 1967). 
In-vitro sedimentation assays 
Actin and MT-binding assays were performed using the Non-Muscle Actin 
Binding Protein Spin-Down Biochem Kit (Cytsokeleton, Inc., CO, USA) and the 
Microtubule Associated Protein Spin-Down Assay Kit (Cytoskeleton, Inc.) 
respectively, according to the manufacturer’s recommendations. Briefly, the 
proteins were pre-spun before the experiment, they were then incubated with the 
polymerised forms of either F-actin or MTs, followed by a high-speed 
centrifugation step. The supernatents were aspirated and boiled in SDS sample 
buffer and the pellets resuspended in SDS sample buffer. Following which, the 
samples were analysed on 10% SDS-PAGE gels for the GAR domain and C-
terminus and 15% SDS PAGE gels were used for the CH domain. All protein 
bands were visualised using Coomassie blue staining. 
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Sequence alignments 
Sequence alignments were performed using the program Jalview (Clamp et al., 
2004) 
Statistical analysis 
Using the ratios obtained from the image processing, Student’s t-tests were 
performed using Microsoft Excel to compare the ratios of G2L3 expressing 
control cells and TSA treated G2L3 expressing cells. 
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Figure Legends 
Figure 1: Schematic representation of the intron-exon boundaries of the 
G2L3 gene and the sequence alignments of the human GAS2 protein 
family. (A) The G2L3 gene consists of eight exons interspersed by seven 
introns. The CH and GAR domains are depicted in red and yellow, respectively, 
and the C-terminus in green. (B) Sequence alignment of the GAS2 family, 
showing the conservation between the amino termini of the GAS2 family 
members. The beta isoforms of G2L1 and G2L2 are shown. Note the high 
degree of conservation between family members. (C) The percentage identities 
between G2L3 and the other GAS2 family members are indicated, as well as the 
percentage identities between the various domains.  
Figure 2: G2L3 is expressed ubiquitously in human tissues and cell lines. 
(A) PCRs were performed on cDNA panels generated from different tissues, 
using primers specific for G2L3, which spanned exon 2 to exon 6. Primers 
designed specifically to recognise β-actin were used as loading controls. (B) 
PCRs were performed using cDNA libraries generated from different cell lines. 
The human tissues, human cell lines (HeLa, HT1080, HFF, HEK293) and mouse 
cell line (NIH 3T3) are indicated above each panel, the sizes of DNA are 
indicated on the left side of the panel in base pairs (bps), and the expected PCR 
product sizes are indicated by arrowheads. Note the low expession of G2L3 in 
brain tissue and its absence in the HT1080 cell line. Data are representative of 
three independent experiments. 
Figure 3: G2L3 binds and localises to both MT and actin cytoskeletons. 
(A,C,D), G2L3 constructs were transiently expressed in NIH3T3 cells, followed 
by fixation and staining using an antibody which recognises α -tubulin (DM1A; 
(Blose et al., 1984) and phalloidin to label actin. (A) G2L3 localises to both 
filamentous actin (white arrowheads) and MTs cytoskeletons (white arrows); (B) 
G2L3 constructs that were expressed as fusion constructs to GFP or mCherry 
(mCh) in NIH3T3 cells: (C) G2L3-CH (CH) and G2L3-ΔC-term (ΔC-term) localise 
to F-actin structures; (D) G2L3-ΔCH (ΔCH), G2L3-ΔGAR (ΔGAR) and G2L3-C-
term (C-term) all localise to MTs and G2L3-GAR (GAR) localises diffusely in the 
cytoplasm. (E) Actin-binding assays were performed using recombinant versions 
of G2L3-CH (CH) and G2L3-C-term (C-term), showing that the CH domain 
directly binds F-actin, whereas the C-term does not. (F) MT-spin down assays 
were performed using G2L3-CH (CH) and G2L3-GAR (GAR) as well as G2L3-C-
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term (C-term), showing that only G2L3-C-term directly interacts with MTs in vitro. 
Both immunofluorescence and binding assay data are representative of three 
independent experiments. Bars, 10µm. 
Figure 4: The individual domains of G2L3 influence the binding strength to 
microtubules and actin. To assess the turnover of indicated proteins in NIH3T3 
cells, circular areas of 1.5-µm diameter were bleached, and recovery was 
measured. (A) FRAP experiments performed on the actin localising constructs. 
Note the slower fluorescence recovery of bleached areas in G2L3-CH (CH) 
expressing cells and much faster recovery in G2L3-ΔC-term expressing cells 
compared to areas in G2L3 expressing cells. (B) FRAP experiments peformed 
on MT localising constructs. Note the similar fluorescence recovery of bleached 
areas in cells expressing G2L3 and G2L3-ΔCH. Conversely, the fluorescence 
recovers faster in the bleached areas in G2L3-ΔGAR and G2L3-C-term 
expressing cells. Either the prebleach (PRE) or the time in seconds is indicated 
in the bottom right hand corner of each image, and the encircled areas indicate 
the bleach regions. (C) The t½s of recovery of the actin binding constructs are 
labelled in red, and the MT binding constructs in blue. Note the t½ of recovery of 
G2L3-CH is almost double that of G2L3, and the t½ of recovery of G2L3-ΔC-term 
is much faster than G2L3. In accordance with (B), the t½ of recovery of G2L3-
ΔCH is similar to G2L3, whereas G2L3-ΔGAR and G2L3-C-term have much 
faster t½s of recovery. Data represent the results from more than n=20 bleach 
regions from n=10 cells. 
Figure 5: The integrity of neither actin, nor MTs is a prerequisite for G2L3 
localisation to MTs or actin cytoskeletons, respectively. (A) NIH3T3 cells 
expressing G2L3 were either treated with 10µM nocodazole (NOC) or 2µM 
cytochalasin D for 30 mins (CYTO D) to determine their effects on G2L3 
localisation. Note that G2L3 can localise to stable MTs (white arrows) and actin 
filaments (white arrowheads) after NOC treatment. Whereas G2L3 predominantly 
localises to MTs (white arrows) after treatment of cells with CYTO D. (B) The 
sub-cellular localisation of G2L3 in cells was quantified after treatment with 
nocodazole or cytochalasin D. Note that G2L3 localises diffusely in a greater 
proportion of cells after NOC treatment, whereas G2L3 localises to MTs in more 
cells after CYTO D treatment. More than 50 cells were counted for each 
treatment. 
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Figure 6: Post-translational acetylation of tubulin enhances G2L3 
localisation to MTs. (A) NIH3T3 cells expressing G2L3-GFP were treated with 
trichostatin A (TSA), and were fixed and costained using antibodies directed 
against α -tubulin (DM1A) and  acetylated α -tubulin (6-11B-1, (LeDizet and 
Piperno, 1991)). (B) G2L3 and MT images were passed through a FFT-2D 
bandpass filter and background subtracted. The resulting image was thresholded 
to MTs, and the cell outline drawn. Following which, the area fraction for G2L3 
positive pixels and MTs were recorded, and the ratio between G2L3: MTs was 
calculated. (C) The enhancement of G2L3 to MTs was quantified as in (B), to 
show that G2L3 localisation was enhanced to MTs after treatment of TSA. More 
than 50 cells were counted for each condition, (p<0.01, student’s t-test). 
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Figure 1: Schematic representation of the intron-exon boundaries of the G2L3 gene and 
the sequence alignments of the human GAS2 protein family. 
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Figure 2: G2L3 is expressed ubiquitously in human tissues and cell lines. 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
Figure 3: G2L3 binds and localises to both MT and actin cytoskeletons. 
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Figure 4: The individual domains of G2L3 influence the binding strength to MTs and actin 
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Figure 5: The integrity of neither actin, nor MTs is a prerequisite for G2L3 localisation to 
MTs or actin cytoskeletons, respectively.  
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Figure 6: Post-translational acetylation of tubulin enhances G2L3 localisation to MTs.  
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Supplementary Figure Legends: 
Supplementary Figure 1: Percentage identities between other family members. 
The percentage identities between GAS2 and G2L1 and the other GAS2 family 
members are indicated, as well as the percentage identities between the various 
domains.  
Supplementary Table 1: Listing the percentage identity of the CH and GAR 
domains combined between hG2L3 and its homologues. Note the conservation of 
G2L3 between species, and that its zebrafish homologue exhibits 65% amino acid 
identity. 
Supplementary Movie 1: Deconvolved stack of NIH 3T3 cells expressing G2L3-CH. 
NIH3T3 cells expressing G2L3-CH (green) were fixed and stained for MTs (blue) and F-
actin (red). Image stacks were taken through the z-axis every 0.2µm, and were 
deconvolved using Deconvolve 3D software (Applied precision, Preston, UK). Playback 
of the deconvolved stack is at 8 frames per second. 
Supplementary Movie 2: Deconvolved stack of NIH 3T3 cells expressing G2L3-ΔC-
term. NIH3T3 cells expressing G2L3-ΔC-term (green) were fixed and stained for MTs 
(blue) and F-actin (red). Image stacks were taken through the z-axis every 0.2µm, and 
were deconvolved using Deconvolve 3D software (Applied precision, Preston, UK). 
Playback of the deconvolved stack is at 8 frames per second. 
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Supplementary Figure 1: Percentage identities between other family members 
 
 
 
 
Supplementary Table 1: Listing the percentage identity of the CH and GAR domains 
combined between hG2L3 and its homologues. 
 
 
 
 
 
 
 
 
 
 
Species 
% AA identity to 
hG2L3 
Pan troglodytes (Chimpanzee) 100 
Bos taurus (Cow) 96 
Mus musculus (Mouse) 93 
Rattus norvegicus (Rat) 93 
Gallus gallus (Chicken) 87 
Danio rerio (Zebrafish) 65 
 106 
5) Results chapter 3 
Functional characterisation of a novel binding partner, end-
binding protein 1 (EB1) to GAS2-like 3 
 
Matthew J Stroud, Christoph Ballestrem* and Richard Kammerer* 
Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, 
University of Manchester, M13 9PT. UK 
 
* Correspondence should be addressed to Chistoph Ballestrem or Richard 
Kammerer 
Wellcome Trust Centre for Cell Matrix Research 
Faculty of Life Sciences, University of Manchester 
Michael Smith Building, Oxford Road 
Manchester, M13 9PT, United Kingdom 
Phone: +44 (0) 161-275-1708 
Fax: +44 (0) 161-275-1505 
 
Email: 
christoph.ballestrem@manchester.ac.uk 
richard.kammerer@manchester.ac.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 107 
 
Abstract 
Proteins involved in mediating the crosstalk between microtubule (MT) and actin 
cytoskeletons are fundamental to many cellular processes and play important 
physiological roles. We recently identified and characterised a new member of 
the spectraplakin superfamily, termed GAS2-like 3. GAS2-like 3 interacts with 
both MTs and F-actin, thus making it a good candidate to mediate 
communication between the two cytoskeletons. Here, we show that the MT-
binding domain of GAS2-like 3 contains two binding motifs for the MT plus-end 
binding protein 1, a master regulator of MT dynamics, EB1. We characterise EB1 
as a new and bona fide interaction partner of GAS2-like 3, which interacts with 
the C-terminus of G2L3 with a high binding strength in vitro. Furthermore, we 
describe a molecular mechanism in which EB1 regulates the recruitment of both 
full-length G2L3 and the C-terminus of G2L3 to MTs in cells. Interestingly we 
found that the complete C-terminus of G2L3 is required to interact with EB1, 
rather than the specific EB1 binding motifs themselves. 
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Introduction 
The integrity of microtubule (MT) and actin cytoskeletons is fundamental to 
cellular integrity, as they provide a molecular framework for both mechanical 
support and an intracellular transport infrastructure (Li and Gundersen, 2008). As 
well as the integrity of the cytoskeleton, crosstalk between MTs and actin is 
essential for normal cellular function. Prominent candidates for this role are the 
spectraplakins, as they have the ability to crosslink MTs and actin (Kodama et 
al., 2003; Leung et al., 1999; Wu et al., 2008). Spectraplakins are multi-domain 
containing proteins with binding sites for both filamentous actin (F-actin) via their 
calponin homology (CH) domains and MTs via their GAS2-related (GAR) domain 
and/ or GSR repeats. Knockout studies performed on the mammalian 
spectraplakin, MT-actin crosslinking factor 1 (MACF1), in mice result in 
embryonic lethality. Despite this, MACF1 -/- cells can be derived and display 
defects in MT dynamics, guidance, cortical tethering, stability and cellular 
polarisation (Kodama et al., 2003). Surprisingly, the expression of a mini-version 
of MACF1 consisting of the CH and GAR domains is necessary and sufficient to 
rescue these perturbations in function, implying these are the key functional 
domains of spectraplakins. Various medical conditions and developmental 
defects arise as a result of mutations in genes encoding spectraplakins, including 
mental retardation, cancer and chronic skin blistering (Sonnenberg and Liem, 
2007), which displays the underlying importance of proteins that link the actin 
and MT cytoskeletons.  
Related to the spectraplakins, is the GAS2 family, which belong to the 
spectraplakin superfamily. The GAS2 family consists of four members, namingly; 
GAS2, GAS2-like 1 (G2L1), GAS2-like 2 (G2L2), and the recently described 
GAS2-like 3 (G2L3) (Stroud et al., 2010, manuscript submitted). GAS2 members 
can be thought of as mini-versions of spectraplakins, as they all contain a 
putative actin binding CH domain, a putative MT-binding GAR domain, however 
they lack the bulky plakin and spectrin repeats. Thus, members of the GAS2 
family are also good candidates to mediate crosstalk between MTs and actin. A 
study performed on G2L1 and G2L2 (Goriounov et al., 2003), as well as our 
recent observations for G2L3 support this speculation. We discovered that G2L3 
binds to MTs and actin via its carboxy (C)-terminus and CH domain, respectively. 
In a quarter of all cells analysed, G2L3 exclusively localised to MTs, and we 
showed that the C-terminus was the driving force behind the localisation to MTs -
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(Stroud et al., 2010, manuscript submitted). Interestingly, the C-terminus of G2L3 
has no predicted secondary structure, which may mediate structural interactions 
with MTs, nor any obvious MT-localisation signals, such as cytoskeleton 
associated protein-Glycine rich (CAP-GLY) domains, tumour overexpressed 
gene (TOG) domains or WD40-repeats as found in other MT-associated proteins 
(MAPs) (Akhmanova and Steinmetz, 2008). However, one noticeable factor 
about the C-terminus of G2L3, is the large number of basic and serine-rich 
stretches of amino acids. In this regard, the C-terminus of G2L3 is similar to 
MAPs including the MT plus-end binding proteins (+TIPS), adenopolyposis coli 
(APC), cytoskeletal-linker protein-associated proteins (CLASPs) and the 
spectraplakins (Akhmanova and Steinmetz, 2008). It has recently been shown 
that a stretch of basic and serine-rich residues, incorporating the amino acids 
Ser/Thr-Xaa-Ile/Leu-Pro, termed the MT-tip localisation signal (MtLS) is 
important for interactions with MT-end-binding protein 1 (EB1) (Honnappa et al., 
2009).  
The Drosophila spectraplakin short-stop (Shot) contains two MtLSs at its C-
terminus, which interact with EB1. These interactions are hypothesised to be 
important when Shot is in its inactive form in the cell interior and the growing MT 
plus-ends are undergoing a ‘search and capture’ mechanism for an activation 
signal to engage with actin. Upon activation, Shot undergoes a conformational 
change to release EB1 and to engage with F-actin via its CH domains, and the 
MT lattice via its GAR domain. When engaged with both cytoskeletons, Shot 
stabilises MTs against lateral movements driven by motor proteins, and guides 
them along F-actin in the cell periphery (Applewhite et al., 2010). This study 
suggests that Shot only binds EB1 in the cell interior, however, another study 
suggests that the interaction between the mammalian spectraplakin, MACF1 and 
EB1 occurs throughout the cytoplasm from the cell interior to peripheral focal 
adhesions (FAs), and is necessary for the MT-actin crosslinking (Wu et al., 
2008). In the latter study, an actin-dependent ATPase activity was identified in 
MACF1 and was found to be essential to recover defects in cell migration in 
MACF1 null cells. The ATPase activity of MACF1 is thought to be essential to 
target MTs to FAs for remodelling, which is fundamental for effective cell 
migration.  
While the specific mechanisms of action of these proteins remain to be resolved, 
it is well established that both of these spectraplakins can interact with EB1 
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through their MtLSs. The MtLS is thought to be key in mediating the interaction 
between a wide variety of binding partners and the EB-homology domain of EB1 
(Honnappa et al., 2009; Honnappa et al., 2005).  
Further examination of the C-terminus of G2L3 revealed that similarly to 
spectraplakins, G2L3 also contains two MtLSs used by spectraplakins to interact 
with EB1. Subsequently, we found that all members of the human GAS2 family 
contain one or more copies of the MtLS. Using G2L3 as a model protein of the 
GAS2 family, we tested whether EB1 can interact with G2L3 and used this model 
to resolve a number of other underlying questions including: 1) Does the C-
terminus of G2L3 interact with EB1 directly? 2) If so, can EB1 regulate the 
localisation of G2L3 to MTs, and 3) which part of the C-terminus is required for 
this interaction? 
In this study we reveal that G2L3 contains 2 MtLSs (SKLP and TLLP) on its C-
terminus, which contribute to its interaction with EB1 directly in vitro and in cells. 
We uncover a molecular mechanism in which this interaction with EB1 drives 
G2L3 localisation to MTs in cells, and that the C-terminus can partially tip-track 
at the plus ends of MTs. Furthermore we identify that the whole of the C-
terminus is required for the interaction with EB1. 
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Results 
Expression and purification of the GAS2-like 3 and End Binding Protein 1 
C-termini 
Sequence analysis of the G2L3-C-terminus (G2L3-C-term) revealed two MTLSs 
(SKLP and TLLP), as highlighted in Figure 1A. In order to verify whether G2L3-
C-term interacts with EB1, we expressed both proteins recombinantly in E. coli. 
We expressed G2L3-C-term as a 6X-Histidine-thioredoxin fusion protein, in order 
to allow purification and increase the solubility of the protein, respectively 
(Kammerer et al., 1998). The C-terminus of EB1 was expressed as a GST-fusion 
protein (termed GST-EB1-C-T), containing a coiled-coil (CC) region abutted to 
the EB-homology domain (EBH), which is thought to bind to MtLSs (Figure 1B) 
(Honnappa et al., 2009). 
Initial attempts to express G2L3-C-term at 37°C in JM109 (DE3) E. coli produced 
low amounts of full-length G2L3-C-term, and high amounts of degradation 
products. We accounted for the large amounts of degradation products as G2L3-
C-term has no predicted secondary structure, thus can be readily cleaved by 
proteases (data not shown). To try and minimise the degradation products, we 
expressed G2L3-C-term in BL21-CodonPlus (DE3) E. coli, which are deficient in 
the Lon and OmpT proteases and can cleave recombinant proteins. These 
bacteria also contain extra copies of the argU, ileY and leuW tRNA genes, which 
helped to overcome the problem of expressing the rare-codon containing G2L3-
C-term. This significantly increased the amount of full-length G2L3-C-term 
expressed, enabling us to use it for the subsequent experiments (Figure 1C). 
Conversely, we were able to express GST-EB1-C-T in large amounts, owing to 
its high solubility. The GST fusion was subsequently cleaved at an engineered 
thrombin cleavage site to produce EB1-C-term. The high degree of solubility and 
lack of degradation imply this protein was correctly folded (Figure 1C). 
  
The C-terminus of GAS2-like 3 interacts directly with End Binding Protein 1 
in vitro with high binding strength 
In order to test whether G2L3-C-term interacts with EB1, we performed 
glutathione-S-transfererase (GST) pulldown assays using GST-EB1-C-T as bait. 
We found that GST-EB1-C-T specifically pulls down G2L3-C-term, as they co-
elute in the elution fraction (Figure 2A). In contrast, G2L3-C-term is not pulled-
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down when incubated with glutathione beads alone, which shows that the 
interaction is specific for EB1. To validate the pull-down data and obtain an 
estimation of the binding strength, we performed solid phase binding assays 
(SPBAs). When G2L3-C-term was plated, a large increase in binding of GST-
EB1-C-T was observed at very low concentrations, which reached a plateau at 
27nM and gave an estimate of kd of 2.1nM (Figure 2B). We also performed the 
reciprocal SPBA by plating EB1-C-term, and found that it also interacts with a 
high binding strength  (estimated kd=77nM) (data not shown). 
These data suggest that G2L3-C-term and EB1-C-term interact in vitro with a 
high binding strength. It is interesting to note that the estimated kd is 1000-fold 
higher than the levels for other EB1-interacting proteins. This may be due to the 
presence of two EB1-binding motifs rather than one, which aids cooperative 
binding. 
 
End Binding Protein 1 enhances localisation of GAS2-like 3 to 
microtubules 
To investigate the function of the interaction between EB1 and G2L3 in cells, we 
co-expressed them in cells in order to determine whether G2L3 localisation was 
affected. We observed a dramatically enhanced recruitment of G2L3 to MTs 
(Figure 3A). We found this effect was specific for EB1, as we did not observe a 
shift of G2L3 localisation when MTs were artificially stabilised using taxol, 
compared to control cells (Figure 3A). Interestingly, the varying expression levels 
of EB1 did not appear to affect G2L3 localisation (data not shown). To quantify 
the enhanced localisation, we first passed the raw image of either G2L3 or MTs 
through a Fast Fourier Transform Bandpass Filter, followed by subtracting the 
background and thresholding the image to MTs (Figure 3B). Each cell was 
subsequently outlined, and the area fraction was measured, which gives the 
percentage positive pixels for the thresholded area. The area fraction value for 
the G2L3 image was divided by the corresponding value for the MT image to 
obtain a ratio of positive pixels (Figure 3B). This ratio was significantly higher 
(p<0.001 using the student’s t-test) for EB1 cotransfected cells (0.74) than G2L3 
expressing control cells (0.48) or G2L3 expressing cells treated with taxol (0.49) 
(Figure 3C). 
These data suggest that EB1 specifically governs G2L3 localisation in cells, and 
this spatial regulation may control G2L3 function. 
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The localisation of the GAS2-like 3 C-terminus is regulated by End Binding 
Protein 1 and shows evidence of tip-tracking 
To demonstrate the interaction of G2L3 with EB1 was mediated by the G2L3-C-
term in cells, we co-expressed G2L3-C-term and EB1 in cells. Similarly to the 
result for G2L3, we observed a dramatic enhancement of G2L3-C-term to MTs 
(Figure 4A). As for G2L3, this effect was specific for EB1, and the ratio of 
positive pixels G2L3-C-term : MTs, (0.71) was significantly enhanced compared 
to control (0.58) or taxol treated cells (0.56) (p<0.001, student’s t-test) (Figure 
4B). 
Other proteins that interact with EB1 have been shown to tip-track at the plus 
ends of MTs (Applewhite et al., 2010; Wu et al., 2008). To determine whether 
G2L3-C-term can tip-track we performed live cell imaging on cells expressing 
both G2L3-C-term and EB1. We found evidence that G2L3-C-term can tip-track 
distal to EB1, however this was not as robust as EB1 tip-tracking (Figure 4C). 
This may be due to the additional direct interaction of G2L3-C-term with MTs 
(Stroud et al., 2010, manuscript submitted). 
These data suggest that G2L3 interacts with EB1 through its C-terminus in cells, 
driving it to MT plus-ends where it may interact with other +TIPs. 
 
The complete GAS2-like 3 C-terminus is required to interact with EB1 
In order to elucidate the key amino acids which mediate the interaction of G2L3 
with EB1, we generated two G2L3-C-term mutants in which the EB1-binding 
motifs were either included or excluded to perform localisation and pull-down 
experiments (Figure 5A). Two mutants were synthesised to encode either the 
first half of G2L3-C-term (termed G2L3-CT1), which contains both MtLSs, or the 
second half, which lacks the MtLSs (termed G2L3-CT2). As a proof of principle, 
G2L3-C-term localised to MTs and was pulled down from cell lysates using GST-
EB1-C-T (Figures 5B and C). Conversely, neither of the truncation mutants 
G2L3-CT1 and G2L3-CT2 localised to MTs in cells (Figure 5B), furthermore 
neither were pulled down using GST-EB1-GST (Figure 5C).  
These data suggest that the whole of the C-terminus of G2L3 is required in order 
to interact with EB1. It is plausible that an as-of-yet unidentified EB1 binding site 
is abrogated by splitting the C-terminus into its two constituent halves. 
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Discussion 
Here we have characterised the MT plus-end binding protein, EB1, as a new 
binding partner of the MT-actin binding protein, G2L3. EB1 directly interacts with 
the C-terminus of G2L3 and regulates the recruitment of G2L3 to MTs. We show 
that the complete C-terminus is required for binding to EB1 rather than the 
specific EB1-binding motifs themselves. 
G2L3 shares a high degree of similarity to the spectraplakins, we thereby 
classified it as a new member of the spectraplakin superfamily (Stroud et al., 
2010, manuscript submitted). There is a notable resemblance between the C-
termini of G2L3 and spectraplakins, as they all contain putative EB1 binding 
sites. The human, mouse, and Drosophila spectraplakins, MACF1, ACF7 and 
Shot, respectively, all interact with EB1 via their C-termini (Applewhite et al., 
2010; Kodama et al., 2003; Slep et al., 2005). However, they display subtle 
differences in sub-cellular localisation to the C-terminus of G2L3. 
Both the C-terminus of the Drosophila homologue, Shot, as well as full-length 
Shot localise to MT plus-ends and can robustly tip-track (Applewhite et al., 
2010). The MtLSs in Shot are crucial for this interaction with MTs and for plus-
end tracking, presumably via EB1. In contrast to Shot, we found that the two 
MtLSs in G2L3 were neither essential for MT localisation nor EB1-interaction. In 
fact G2L3 requires the entirety of its C-terminus for both MT localisation and EB1 
interaction. To explain this we propose the following scenarios: The first of which 
could be that phosphorylation of serine or threonine residues in the vicinity of the 
MtLSs inhibits the interaction with EB1. In support of this, both the MtLSs on 
G2L3 are surrounded by putative phosphorylation sites for glycogen synthase 
kinase 3β (GSK3β). GSK3β is known to phosphorylate the plus-tips, APC and 
the CLASPs (Akhmanova and Steinmetz, 2008), which abrogates their 
localisation to MTs, presumably by inhibiting their interaction with EB1 
(Honnappa et al., 2009). Therefore, it is possible GSK3β phosphorylated the 
G2L3-CT1 and G2L3-CT2 mutants at different levels, to modulate their binding 
strength to EB1. Alternatively, splitting the C-terminus into two halves could 
destroy an unidentified EB1 binding motif. Whereas the roles of MtLSs in binding 
to EB1 have been well documented, other uncharacterised EB1-binding motifs 
exist. For example, diaphanous-related formin, mDia2, binds to EB1 via an 
unknown mechanism (Wen et al., 2004). In concomitance with mDia2, it is 
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apparent that some EB1-binding motifs remain elusive and their elucidation will 
require further investigation. 
We speculated previously that G2L3 may serve to guide MTs along actin stress 
fibers and target them to focal adhesions (FAs) (Stroud et al., 2010, manuscript 
submitted), as is observed for the spectraplakin, ACF7 (Wu et al., 2008). This 
guidance would be mediated by a static interaction between the F-actin and MTs 
via its CH domain and C-terminus, respectively. However, one caveat of this 
static cross-linking is the explanation of how MTs are targeted to FAs, which are 
constantly moving away from actin stress fibers? We now have evidence to 
support a dynamic interaction between G2L3 and MT plus-ends via EB1, which 
would enable G2L3 to target MTs to FAs and subsequently regulate their 
turnover. As well as a possible role in regulating FA dynamics and cell migration 
during interphase, the interaction with EB1 opens a plethora of possible 
functions, including regulation of the kinetochore during mitosis (Tirnauer et al., 
2002). The high number of putative phosphorylation sites in the C-terminus 
suggests that phosphorylation of G2L3 may regulate its interaction with EB1. 
Further work will be necessary to establish whether G2L3 localisation is 
dependent on phosphorylation, and the functional significance of the interaction 
between G2L3 and EB1. 
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Materials and Methods 
Cell Culture and Transfections 
All cells were grown in DMEM (Sigma Aldrich, Dorset, UK) supplemented with 
10% FBS, and 1% glutamine in a 5% CO2 in a humidified incubator, and 
passaged in a 1:10 dilution every 3 days. For transfections, cells were plated in 
6-well dishes (for immunofluorescence) or 10cm petri dishes (for large scale) a 
day before transfections. For small and large-scale transient transfections, 1-
1.5µg or 8µg of DNA respectively, was transfected into cells using Lipofectamine 
Plus (Invitrogen, Paisley, UK) in accordance with manufacturer’s instructions. For 
immunofluorescence, cells were replated after 3-4 hours in glass-bottomed 
dishes (MatTek Corporation, Ashland, USA) coated with 10 µg/mL bovine 
fibronectin (pFN; Sigma). For treatment with taxol, cells were incubated for 30 
mins with 10µM paclitaxel (Sigma). For pulldown experiments, cells were 
washed thrice in PBS, and once in complete DMEM, and left overnight before 
lysis the following day. 
Fixed immunofluorescence Imaging 
Cells were fixed and permeabilised with 3% paraformaldehyde (Sigma) 
containing 0.25% Triton X-100 (Sigma) and 0.05% glutaraldehyde (Sigma) for 15 
mins, before being washed in PBS (Lonza, Verviers, Belgium). Autofluorescence 
from reactive amine groups was quenched using 0.01% sodium tetrahydroborate 
(Sigma) in PBS for 15 mins before being washed in PBS. Subsequently cells 
were incubated for 45 mins with anti-tubulin at 1:500 dilution (DM1A, Sigma), 
followed by three washes with PBS. Secondary antibodies conjugated to either 
Cy2, 3 or 5 (Jackson ImmunoResearch Laboratories, Suffolk, UK) were then 
applied for 30 mins. In the case of colabelling for actin, Texas Red or FITC-
labelled phalloidin (Invitrogen) was added together with the secondary antibody). 
Cells were then washed three more times in PBS before being imaged using an 
oil-immersed 100X objective, with 1.35 numerical aperture on an inverted 
microscope (IX71; Olympus) controlled by a Deltavision system (Applied 
Precision, Washington, USA). Images were captured using a Coolsnap HQ CCD 
camera (Princeton Instruments, Lurgan, UK). 
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Live-cell Imaging 
Cells were washed thrice in PBS, and DMEM was replaced with pre-warmed 
Ham’s F12 medium supplemented with 25mM HEPES, 1% L-glutamine, 1% 
penicillin/ streptomycin and the pH was adjusted to 7.3 with NaOH. Cells were 
imaged using an oil-immersed 100X objective, with 1.35 numerical aperture (NA) 
on an inverted microscope (IX71; Olympus) controlled by a Deltavision system 
(Applied Precision, Washington, USA). Movies were captured using a Coolsnap 
HQ CCD camera (Princeton Instruments, Lurgan, UK). 
 
Image Processing 
Images were processed using ImageJ version 1.43R. For colocalisation studies 
and calculation of the ratio of G2L3 / MTs for EB1 analysis, images were 
background subtracted using a FFT-2D-bandpass filter, overlay images were 
created. From these a threshold was set to restrict analyses to MTs, and the 
outline of the cell was drawn followed by measuring the percentage area of 
positive pixels. This was repeated for G2L3 and divided by the value given for 
MTs to give a ratio theoretically between zero and one. Adobe Photoshop CS4 
was used in the preparation of figures for this manuscript. 
 
Sub-cloning 
For immunofluorescence, G2L3 and G2L3-C-T were cloned into pEGFP-N1 or 
mCherry-N1 vectors (Clontech) using the restriction endonucleases NheI and 
HindIII at the amino acids indicated in Figure 1A. G2L3-C-T was also cloned into 
pEGFP-C1 vector (Clontech) using the restriction endonuclease BamHI. EB1-
GFP was a kind gift from Shoichiro Tsukita’s lab. For recombinant expression in 
E. coli, G2L3-C-T and GST-EB1-C-T were cloned into the pHisTrx and pHisGST 
vectors, respectively (Kammerer et al., 1998) using either the restriction 
endonucleases BamHI or EcoRI and BamHI, respectively. All recombinant insert 
DNA was verified by DNA sequencing. 
 
Protein expression and purification 
The recombinant GST-EB1-C-T and G2L3-C-T constructs were expressed in E. 
coli JM109 (DE3) host strain (Merck Biosciences) and BL21 CodonPlus (DE3) 
host strain (Stratagene, UK), respectively, as previously described (Kammerer et 
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al., 1995) using an autoinduction protocol (as described by (Studier, 2005)). The 
6xHis-tagged G2L3-C-T was purified by immobilised metal affinity 
chromatography on Ni2+-Sepharose (GE Healthcare). The GST-tagged EB1-C-T 
was purified similarly, except using glutathione-coated Sepharose beads (GE 
Healthcare). Purification was performed under denaturing condition using 8 M 
urea as described in the pET system manual (Merck Biosciences). Removal of 
the GST tag by thrombin was performed as previously described (Kammerer et 
al., 1995). Determination of protein concentration was achieved by the 
absorbance of tryptophan and tyrosine residues at 280 nm (Edelhoch, 1967). 
 
Glutathione S-Transferase pull-down assay using recombinant proteins 
G2L3-C-T was incubated in a 1.5X molar excess with GST-EB1-C-T in PBS 
containing 40mM EDTA. Glutathione-coated Sepharose beads (GE Healthcare) 
were resuspended with PBS containing GST-EB1-C-T (positive control), G2L3-
C-T (negative control) or their respective combination. After incubation, the 
beads were washed five times in PBS and the proteins eluted by being boiled in 
2X SDS-loading buffer for 10 mins. These were then analysed on a 15% SDS-
PAGE gel. 
 
Solid Phase Binding Assay 
Wells of Costar high binding microtitre plates (Corning Costar, UK) were coated 
with purified G2L3-C-T at 10µg/mL. Wells were blocked with blocking buffer [5% 
BSA (w/v) in PBS], followed by 3 washes with 200 µL washing buffer [0.1% BSA 
(w/v) in PBS]. Wells were incubated at the indicated concentrations of EB1-GST 
or GST (control) and washed 3X. Mouse-α-GST antibodies (500ng/mL) (GE 
Healthcare) were added to wells followed by 3 further washes. GST-binding 
proteins were detected using horseradish peroxidase (HRP)-conjugated anti-
mouse antibody (Jackson Immunoresearch) diluted 1:5000 in wash buffer. Wells 
were washed 4 times before the addition of ABTS substrate [0.55mg/mL 2,2’-
azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), 0.0026% (v/v) H2O2 , 0.1M 
sodium acetate and 50mM NaH2PO4, pH5.0]. Absorbance readings at 405nm 
were measured using a Powerwave 340 multiscan plate reader (Biotek, USA). 
Each experimental condition was assayed in at least three replicate wells and 
background attachment to BSA-blocked wells subtracted from all measurements. 
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Means and standard error of the means were calculated for each experimental 
condition using Microsoft Excel 2003 (Microsoft, USA). Graphs were plotted and 
binding affinities estimated using the Hill equation function on Origen Pro 8 
(OriginLab, Northampton, USA). 
 
Glutathione S-Transferase pull-down assay from cell lysates 
COS cells were washed with PBS and trypsinised. They were subsequently 
centrifuged and lysed in 500µL ice cold lysis buffer (1% NP40, 50mM Tris pH7.4, 
120mM NaCl, 2.5mM EGTA pH 7.4, 10mM MgCl, supplemented with 2X 
protease inhibitor cocktail solution). Lysates were passed 10X through a 27G 
needle, and centrifuged in a precooled centrifuge at 4°C for 15mins at 800g in 
order to remove the insoluble fraction. An aliquot of the supernatant was taken 
and placed in SDS-loading buffer as the total cell lysate, the remaining 
supernatant was precleared with Glutathione-coated Sepharose beads (GE 
Healthcare) for one hour at 4°C, followed by centrifugation at 2000g and 
aspiration of the supernatant. During preclearing, washed Glutathione-coated 
Sepharose beads were incubated with either Glutathione S-Transferase (GST) 
conjugated-EB1 or GST alone (control) in order to attach the bait protein to the 
bead. After preclearing, the EB1-GST or GST coated beads were washed thrice 
in PBS containing 0.01% Tween 20 (PBS-T), and were resuspended in the 
precleared lysate, and rotated for an hour at 4°C. The samples were centrifuged 
at 2000g, and an aliquot of the unbound fraction was taken. The beads were 
subsequently washed 4 times in PBS-T and the bound proteins were eluted from 
the beads in 2X SDS-loading buffer at 100°C for 10 mins. The individual fractions 
were then separated by SDS-PAGE and analysed by immunoblotting, using an 
anti-GFP antibody (1:1000, Roche) 
 
Statistical analysis 
Using the ratios obtained from the image processing, Student’s t-tests were 
performed using Microsoft Excel to compare the ratios of G2L3 expressing 
control cells, taxol treated G2L3 expressing cells, and EB1 with G2L3 co-
expressing cells. 
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Figure Legends 
 
Figure 1: Schematic representation of GAS2-like3 (G2L3) and end-binding 
protein 1 (EB1). (A) G2L3 consists of a calponin homology (CH) domain, a 
GAS2-related (GAR) domain and an extended C-terminus. Note that the two 
MtLSs (SKLP and TLLP) are located at the C-terminus. (B) EB1 contains an N-
terminal CH domain, which binds to MTs, followed by a coiled-coil (CC) region, 
which is abutted to the EB-homology (EH) domain. Note that the EH domain 
contains the binding sites for MtLSs and the C-terminus of EB1 was abutted to 
glutathione-S-transferase (GST) for expression and purification. (C) The 
recombinant proteins used for the in vitro binding assays in this study are the 
predicted molecular weight and are denoted by asterisks. 
 
Figure 2: G2L3-C-term interacts directly with EB1 in vitro with high binding 
strength. (A) GST pulldown assay, using GST-EB1-C-T as bait and G2L3-C-
term as prey; the unbound and bound fractions are denoted as I and O, 
respectively. Left panel: G2L3-C-term was incubated with GST-EB1-C-T, 
followed by incubation with glutathione-coated beads in the presence of 20mM 
EDTA. Note the two proteins are found in the bound fraction, indicating they 
interact. Middle panel: GST-EB1-C-T was incubated with glutathione-coated 
beads in the presence of 20mM EDTA (as a positive binding control). Right 
panel: G2L3-C-term was incubated with GST, followed by incubation with 
glutathione-coated beads in the presence of 20mM EDTA. Note that when 
incubated with GST alone, G2L3-C-term is not found in the bound fraction, 
indicating that the interaction is specific for EB1. (B) Solid phase binding assay, 
where G2L3-C-term was plated on plastic and the concentration of GST-EB1-C-
T was increased. Note the rapid increase of binding at very low concentrations of 
GST-EB1-C-T. The values for GST-EB1-CT were normalised by subtracting the 
values for GST alone, and plotted. Subsequently a Hill plot was fitted to estimate 
a kd of 2.1nM. The results for both experiments are indicative of more than three 
independent experiments. 
 
Figure 3: EB1 enhances the localisation of G2L3 to MTs. (A) NIH3T3 cells 
co-expressing G2L3 with EB1 were fixed and stained using an antibody directed 
against α -tubulin (DM1A, (Blose et al., 1984)). NIH3T3 cells expressing G2L3 
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were either treated with 10µM taxol for 30 mins, or left untreated (control), before 
fixation and staining for α-tubulin and phalloidin to label actin. Note the dramatic 
enhancement of G2L3 to MTs when coexpressed with EB1, compared to control 
or taxol-treated cells (white arrowheads). (B) G2L3 and MT images were passed 
through a FFT-2D bandpass filter and background subtracted. The resulting 
image was thresholded to MTs, and the cell outline drawn. Following which, the 
area fraction for G2L3 positive pixels and MTs were recorded, and the ratio 
between G2L3: MTs was calculated. (C) The ratios calculated in (B) of G2L3: 
MTs for EB1-coexpressing cells, taxol treated cells and control cells are 
displayed. Note the significant enhancement of G2L3 to MTs in EB1 co-
expressing cells compared to taxol-treated and control cells (p<0.001, student’s 
t-test). Bars, 10µm. 
 
Figure 4: The localisation of G2L3-C-term is regulated by EB1, and shows 
evidence of plus-end tip-tracking. (A) NIH3T3 cells co-expressing G2L3-C-
term with EB1 were fixed and stained using an antibody directed against α -
tubulin (DM1A, (Blose et al., 1984)). NIH3T3 cells expressing G2L3-C-term were 
either treated with 10µM taxol for 30 mins, or left untreated (control), before 
fixation and staining for α-tubulin and phalloidin to label actin. Note the dramatic 
enhancement of G2L3-C-term to MTs when coexpressed with EB1, compared to 
control or taxol-treated cells (white arrowheads). (B) The ratio of positive pixels 
G2L3-C-term: MTs as calculated in (Figure 4B) for EB1-coexpressing cells, taxol 
treated cells and control cells are displayed. Note the significant enhancement of 
G2L3-C-term to MTs in EB1 co-expressing cells compared to taxol-treated and 
control cells (p<0.001, student’s t-test). (C) Still images generated from live 
movies of NIH3T3 cells coexpressing G2L3-C-term and EB1. Note the 
localisation of G2L3-C-term to the growing plus-end of MTs (white and red 
arrowheads). Time is indicated in seconds at the bottom right corner. Bars, 
10µm.  
 
Figure 5: The complete G2L3-C-term is required for interaction with EB1. 
(A) Schematic representation of the G2L3-C-term mutants expressed as GFP-
fusions for localisation studies and GST pulldown assays from cell lysates. (B) 
NIH3T3 cells expressing the indicated constructs were fixed and stained for α -
tubulin as in Figure 3. Note the localisation of G2L3-C-term to MTs (white 
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arrowheads), whereas G2L3-CT1 and G2L3-CT2 localise diffusely in the 
cytoplasm. (C) GST pulldown assays using GST-EB1-C-T as bait to pulldown the 
indicated G2L3-C-term mutants from cell lysates. Note that GST-EB1-C-T can 
pulldown G2L3-C-term, however it fails to pulldown G2L3-CT1 and G2L3-CT2. 
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Figure 1: Schematic representation of GAS2-like 3 and end-binding protein 1. 
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Figure 2: G2L3-C-term interacts directly with EB1 in vitro with high binding strength. 
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Figure 3: EB1 enhances the localisation of G2L3 to MTs. 
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Figure 4: The localisation of G2L3-C-term is regulated by EB1, and shows evidence of 
plus-end tip-tracking. 
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Figure 5: The complete G2L3-C-term is required for interaction with EB1. 
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6) Final Discussion                                                                                                                       
The overall aims of this study were to characterise the new protein, G2L3, to 
further the understanding of how it is regulated and provide insights into its 
function. This study has provided valuable data on the localisation and binding of 
G2L3, and its regulation of localisation to MTs by EB1 and tubulin acetylation, 
however, its functional role remains elusive. The potential functions of G2L3 and 
how future experiments may help to identify and dissect these roles are 
considered below. 
The Drosophila homologue of the GAS2 family is essential for 
development 
The fact that members of the GAS2 family are widely conserved through 
evolution suggests they play an important function. Intriguingly, Drosophila only 
express a single homologue of the GAS2 family, termed ‘Pigs’, implying that 
studies in flies could shed light on the function of G2L3. Pigs is a direct target of 
Notch signalling and is thought to be essential for muscle development and the 
organisation of the fly ovariole (Pines et al., 2010). Interestingly, Notch-directed 
expression of Pigs resulted in a negative feedback mechanism in which Pigs 
downregulates Notch signalling. The expression of Pigs and its feedback on 
Notch signaling could be essential for other downstream targets of Notch, as well 
as Pigs expression itself. Notch signalling controls a host of developmental 
pathways, as well as pathways involving cancer (Artavanis-Tsakonas et al., 
1999; Nickoloff et al., 2003). It has been reported that Notch signalling induces 
the expression of proteins, such as SNAIL-1, which are required for epithelial to 
mesenchymal transition (which is an essential step in the initial stages of 
metastasis), and for increased motility and invasiveness (Sahlgren et al., 2008). 
With the evidence that Pigs downregulates Notch signalling in flies, it is plausible 
to connect the loss of G2L3 to human cancers that are dependent on Notch 
signalling. Experiments to determine whether G2L3 is a downstream target of 
Notch would provide insight into a potential role of G2L3 in both development 
and cancer. 
In contrast to flies, which have a single member of the GAS2 family, vertebrates 
contain four members of the GAS2 family. It is likely that each member of the 
GAS2 family plays a tissue-specific role. For example, GAS2 is found mainly in 
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lung tissue, G2L1 in testis and brain, G2L2 in skeletal muscle, whereas G2L3 
mRNA is found in many tissues. In accordance with a tissue specific function in 
vertebrate development, G2L1 has been identified as a target gene for the 
thyroid hormone receptor in human erythroid cells, implying it could play a key 
role in erythroid cell development (Gamper et al., 2009). 
The similarity to spectraplakins implies GAS2-like 3 may have 
similar roles 
As discussed in the second results chapter, G2L3 shares a distinctive similarity 
to the spectraplakins. It is striking that despite spectraplakins containing multiple 
domains, only two of these (the CH and GAR domains) have apparent functional 
roles. Notably, G2L3 only contains these two domains, thus can be thought of as 
a ‘mini-version’ of a spectraplakin. The spectraplakin, ACF7, has been shown to 
govern MT dynamics, guidance, cortical tethering, stability and cellular 
polarisation. Many of these functions can be explained at least in part by actin-
MT connections (Kodama et al., 2003). There is also evidence to suggest that 
ACF7 plays a role in focal adhesion dynamics, and thus cell migration (Wu et al., 
2008).  
To determine whether G2L3 can play similar roles to ACF7, RNA interference 
could be used to knockdown G2L3 expression. One potential problem with this 
approach could be the redundancy of the spectraplakins and the GAS2 family 
members. Thus the effects of knocking down G2L3 would require careful 
analysis, and could require the simultaneous knockdown of the other proteins 
that confer redundancy. A possible way to avoid knocking-down many proteins 
would be to use HT1080 cells, which do not contain G2L3 at the mRNA level, 
implying they do not express G2L3 protein. Alternatively, cells from Pigs -/- 
Drosophila could be used, and G2L3 could be expressed in these cells to try and 
the rescue the aberrant phenotypes observed in these cells. 
The localisation of G2L3 to MTs and actin make it a good candidate for a role 
downstream of polarisation mediators, such as the Rho GTPases. IQGAP1 is an 
effector of the Rho GTPase, Cdc42, and has been shown to interact with the 
+TIP, APC (Etienne-Manneville and Hall, 2003). APC is a known binding partner 
of EB1 (Honnappa et al., 2005), thus it is possible that G2L3 indirectly interacts 
with members of the Rho GTPase family. Using HT1080 cells as a model for 
cells lacking G2L3, the importance of G2L3 in cell polarisation could be 
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determined using scratch-wound assays. It would be interesting to express G2L3 
in HT1080 cells to investigate whether this effects cell polarisation. Similarly, the 
effect of expressing G2L3 in HT1080 cells on cell adhesion and migration could 
be assessed using cell-attachment and migration assays, respectively.  
Owing to the interaction of G2L3 with the master regulator of MT dynamics, EB1, 
another plausible role of G2L3 is in regulating MT dynamics. MTs in ACF7-null 
endodermal cells undergo longer periods of growth and shorter periods of 
pausing than wild-type cells, and a subset of these MTs in ACF7-/- cells fail to 
grow along actin filaments (Kodama et al., 2003). Both of these defects can be 
rescued by expressing a version of ACF7 encoding its CH and GAR domains 
(the equivalent of G2L3), implying that G2L3 may be acting redundantly in ACF7 
-/- cells. G2L3 knockdown experiments on ACF7 -/- cells may reveal whether the 
lack of G2L3 leads to more profound defects in MT dynamics and growth 
trajectories. 
ACF7 has been shown to associate with the +TIP, EB1 (Wu et al., 2008). We 
identified that EB1 can recruit G2L3 to MTs, however the function of this spatial 
regulation is unclear. The interaction of G2L3 with EB1 may play a similar role to 
ACF7’s interaction, in which ACF7 uses its actin-based ATPase to guide the 
+TIP complex along actin stress fibers towards focal adhesions. The interaction 
mediated by ACF7 and EB1 between actin and MTs is dynamic, as stress fibers 
associated with focal adhesions are constantly moving away from the focal 
adhesions at a rate of ~0.2-0.4 µm/ min. In contrast to ACF7, no ATPase activity 
of G2L3 is predicted by sequence analysis. Given the apparent lack of ATPase 
activity in G2L3, it is possible the C-terminus of G2L3 may provide a binding site 
for an actin-based motor, such as a member of the myosin family. This would 
enable G2L3 to dynamically guide the +TIP complex along actin stress fibers via 
its C-terminus in a manner similar to ACF7. G2L3 may also form a static 
crosslink between MTs and actin mediated via its C-terminus and CH domain, 
respectively, which would not require the action of a motor to move along actin 
filaments. 
To elucidate the underlying mechanisms of how G2L3 could crosslink MTs and 
actin it would be important to establish new binding partners of G2L3. A possible 
way to isolate novel interactions would be to perform coimmunoprecipitation 
experiments using G2L3-GFP, followed by mass-spectrometry (MS). 
 133 
Complementary to the MS-based approach yeast-two hybrid screens could be 
performed to identify lower-affinity binding partners. 
Potential roles of GAS2-like 3 in apoptosis and regulation of 
mitochondrial dynamics 
Communication between the cytoskeleton and mitochondria is key to the 
regulation of apoptosis and mitochondrial dynamics (Anesti and Scorrano, 2006; 
Boldogh and Pon, 2007). All neurodegenerative diseases are associated with 
cytoskeletal defects and/or deficiencies in the regulation of mitochondrial 
function. Recent data indicated that overexpression of G2L3 in cells, activated 
the executioner caspase, caspase 3, which suggests that G2L3 induces 
apoptosis (See Appendix 1, Figure 8A). Interestingly, GAS2, which is the closest 
relative of G2L3, has been shown to be involved in signalling pathways 
controlling cell growth, apoptosis and cancer (Benetti et al., 2005; Benetti et al., 
2001; Brancolini et al., 1995; Lee et al., 1999). Despite the evidence of GAS2 in 
apoptosis (Brancolini et al., 1995; Brancolini et al., 1997), the molecular basis of 
how it may regulate cell death is unknown.  
Classical apoptosis is usually initiated by mitochondria, which are known to host 
mediators of the apoptotic machinery (Karbowski and Youle, 2003; Taylor et al., 
2008). As well as G2L3 localising on both F-actin and MTs, G2L3 localised to 
distinct foci on mitochondria in a subset of cells, suggesting G2L3 may play a 
very important role in apoptosis (Appendix 1, Figures 8B and 8C). The 
recruitment of G2L3 to mitochondria may lead to events which induce apoptosis, 
such as permeabilisation of the outer mitochondrial membrane by B-Cell 
Lymphoma 2 (BCL-2) associated X protein (Bax) and BCL-2 antagonist or killer 
(Bak), resulting in cytochrome C release, and subsequent caspase activation 
(Taylor et al., 2008). Time-lapse imaging revealed that G2L3 specifically 
localised to distinct foci, which undergo fusion and fission events (Appendix 1, 
Figure 8D).  
Apoptosis may trigger fragmentation (fission) of mitochondria, showing that there 
is an intimate relationship between apoptosis mediating proteins (e.g. Bax and 
Bak), and those that regulate fusion and fission of mitochondria (Youle and 
Karbowski, 2005). 
Several important questions arise from these data, for example, does G2L3 
control the intrinsic pathway of apoptosis, or is cell death triggered as a 
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consequence of G2L3 perturbing mitochondrial dynamics? It would be important 
to investigate whether G2L3 induces classical apoptosis through Bax/Bak- 
mediated permeabilisation of the outer mitochondrial membrane. To test this 
hypothesis, G2L3 could be overexpressed in Bax/Bak -/- cells, and the levels of 
active caspases determined. Since G2L3 overexpression results in caspase 
activation, it would be necessary to use an inducible vector system allowing the 
rapid activation of G2L3 to follow its potential pathway of destruction in live cells. 
Crucially, inducible expression of G2L3 could also be used to analyse the effects 
on mitochondrial dynamics, and investigate whether the rates of fusion and/ or 
fission are perturbed. Knockdown and rescue experiments would need to be 
performed to elucidate the functional domains of G2L3 involved in these roles.  
Physiological roles of G2L3 and working model of G2L3 function 
Neurodegenerative diseases, such as Alzheimer’s are known to be caused by 
dysfunction of both the cytoskeleton and mitochondrial dynamics. However, the 
molecular basis of how the two processes are interlinked remains unknown. 
Mutations in genes encoding spectraplakins result in various medical conditions 
including neurodegeneration, cancer and skin blistering (Sonnenberg and Liem, 
2007). Given the similarity of G2L3 to spectraplakins, and the fact that G2L3 
associates with mitochondria, as well as with MT and actin cytoskeletons, G2L3 
is a promising candidate for a key mediator of communication between these 
cellular components. With the potential roles G2L3 may play, it could be 
fundamental to diseases involving mitochondria and cytoskeleton dysfunction. 
The working model of G2L3 function in cells is proposed below (Figure 6.1). 
G2L3 could form both static and dynamic interactions with MTs and actin. In a 
manner that is akin to ACF7, the dynamic interaction of G2L3 with MTs is via 
EB1. Whereas ACF7 contains an intrinsic ATPase to guide it along actin, G2L3 
apparently lacks this motor activity, thus the dynamic association with actin could 
be mediated indirectly using an actin-based motor, such as myosin V. This would 
enable the guidance of MTs along actin stress fibers to focal adhesions, which is 
essential for focal adhesion turnover and cell migration (Kaverina et al., 1999). 
The dynamic interaction may also serve to regulate MT dynamics at the plus-
ends by ensuring that frequencies of MT growth, pausing and collapse are 
maintained. Loss of G2L3 may result in a decreased frequency of pausing and 
increased growing frequencies as observed for ACF7 (Kodama et al., 2003).  
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Figure 6.1: Potential roles of G2L3 in cells.  
See text for description. 
 
After nascent contacts between MTs and actin have been established via 
dynamic interactions, other molecules of G2L3 may be recruited to form static 
interactions. This additional recruitment would serve to strengthen the MT-actin 
crosslinking via the C-terminus and CH domain, respectively. Once the static 
crosslinks are established, a conformational change may expose binding sites on 
G2L3 for mitochondrial recruitment. This would ideally situate the mitochondria to 
cater for the energy-demanding processes of intracellular transport along MTs 
and actin and cell migration. The junctions formed by G2L3 between actin, MTs 
and mitochondria in cells would also be an ideal locale for sensing small 
changes in the cytoplasm and reacting to them. For example, in terms of energy 
demand, guidance cues and signals to induce apoptosis.  
In terms of apoptosis, G2L3 may either act upstream or downstream of 
Cytochrome C release from the mitochondria. The possibility of it acting 
upstream is favoured, as G2L3 localises to distinct mitochondrial foci that 
undergo fusion and fission. Upon the cell’s decision to undergo apoptosis, G2L3 
may undergo a conformational change or cleavage for it to localise exclusively to 
mitochondria and start the apoptosis cascade. Alternatively, G2L3 may perturb 
mitochondrial dynamics, thus indirectly stimulate apoptosis. Currently, we have 
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evidence to support both of these possibilities. Clearly further work is needed to 
uncover the molecular mechanisms underlying G2L3-induced apoptosis. 
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8) Appendix 1: Recent data implying G2L3 is involved in 
apoptosis 
 
 
Figure 8.1: G2L3 induces caspase dependent apoptosis and localises to actin, MTs and 
sites of mitochondrial fusion and fission.  
(A) NIH3T3 fibroblasts were transfected with GFP (control) or G2L3-GFP and the percentage of 
cells with active caspase 3 were analysed after 24hrs. As a positive control, untransfected cells 
were treated with staurosporine (STS) to artificially induce apoptosis. Note the significant 
increase in active caspase 3 in cells transfected with G2L3 compared to GFP (p<0.001), 
student’s t-test. Error bars=standard error of the mean, results are representative of three 
independent experiments. (B) NIH3T3 cells expressing G2L3-GFP, were fixed and stained for 
microtubules (MTs). Note the colocalisation of G2L3 along MTs, and to discrete punctate spots. 
(C) Cytochrome C co-labelling reveals that G2L3-GFP positive punctate spots localise on 
discrete foci on mitochondria. (D) Time-lapse recordings of NIH3T3 cells expressing dsRed-
Mitotracker and G2L3-GFP reveal the localisation of the latter at sites of mitochondrial division 
(fission; upper panel) and fusion (lower panel). G2L3 localisation is outlined by arrowheads.       
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9) Appendix 2: Buffers and Media 
1% (w/v) Agarose gel (for DNA analysis)  1% (w/v) agarose 
       1 x (v/v) TAE 
 
Autoinduction media    25 mM Na2HPO4 
25 mM KH2PO4  
50 mM NH4Cl; 
5 mM Na2SO4  
2 mM MgSO4  
2.5 mM Glucose 
Ca2+ (2 mg/L)  
0.5% (v/v) Glycerol  
0.2% (w/v)Lactose  
Ampicillin (200 µg/ml) 
 
Binding buffer (8x)     40mM Imidazole 
       4M NaCl 
       160mM Tris 
       pH 7.9 
 
Charge buffer (8x)     400mM Nickel sulphate 
 
DNA loading buffer (6x)    0.25% (v/v) Bromophenol blue 
       30% (v/v) Glycerol in water 
 
Elute buffer (4x)     4M imidazole 
       2M NaCl 
       80mM Tis-HCl 
pH 7.9 
 
LB-Agar      170mM NaCl 
       1.0% (w/v) Tryptone 
       0.5% (w/v) Yeast extract 
       2.0% (w/v) Agar  
 
LB-Broth      170mM NaCl 
       0.8% (w/v) Tryptone 
       1% (w/v) Yeast extract 
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NP-40 Lysis Buffer     50mM Tris-HCl, pH 7.4 
       120mM NaCl 
       2.5mM EDTA 
       10mM MgCl2 
       1% (v/v) NP-40 
 
Phosphate Buffered Saline    137mM NaCl 
       2.7mM KCl 
       4.3mM Na2HPO4.7H2O 
       1.4mM KH2PO4 
 
SDS-PAGE resolving gel (7.5-15% w/v)  7.5-15% (v/v) Acrylamide/ bisacrylamide 
       375mM Tris-HC,l pH 8.8 
       0.1% (w/v) SDS 
       0.05% (w/v) Ammonium persulphate 
       0.05 (v/v) TEMED 
 
SDS-PAGE stacking gel (4% w/v)   4% (v/v) acrylamide/bisacrylamide 
       125mM Tris-HCl,  pH 6.8 
       0.1% (w/v) SDS 
       0.05% (w/v) Ammonium persulphate 
       0.1% (v/v) TEMED 
 
SDS-PAGE gel tank buffer (10x)   250mM Tris 
       2.5M Glycine 
       0.1% (w/v) SDS 
       pH 8.3    
    
SDS-PAGE sample buffer (2x)   100mM Tris-HCl, pH6.8 
       200mM Dithiothreitol 
       4% (w/v) SDS 
       0.2% (w/v) Bromophenol blue 
       20% Glycerol 
 
SDS-PAGE gel staining solution   0.25% (w/v) Comassie brilliant blue 
       7.5% (v/v) Acetic acid 
       50% (v/v) Methanol 
 148 
       42.2% (v/v) Water 
 
SDS-PAGE gel destaining solution  45% (v/v) Methanol 
       50% (v/v) Water 
       5% (v/v) Acetic acid 
 
SPBA substrate     100mM NaOAc  
50mM NaH2PO4 
40mM ABTS 
250mM H2O2 
 
Strip buffer (4x)     400mM EDTA 
       2M NaCl 
       80mM Tris-HCl, pH 7.9 
 
Thrombin cleavage buffer    150mM NaCl 
       20mM Tris-HCl, pH 8.4 
        
Transfer buffer     10mM Na2B4O7.10H2O 
  
Tricine Gel: Acrylamide A    48%Acrylamide/1.5% Bisacrylamide 
 
Tricine Gel Buffer (1X)    3M Tris-HCl, pH 8.4 
       0.3% (w/v) SDS  
Tricine Gel Lower Reservoir (1X)   200mM Tris-HCl, pH 8.9 
        
Tricine Gel Upper Reservoir (1X)   100mM Tris-HCL, pH 8.25 
       100mM Tricine 
       0.1% (w/v) SDS  
    
Tris-acetate buffer (TAE) (50x)   2M Tris Base 
       1M Glacial acetic acid 
       0.5M EDTA, pH 8 
        
Wash buffer (8x)     480mM Imidazole 
       4M NaCl 
160mM Tris-HCl, pH 7.9 
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10) Appendix 3: Vector Maps 
pHisTrx 
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pEGFP-N1 
 
 
pEGFP-C1 
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Cellular entry of paramyxoviruses requires the coordinated
action of both the attachment (G/H/HN) and fusion (F) glycopro-
teins, but how receptor binding activates G to trigger F-mediated
fusion during viral entry is not known.Here, we identify a receptor
(ephrinB2)-inducedallostericactivationsite inNipahvirus (NiV)G
involved in triggeringF-mediated fusion.We first generateda con-
formational monoclonal antibody (monoclonal antibody 45
(Mab45)) whose binding to NiV-G was enhanced upon NiV-G-
ephrinB2 binding. However, Mab45 also inhibited viral entry, and
its receptor binding-enhanced (RBE) epitope was temperature-de-
pendent, suggesting that the Mab45 RBE epitope on G may be
involved in triggering F. TheMab45RBE epitopewasmapped to the
base of the globular domain (6S4/1H1). Alanine scan mutants
within this regionthatdidnotexhibit thisRBEepitopewerealsonon-
fusogenic despite their ability to bind ephrinB2, oligomerize, and
associatewithFatwild-type (WT) levels.Althoughcirculardichro-
ism revealed conformational changes in the soluble ectodomain of
WT NiV-G upon ephrinB2 addition, no such changes were
detected with soluble RBE epitope mutants or short-stalk G
mutants.Additionally,WTG,butnot aRBEepitopemutant, could
dissociate fromFupon ephrinB2 engagement. Finally, using a bio-
tinylated HR2 peptide to detect pre-hairpin intermediate forma-
tion, a cardinal feature of F-triggering, we showed that ephrinB2
binding toWTG, but not the RBE-epitope mutants, could trigger
F. In sum, we implicate the coordinated interaction between the
baseofNiV-Gglobularheaddomainand the stalkdomain inmedi-
ating receptor-induced F triggering during viral entry.
The paramyxoviruses comprise a group of important human
pathogens, such as measles, mumps, human parainfluenza
viruses, and the highly pathogenic Nipah (NiV)4 and Hendra
(HeV) viruses. NiV infections have a mortality rate in humans
of up to 75%, and NiV is classified as a BSL4 pathogen because
of its bio- or agro-terrorism potential (1). The efficacy of entry
inhibitors targeted against HIV suggests that a better under-
standing of Paramyxovirus entry and fusion will facilitate sim-
ilarly efficacious antiviral therapeutics.
Although past studies have identified regions in either the
fusion (F) or attachment (G/H/HN) glycoproteins that are
important for membrane fusion or F-G/H/HN association
(2–10), the region(s) inG important for receptor-activated trig-
gering of F-mediated fusion remains unknown. Currentmodels
of Paramyxovirusmembrane fusion posit that receptor binding
to the attachment glycoprotein (G, H, or HN) triggers a confor-
mational cascade in the fusion protein (F). Such F-triggering
results in fusion peptide (FP) exposure, which involves forma-
tion of a pre-hairpin intermediate and subsequent six-helix
bundle formation (11). The energy released upon refolding into
the stable six-helix bundle ground state iswhat drives the fusion
of the viral and host-cell membranes. These are common func-
tional and structural features responsible for membrane fusion
for all enveloped viruses regardless of whether the fusion pro-
tein has predominantly trimeric-helical coiled-coil (Class I),
(Class II), or a combination of and (Class III) core structures
(12). Important human pathogens such as the HIV, influenza,
and various paramyxoviruses have Class I fusion proteins, and
their similar structural features point to similar membrane
fusion mechanisms (11, 12). Besides sharing trimeric coiled-
coil structures, they are synthesized as precursors that are
cleaved into a metastable conformation; cleavage generates a
new hydrophobicN terminus FP that gets released and inserted
into the target cell membrane upon triggering (11, 12). Class I
fusion proteins have two heptad repeat regions, HR1 and HR2,
at their N and C termini, respectively, that fold up onto each
other during six-helix bundle formation to bring aboutmerging
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marked “advertisement” in accordancewith 18U.S.C. Section 1734 solely to
indicate this fact.
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of target cell and viral membranes (12). For Paramyxovirus F
proteins, the C-terminal HR2 region is generally thought to be
pre-formed, but the N-terminal HR1 region is formed only
upon F-triggering and FP insertion (11, 13). The formation of
this trimericHR1 core just before six-helix bundle formation, is
known as the pre-hairpin intermediate.
Despite their common features, viral fusion proteins vary in
their detailed structures, triggering factors, and number of viral
surface proteins involved. For paramyxoviruses, receptor bind-
ing and fusion functions are carried out by two distinct trans-
membrane proteins (attachment (G, H, or HN) and fusion (F)
proteins, respectively), and with few exceptions both are
required for membrane fusion. The underlying mechanism of
fusion triggering by the attachment protein may vary depend-
ing on their use of protein versus carbohydrate receptors (14).
For example, we and others have observed an inverse correla-
tion between fusogenicity of the F protein and the avidity of the
F/G or F/H interactions for NiV and measles virus (2, 3, 5, 15,
16), both of which use protein-based receptors; however, for
Newcastle disease virus, a glycan-using Paramyxovirus, there
seems to be a direct correlation between fusogenicity and the
avidity of F/HN interactions (8).
For the paramyxoviruses, the early steps in the fusion cas-
cade, particularly how H/HN “triggers” F, are not well under-
stood, and the region(s) in H/HN responsible for F triggering
remains unclear, although the stalk domain ofH/HNappears to
be important for F triggering or for interaction with F (5–8).
For NiV, the G attachment glycoprotein binds either the eph-
rinB2 (B2) or ephrinB3 (B3) protein receptors (17–19), but it is
not known how receptor engagement induces G to undergo the
allosteric changes involved in triggering F. However, by homol-
ogy toHorHN, it is likely that the stalk domain inNiV-G is also
involved in F-triggering (20). Here we analyze the early steps in
the fusion cascade for NiV and identify a specific region in
NiV-G distinct from the receptor binding site that is involved
in 1) B2-induced changes that trigger FP exposure in F, 2) mod-
ulating the avidity of F/G interactions resulting in displacement
of F from G, and 3) transducing receptor-induced membrane
fusion. Our results offer testable hypotheses as to whether this
model of fusion cascade holds true for other paramyxoviruses
that use protein-based receptors.
EXPERIMENTAL PROCEDURES
Expression Plasmids—HA andAU1 tagged codon-optimized
(CO) NiV-G (G) and NiV-F (F) expression plasmids, respec-
tively (21), and G deletion mutants 1, 2, 3, 4, 9, 11, and 14 (17),
were previously described. Deletion mutants 4 and 9 and
triple Ala site mutants 4-1, 4-2, 4-3, 4-4, and 4-5 were made by
site-directedmutagenesis of the COwild-type (WT) G plasmid
using the QuikChangeTM kit (Stratagene). All mutations were
confirmed by sequencing the entire open reading frame.
Cell Culture—The growth conditions for CHO-pgsA745
(CHO), CHOB2-pgsA745 (CHOB2), Vero, and 293T cells have
been previously described (2, 17).
Antibody Production and Quantification of Cell Surface
Expression and Antibody Binding Levels by Flow Cytometry—
Production of rabbit anti-G and anti-F antisera fromCOG and
F plasmids was previously described (2, 3, 17), and production
of rabbit monoclonal anti-G antibodies was essentially as
described for anti-F monoclonal antibodies (3). Sera or hybri-
doma supernatants containing anti-F- or anti-G-specific activ-
ities were used at 1:1000 dilution for flow cytometry on NiV-F/
G-transfected cells, and bound antibody was detected as
previously described (2, 3). For ephrinB2 (B2) binding assays,
soluble B2-humanFc protein (R&D) was added at 10 nM and
detected using anti-human Fc secondary antibodies (Caltag) as
indicated previously (17).
Quantitation of Cell-Cell Fusion—COWT or mutant G and
CO WT F expression plasmids (1:1 ratio, 1 g of total) were
transfected into 293T cells grown in 12-well plates at 70% con-
fluency. 12–18 h post-transfection, cells were 4,6-diamidino-
2-phenylindole-stained, and syncytia formation was quantified
as indicated previously (2, 3, 21).
Circular Dichroism (CD)—Changes in the secondary struc-
ture of NiV-G were monitored by CD spectroscopy in a Jasco-
715 spectrometer. Data were collected between 200 and 240
nm, keeping the high voltage below noise levels at all times.
Experiments were repeated three times, and each trial was the
average of three scans at 20 nm/min and 0.2 nm of resolution.
PBS buffer (phosphate-buffered saline supplemented with
500 M Mg2Cl and 900 M CaCl2) (22) was used in a 300-l
cuvette at room temperature. CD spectra of ephrinB2 (B2) (2.5
M), soluble G (1.2M), and B2:Gmixture were collected. Data
were corrected by subtracting the buffer signal. The theoretical
spectrum of the B2:G mixture, assuming no interprotein inter-
action, was calculated by the linear addition of the individual B2
and G scans, and the changes in the ellipticity were calculated
by subtracting the experimental B2:G data from the theoretical
spectrum. The change in ellipticity magnitude was calculated
by averaging the ellipticity values between 223 and 208 nm in
both theoretical and experimental data.
NiV-F/NiV-G Co-immunoprecipitation—NiV-F/G vesic-
ular stomatitis virus pseudotyped virions were allowed to mix
withCHOcells (negative control) orCHOB2 cells for 2 h at 4 °C
then triggered at 37 °C for 0, 15, or 60 min and lysed in 1%
Triton-X100. Gwas immunoprecipitated under each condition
using rabbit anti-G polyclonal antibodies as previously
described (2, 3, 21). Co-immunoprecipitated F was detected by
Western blotting using the primary anti-AU1 tag antibodies,
and signals were quantified by densitometry as previously
described (2, 3).
Triggering of NiV-F—CHO cells were transfected withWT F
and WT or mutant G expression plasmids as well as a green
fluorescent protein expression plasmid at a 10:10:1 ratio,
respectively. 18 h post-transfection, a 1:1 ratio of the trans-
fected cells and either CHO (negative control) or CHOB2 cells
were mixed and incubated for 45 min at 4 °C or 37 °C in the
presence of excess (500 M) biotinylated HR2 peptide (biotin-
KVDISSQISSMNQSLQQSKDYIKEAQRLLDTVNPSL). Sub-
sequently, the cells were washed with wash buffer (1% FBS in
phosphate-buffered saline), fixed in 0.5% paraformaldehyde in
wash buffer, and washed again 2X with wash buffer. The bio-
tinylated HR2 peptide bound to F was detected using streptavi-
din-allophycocyanin and quantified by flow cytometric analy-
sis. To enhance our signal:noise ratio and to focus only on
F-expressing cells, green fluorescent protein (GFP) cells
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were gated and analyzed for their allophycocyanin (HR2-biotin
binding) signals.
RESULTS
Enhanced Binding of Monoclonal Antibody 45 (Mab45) to
NiV-G (G) Induced by EphrinB2 Receptor Binding—Receptor-
induced conformational epitopes can be suggestive of confor-
mational changes in viral envelopes that eventually lead to
membrane fusion and viral entry. This is exemplified by CD4-
induced coreceptor binding epitopes in HIV gp120. Binding to
coreceptor after CD4-induced conformational changes in HIV
gp120 triggers fusion peptide exposure in gp41 and the subse-
quent six-helix bundle formation that eventually leads tomem-
brane fusion (23, 24). NiV also uses a protein-based receptor
and a type I fusion protein, although in this Paramyxovirus, the
receptor-interacting attachment glycoprotein (G) is physically
distinct from the fusion (F) protein. To determine whether
receptor engagement of G also results in conformational
changes that lead to F triggering and fusion peptide exposure,
we first sought to develop conformational antibodies against
NiV-G that exhibit a receptor-induced epitope. Fig. 1A shows a
representative set ofNiV-G-specific rabbit polyclonal (806) and
monoclonal antibodies (Mab26 and Mab45) obtained via
genetic immunization with expression plasmids for codon-op-
timized Nipah matrix M, F, and G (see “Experimental Proce-
dures”). Note that both Mab26 and the polyclonal anti-NiV-G
antiserum (806) showed a relative decrease inNiV-Gbinding in
the presence of soluble ephrinB2 (B2), the cognate receptor for
henipaviruses, suggesting that B2 may compete for the binding
epitopes of these antibodies. In contrast, Mab45 bound better
to G in the presence of soluble B2 (Fig. 1A). CHO cells express-
ing full-length G were used in these assays because they do not
express endogenous henipavirus receptors (17, 18), and thus,
we could control for receptor engagement by adding exogenous
soluble B2. The enhancement of Mab45 binding to G upon B2
engagement was observed at 20 and 37 °C (Fig. 1, A and C) but
not at 4 °C (Fig. 1B), suggesting that the receptor-induced
enhancement of Mab45 binding to NiV-G was a temperature/
energy-dependent process.
To further examine the specificity of this phenomenon,
increasing amounts of soluble ephrinB1 (B1), ephrinB2 (B2), or
ephrinB3 (B3) were added to CHO cells expressing NiV-G and
were allowed to incubate at 37 °C for 15 min in the presence of
a constant amount of Mab45 (0.2 g/ml). Fig. 1C shows that
there was a dose-dependent enhancement ofMab45 binding to
G when titrating in B2 and to a much lesser extent, B3, and not
at all for B1. This was consistent with the much higher affinity
of B2 than B3 for NiV-G (18). Indeed, the EC50 of the dose-
response curve for B2-enhanced Mab45 binding was remark-
ably close to the established Kd of ephrinB2 for NiV-G (0.1
nM). Additionally, a receptor binding-deficient NiV-G mutant,
E533Q, which is expressed and can be bound by Mab45 at WT
levels (25), displayed no enhancement of Mab45 binding upon
the addition of B2, underscoring that receptor binding to
NiV-Gwas necessary for the enhancement ofMab45 binding
(Fig. 1C). Altogether, these results suggested that upon B2
binding, a structural change occurred in NiV-G that allowed
Mab45 to bindmore efficiently and that such a change(s) was
energy-dependent.
Mapping of the Mab45 Conformational Epitope in NiV-G—
BecauseMab45 binding toNiV-Gwas enhanced upon receptor
binding and yet Mab45 was still able to block NiV entry (Fig.
1D), we hypothesized that Mab45 receptor binding-enhanced
(RBE) epitope may be important for the receptor-induced
changes in G that lead to F triggering and membrane fusion.
Thus, we first sought tomap theMab45 epitope onNiV-G. The
Mab45 epitope was conformational, asMab45 did notWestern
blot, and screening of overlapping 22-mer peptides spanning
the entire ectodomain of NiV-G did not result in any positive
hits (supplemental Fig. 1). Next, we utilized a series of well
expressed, previously described soluble NiV-G deletion
mutants (17) in a pre-absorption/competition assay to show
that region 4 and 9 (Fig. 2A and supplemental Fig. 2) were
important for Mab45 and Mab26 binding, respectively. Then,
we confirmed these results in the context of the full-length
NiV-G protein by deleting the regions 4 or 9 andmeasuring the
direct binding of Mab45 and Mab26 to these deletion mutants
expressed on CHO cells. Fig. 2B shows that although the 4
mutant boundmonoclonal anti-HA tag orMab26 antibodies, it
did not bind Mab45. Conversely, although expressed at lower
levels at the cell surface, 9 bound anti-HA orMab45 antibod-
ies but notMab26 (Fig. 2B). Thus, we confirmed that region 4 in
G, located at the 6S4/1H1 region (amino acids 195–211) at
the base of the head domain, is important for Mab45 binding,
whereas region 9, within the 3H1/3H2 region (amino acids
371–392) at the top of the head domain near the receptor bind-
FIGURE 1. Enhanced binding of Mab45 to NiV-G (G) induced by ephrinB2
(B2) receptor binding. A, polyclonal (806) and monoclonal (Mab26 and
Mab45) anti-NiV-G antibodies binding to full-length NiV-G expressed in
CHOpgsA745 (CHO) cells in the presence or absence of soluble B2 protein at
room temperature (20 °C) as detected by flow cytometry. % normalized
binding indicates MFI values normalized to the MFI values obtained in the
absence of soluble B2 (set at 100% for each antibody examined). Average
S.E. are shown, n  3. B, similar experiment to A, except performed at 4 °C.
C, bindingofMab45 toCHOcells expressingGormutant E533Qat37 °Cwhen
increasingconcentrationsof soluble ephrinB1 (B1), ephrinB2 (B2), or ephrinB3
(B3) were used. Logarithmof themolar concentration of the soluble ephrinBs
usedwasplotted against%normalizedbinding, calculated as inA. Average
S.E. are shown, n  4. D, the inhibitory properties of 806, Mab26, or Mab45
antibodies were measured bymixing the indicated concentrations with NiV/
vesicular stomatitis virus renilla luciferase pseudotyped particles immedi-
ately before infectionof Vero cells. Data are shownas% inhibitionnormalized
to luciferase activity in the absence of any antibodies. Average  S.E. are
shown; n 3.
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ing site, is important forMab26 binding (supplemental Fig. 3A)
(26, 27).
To further map the putative Mab45 epitope, we constructed
a series of triple alanine scan mutants within region 4 (mutants
4-1 through 4-5, Fig. 2C). We determined the relative levels of
binding of these mutant proteins to anti-HA, Mab45, and
Mab26 by flow cytometry using CHO cells expressing the full-
length WT or mutant G proteins in the absence of any eph-
rinB2. Fig. 2D shows the levels of Mab45 and Mab26 binding
normalized to the anti-HA levels to correct for any cell surface
expression differences. Surprisingly, although deletion of the
entire region 4 (4) abolished Mab45 binding to NiV-G, none
of the triple alanine mutants showed a significant decrease in
Mab45 binding. These results may imply that the Mab45
epitope was complex and was not determined by any short pri-
mary linear sequence, even within region 4. Alternatively,
because Mab45 was a conformational antibody as mentioned
above, deletion of region 4 may have resulted in a gross pertur-
bation of NiV-G that abrogated Mab45 binding as an indirect
effect. Thus, region 4, which we posited as being part of the
putativeMab45 epitope,mayhave nodirect but only an indirect
involvement with the RBE epitope that we hypothesized as
being involved in the receptor-induced changes in G that lead
to membrane fusion.
Role of the Region of G inMembrane Fusion—To further clar-
ify whether region 4 (6S4/1H1) or the putative Mab45
epitope plays an active role in the receptor-induced conforma-
tional cascade that leads to Nipah virus fusion, we analyzed the
receptor binding and fusogenic
capabilities of the region 4 mutants
when coexpressed with F. The 4
mutant itself was relatively well
expressed and bound to B2 at 50%
that ofwild-type levels butwas com-
pletely defective in a syncytia forma-
tion assay (Fig. 2E). Interestingly,
although WT G and mutant pro-
teins 4-1 and 4-2 formed syncytia
with an efficiency that paralleled
their ability to bind B2, almost no
syncytia formation was observed for
the 4-3, 4-4, and 4-5 mutant pro-
teins despite them being 1)
expressed at significant levels at the
cell surface (Fig. 2D), 2) able to bind
soluble B2 (Fig. 2E), 3) able to asso-
ciate with F (supplemental Fig. 4A),
and 4) able to form G oligomers
(supplemental Fig. 4B).
Because there were no obvious dif-
ferences between the fusion-compe-
tent (4-1, 4-2) and fusion-defective
(4-3, 4-4, 4-5)mutants in terms of the
four above-mentioned criteria for the
conformational integrity of NiV-G,
we asked whether the fusion-compe-
tent and fusion-defective mutants
were able to undergo the receptor-in-
duced changes that potentially lead to fusion. Thus, we deter-
mined whetherMab45 RBE epitope was associated with the fuso-
genic capacities of the region 4 mutant proteins.We subjected all
region 4 mutants to the B2-enhanced Mab45 binding assay
described in Fig. 1C. Remarkably, the fusion-competent mutants
4-1 and 4-2 displayedWT levels of Mab45 binding enhancement
with similar EC50 values for the amount of B2 used (0.1 nM),
whereas the fusion-defective 4-3, 4-4, and 4-5 mutants did not
show any Mab45 binding enhancement regardless of how much
B2was added (Fig. 2F). These results suggest a role for the involve-
ment of the RBEMab45 epitope in the receptor-induced changes
in NiV-G that lead to membrane fusion. In particular, the region
demarcated by the alanine scan mutants 4-3 to 4-5 of NiV-G
(ISYTLPVVG) may play a role in membrane fusion by mediating
the receptor-induced conformational changes that lead to F
triggering.
EphrinB2 Binding to NiV-G Induces Secondary Structure
Changes in NiV-G That Are Correlated with Fusogenicity—
Based on the above results, we hypothesized that the non-fuso-
genic region 4 mutants of G (e.g. 4-5) will not undergo the post
receptor-binding structural changes that lead to F triggering and
membrane fusion. In addition to the receptor-induced enhance-
ment of Mab45 binding, we sought to obtain independent bio-
physical evidenceof conformational changes inNiV-G inducedby
B2 binding. We performed CD studies on the entire soluble
ectodomain ofWTNiV-G (amino acids 71–602) and the equiva-
lent soluble 4-5mutant protein whenmixed individually with sol-
uble B2.We took advantage of the linear characteristics of the CD
FIGURE 2. Role of the 6S4/1H1 region of G in membrane fusion and Mab45 binding enhancement.
A, schematic ofNiV-G showing the various domains. Deletion sites 1, 2, 3, 4, 9, 11, and 14 are depicted, and their
sequences are shown in supplemental Table 1. B, binding of anti-HA, Mab26, andMab45 to CHO cells express-
ingWT or deletionmutant G constructs4 and9, asmeasured by flow cytometry. Average S.E. are shown,
n  3. Both Mab45 and Mab26 are conformational antibodies, as they do not Western blot. C, sequence of
region 4 of G showing the location of the triple Ala mutations 4-1, 4-2, 4-3, 4-4, and 4-5 constructed in the
context of full-length G. D, binding of the full-length WT and the indicated mutant G proteins to Mab26 and
Mab45 by flow cytometry, normalized to their anti-HA antibody binding levels. Average S.E. are shown, n
3. E, levels of binding of region 4mutants to polyclonal anti-NiV-G antiserum 806 or to soluble ephrinB2 (B2) in
CHO cells and levels of syncytia formation in 293T cells normalized to anti-HA antibody binding to correct for
any discrepancies in cell surface expression levels. Average S.E. values are shown, n 3. F, levels of binding
ofWT and region 4mutant proteins toMab45 at various concentrations of B2, normalized toMab45 binding in
the absence of B2 (set at 100%) as in Fig. 1C. Data were plotted using Prism, and average  S.E. values are
shown, n 3.
Receptor-induced Fusion Cascade in NiV
JANUARY 16, 2009•VOLUME 284•NUMBER 3 JOURNAL OF BIOLOGICAL CHEMISTRY 1631
 at The John Rylands University Library, on M
ay 11, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
http://www.jbc.org/content/suppl/2008/11/19/M807469200.DC1.html
Supplemental Material can be found at:
signals. The combined CD spectra of two proteins in a solution is
the linear addition of the individual CD signals coming from each
individual proteinwhen there areno interprotein interactions that
lead to conformational changes (28). Only when there is a confor-
mational change do the experimental CD spectra of the protein
mixture deviate from the linear sum of the individual proteins.
Interestingly, we detected a deviation from the theoretical CD
spectrauponB2binding toNiV-Gbutnot to the4-5mutant (com-
pareFig. 3,AwithB, green linesanddottedblack lines represent the
experimental and theoretical spectra, respectively), indicating a
conformational change in the secondary structureof at leastoneof
these two proteins. Because the identical soluble B2 protein was
used to bind bothNiV-G and 4-5 proteins, Fig. 3,A andB, and the
soluble NiV-G proteins gave amuchmore pronounced CD signal
than that of B2 (Fig. 3 A and B, blue and red lines, respectively),
these data strongly suggest that the conformational change that
resulted in the change inCD spectra came fromNiV-G.Note that
the 4-5mutantGproteinwas expressedwell and boundB2 atWT
levels in both the full-length and soluble versions (Figs. 2E and 3E)
butwas fusion-defective (Fig. 2E), implicating a link between fuso-
genicity and the B2-induced a conformational change in G.
As an additional control, we tested another soluble NiV-G
with a truncated stalk domain (GStalk), as the stalk domain of
paramyxoviral attachment proteins is also critically involved in
F-triggering (5–8). Fig. 3C shows that B2 binding to GStalk
did not induce any secondary structural changes, as evidenced
by the lack of deviation between the observed and theoretical
CD spectra even though GStalk was clearly able to bind B2
(Fig. 3E). Fig. 3D quantifies the relative changes in the CD spec-
tra ([]) upon B2 binding to NiV-G, the 4-5 mutant, and the
GStalk construct. The change in
CD spectra differences observed for
NiV-G was modest but highly sig-
nificant (p  0.002 and p  0.008,
Student’s t test) when compared
with the GStalk or the 4-5 mutant,
respectively, suggesting an interac-
tive role between the base of the
globular head and the stalk domain
of NiV-G in B2-induced conforma-
tional changes. Because the identi-
cal soluble B2 was added in all cases,
the secondary structural changes
likely come from G and not B2.
Remarkably, the recently solved
structures of NiV-G complexed
with B2 or B3 indicate that the
region demarcated by the 4-4 and
4-5 mutants is highly flexible and,
indeed, comprises the only few res-
idues that cannot be resolved in the
B2-NiVG complex (26, 27).
Lack of G “Activation” Correlates
with a Lack of F Dissociation from
G—For paramyxoviruses that use
protein-based receptors, we and
others have shown an inverse corre-
lation between fusogenicity and the
avidity of F/H or F/G interactions (2, 3, 5, 15, 16), suggesting
that dissociation of F from G after receptor engagement is the
rate-limiting parameter in the fusion cascade. Thus, we hypoth-
esized that B2-induced activation of G, as measured by the
temperature-dependent enhancement of Mab45 binding and
changes in CD spectra, will result in a relative dissociation of F
from G. To test this hypothesis, we mixed NiV F/G
pseudotyped vesicular stomatitis virus virions with CHO cells
that constitutively expressed B2 (CHOB2) (18) or not (CHO),
and allowed them to bind for 2 h at 4 °C to synchronize the
infection process. Thereafter, wemoved the cell/virusmixtures
to 37 °C for 0, 15, or 60 min. At the indicated time points, the
cell/virus mixture was lysed, immunoprecipitated with anti-G
specific antibodies, and Western-blotted for the amount of F
that was co-immunoprecipitated. Fig. 4A shows that in the
absence of B2, the amount of F0/F1 on virions that was co-
immunoprecipitated with G did not change over time, whereas
in the presence of B2 (Fig. 4B) there was a clear reduction of F1
and, to a lesser extent F0, which was co-immunoprecipitated
with G over time. Densitometric data show that co-immuno-
precipitated F1 was reduced by 50 and 80% at 15 and 60 min,
respectively, after shifting to 37 °C (Fig. 4D). Strikingly, the
non-fusogenic 4-5 mutant G protein, which did not exhibit
B2-induced activation, also did not show a dissociation of F0/F1
from G over time (Fig. 4, C andD) in the presence of B2. These
results suggest that the region roughly demarcated by the 4-5
mutant may be involved in the conformational cascade that
leads to receptor-induced F/G dissociation and perhaps the
downstream triggering of F.
FIGURE 3. EphrinB2 binding to NiV-G induces secondary structure changes in NiV-G that are correlated
with fusogenicity.A, changes in the secondary structureof solubleG (blue) at 1.2MweremonitoredusingCD
spectroscopy upon the addition of B2 (red) at 2.5M. A theoretical spectrum is shownusing a black dashed line,
and the experimental G:B2 scan is shown in green. The difference between the latter two lines reflects differ-
ences in secondary structure. B and C, same experiment as in A, except replacing WT G for soluble 4-5 and
Gstalk proteins, respectively. The GStalk protein lacked amino acids 71–154 of the stalk domain. D, the
difference between experimental and theoretical data ( []) were generated by averaging the CD signals
between223and208nmand subtracting theexperimental signal (green line) coming from the indicatedGand
B2mixture fromthe theoretical signal (blackdashed line). Data are theaverageS.E.,n3. E, solubleWTG, 4-5,
or GStalk mutant proteins coating a maxisorb plate bound soluble B2 similarly in an ELISA enzyme-linked
immunosorbent assay format assay. A sigmoidal dose response curve is shown (data are the average S.D.,
performed in triplicate).
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Lack of G Activation Results in the Inability to Trigger F—To
further study whether the inability to undergo receptor-in-
duced activation in the non-fusogenic (region 4)mutant G pro-
teins was related to the inability to trigger F, we developed a
triggering assay for the NiV-F protein. Current models of
paramyxoviral membrane fusion suggest that F triggering
involves formation and exposure of the HR1 (13) that is coinci-
dent with fusion peptide insertion into the target cell mem-
brane (10). The HR1 and HR2 in this pre-hairpin intermediate
then fold together to form the 6-helix bundle that drives mem-
brane fusion. HR2 peptides in NiV-F are thought to inhibit
membrane fusion by binding to the exposed HR1 region (2, 3,
29), and thus, we assayed whether we could detect F-triggering
by HR2 peptide binding to the exposed HR1 region during the
pre-hairpin intermediate stage under permissive conditions.
First, we constructed a biotinylated peptide that contained the
sequence of the HR2 region of NiV-F previously determined to
inhibit NiV infection and fusion (HR2-biotin) (2, 29). This pep-
tide was able to inhibit viral entry efficiently at an IC50 of 10 nM
(supplemental Fig. 5A). Next, we showed that HR2-biotin pref-
erentially bound to an artificially trimerizedHR1 core designed
to mimic the inner HR1 core of the six-helix bundle (supple-
mental Fig. 5, B–D). To detect F triggering, CHOB2 cells were
first mixed with CHO cells expressing the NiV-F and G glyco-
proteins for 2 h at 4 °C to synchronize receptor binding. The
HR2-biotin peptide was then added to the cell mixture, and the
fusion process was induced or not by incubating them at 37 or
4 °C, respectively, for another 45 min. HR2-biotin binding as a
surrogate marker for F triggering or pre-hairpin intermediate
formation was detected by fluorescence-activated cell sorter
analysis using allophycocyanin-conjugated streptavidin. To
focus only on F-expressing cells, NiV-F/G was co-transfected
with a fluorescent protein expression (GFP) expression plas-
mid, and GFP cells were gated and analyzed for their allo-
phycocyanin (HR2-biotin binding) signals. For WT F/G, we
were able to detect a significant increase in HR2-biotin binding
over background levels at 37 °C, but not at 4 °C, and in the
presence of B2 but not in its absence (Fig. 5,A andB), indicating
that binding of biotinylated HR2 peptide was a sensitive and
specific assay for detecting F triggering.
We then applied this assay to some of the (region 4) G
mutants that were unable to undergo B2-induced conforma-
tional changes described above. Compared withWTG, the 4-4
FIGURE 4. Lack of G activation correlates with lack of F dissociation from
G. A, co-immunoprecipitation of NiV-F using anti-NiV-G antibodies (top) from
F/G/vesicular stomatitis virus pseudotyped virions allowed to mix with CHO
cells (negative control) for 2 h at 4 °C then triggered at 37 °C for 0, 15, or 60
min, and lysed in 1% Triton X-100. Amounts of NiV-F in the viral/cell lysate
(middle) and amounts of immunoprecipitated G under each condition (bot-
tom) are shown. Co-IP, co-immunoprecipitation. B, same experiment as in A
but using CHOB2 instead of CHO cells. C, same experiment as in B except
using the 4-5 mutant G protein instead of the WT G protein. One representa-
tive experiment of three is shown.D, quantification of the effects of ephrinB2
binding on F/G interactions. The bands in A–Cwere quantified by densitom-
etry using a VersaDoc Imaging System (Bio-Rad). For each time point and
experimental condition, the normalized co-immunoprecipitation (Co-IP) F
ratio was calculated as the ratio of co-immunoprecipitated F0 or F1 signals
(from A–C, top panels) over the total F0 or F1 signals in the cell lysates (A–C,
middle panels) (to normalize for F expression levels) divided by the total
amount of immunoprecipitated G (A–C, bottom panels), as shown in the for-
mulas below. For each experimental condition, the normalized co-immuno-
precipitation F ratio at various timepointswasnormalized to the ratio obtained
at time0,whichwassetat1unit.NotethatF1dissociatedfromWTGmorethanF0
in the presence of B2. Data are the average S.E. are shown, n 3. Normalized
co-immunoprecipitation (Co-IP) F0 ratio (Co-IPF0/(F0 incell lysates))/(G IP); nor-
malized co-IP F1 ratio (Co-IP F1/(F1 in cell lysates))/(G IP).
FIGURE 5. Lack of G activation results in inability to trigger F. A, CHO cells expressing F andGweremixedwith either CHO cells (negative control) or CHOB2
cells for 2 h at 4 °C. Cell mixtures were brought to 37 °C or kept at 4 °C for 45moremin to allow for triggering of F or not in the presence of 500 nM biotinylated
HR2 peptide. B, the MFI values are summarized for 4 or 37 °C and in the absence (B2) or presence (B2) of B2 for the F/G (WT), F/4-4, and F/4-5 protein pairs.
Data are the average S.E. are shown, n 3. The p value for the MFI of the (B2) versus (B2) conditions at 37 °C for WT F/G was 0.02.
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and 4-5 mutants were unable to trigger F as shown by their
relative lack of HR2 peptide binding (Fig. 5A). The mean chan-
nel fluorescence values from this fluorescence-activated cell
sorter-based assay are summarized in Fig. 5B. The 4-4 mutant
displayed a complete lack of HR2 peptide binding under per-
missive conditions, whereas the 4-5 mutant showed only a
small amount of HR2 peptide binding in the presence of B2 at
37 °C (30% increase in mean fluorescence intensity (MFI)
compared with	300% increase in MFI for WT G).
DISCUSSION
Here we identified a region (ISYTLPVVG) at the base of the
globular head domain of NiV-G (6S4/1H1) to be involved in
B2-induced changes in G that trigger FP exposure in F. This
region is likely critical for transducing the receptor-induced
signals that result in virus-cell membrane fusion. Mutations
within this region inNiV-G (mutants 4-4 and 4-5) abrogated or
greatly decreased1)membrane fusion (Fig. 2E), 2) temperature-
dependent enhancement ofMab45 binding (Fig. 2F), 3) second-
ary structural changes detected by CD (Fig. 3B), 4) receptor-
induced F dissociation from G (Fig. 4C), and 5) pre-hairpin
formation during F triggering (Fig. 5). These five phenotypes
were all induced in WT G upon B2 engagement. The 6S4/
1H1 region demarcated by the 4-4 and 4-5 mutants were
involved in all the above phenotypes related to the fusion cas-
cade, and yet the 4-4 and 4-5 mutants do not seem to affect the
overall structure nor the receptor binding ability of the attach-
ment protein (Fig. 2E and supplemental Fig. 4). The explosion
of recent structural data on paramyxoviral attachment and
fusion proteins have added greatly to our understanding of the
paramyxoviral fusion cascade, and recent reviews have empha-
sized the importance of understanding the mechanisms by
which G triggers F and of identifying regions in G involved in F
triggering as future significant goals (11–14, 20). Mutations
have been described in other paramyxoviral attachment pro-
teins (primarily in their stalk region) that do not affect receptor
binding but are nevertheless fusion-defective, perhaps due to
defect in F and G/H/HN association or a defect in triggering (7,
30–39). However, our results indicate the identification at least
in part of a long sought receptor-induced activation site in G
that triggers F and, importantly, implicates both this region and
the stalk domain in mediating the receptor-induced allosteric
signal during the fusion cascade.
For paramyxoviruses that use glycan-based receptors, strong
data exist that argue against conformational changes in the
globular head of HN upon receptor binding (40–44), although
there seems to be a consensus that some change must occur,
perhaps in the stalk domain, and at the level of the quaternary
structure of the attachment protein (43, 45) upon receptor
binding in order for F-triggering to proceed. In the recently
published structures of henipavirusG, there do not appear to be
significant conformational differences between the receptor
bound or unbound state (26, 27). However, none of the pub-
lished paramyxoviral attachment protein structures include the
stalk domain, and thus, it is not clearwhether the issue of recep-
tor-induced conformational changes can be resolved in studies
without the stalk domain, as clearly, some sort of allosteric
transfer of receptor-induced signals need to occur for the fusion
cascade to proceed (14, 20). Here, we provide evidence for
receptor-induced allosteric changes in G by both temperature-
dependent Mab45 binding enhancement and changes in CD
spectra (Fig. 1 and 3). Notably, the lack of the stalk domain in G
(mutant GStalk) prevented CD spectra changes upon B2
binding (Fig. 3C). Thus, it is possible that to observe changes in
the G protein upon receptor binding, either the full-length pro-
tein (as in the case of our cell surfaceMab45 binding assay) or at
least the whole soluble ectodomain (as in our stalk-domain
containing G for our CD experiments) is necessary. The 6S4/
1H1 region and stalk domain regionsmay act in concert in the
fusion process; this notion is supported by their close spatial
proximity (supplemental Fig. 3) and previous Paramyxovirus
studies that implicate the stalk domain in membrane fusion
(5–8).
Our results present evidence forMab45 ability to enhance its
recognition of WT G upon its binding to B2 at 37 or 20 °C but
not at 4 °C. The temperature dependence of this phenomenon
is noteworthy asmembrane fusion has been clearly shown to be
an energy-dependent process, as only pre-hairpin intermedi-
ates of fusionwhich undergo FP exposure and insertion into the
target membranes, but not complete fusion, have been
observed at temperatures lower than 37 °C but higher than 4 °C
(10, 12, 13). Thus, the enhancement of Mab45 binding to G
uponB2 engagement at 20 or 37 °C, but not at 4 °C, is consistent
with previous membrane fusion studies and can be used as a
tool to detect receptor-induced activation of G.
In the recently solved structures of henipavirus-G proteins,
the 6S4/1H1 region, especially residues PVV, either failed to
give resolvable electron density maps or were specifically men-
tioned as a highly flexible region (26, 27). Remarkably, this
region, demarcated by our 4-4 and 4-5 mutants and part of the
Mab45 RBE epitope, plays a role in the receptor-induced trig-
gering of F. Altogether, these results suggest that the flexibility
of this region is important for the fusion process. Moreover,
when we modeled NiV-G as a dimer after the hPIV3 crystal
structure (supplemental Fig. 3B) (42), this region was situated
partially at the dimer interface, suggesting that the flexibility of
this interdimeric interface is important for the fusion process.
We speculate this flexibility reflects that NiV-G may exist in
multiple conformations, some of which are accessible for
Mab45 binding. EphrinB2 binding may collapse these confor-
mations to a common stable ground state that exposes the RBE
epitope, perhaps by re-orienting the globular head domains in a
way that allows for better Mab45 binding. The Mab45 RBE is,
therefore, a surrogate marker for a receptor-induced stabiliza-
tion of the metastable NiV-G. In addition, we observed a rela-
tive dissociation of theG/F proteins upon receptor binding, and
such dissociationwas abrogated for the 4-5mutant. Although it
is unlikely that the PVV region directly interactswith F, because
mutations in this region (4-4 and 4-5) did not significantly
affect the F/G interactions per se (supplemental Fig. 4A) but
only B2-induced F/G dissociation, it suggests that this hyper-
flexible PVV region in G interacts with the stalk domain in a
manner required to trigger F. Interestingly, Broder and
co-workers (4) also implicated the stalk domain of Hendra
virus-G in the receptor-induced changes thatmediate fusion. In
addition, we have a panel of cysteine mutants in the stalk
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domain with similar phenotypes to those observed for the
mutants in this hyperflexible 6S4/1H1 region.5
In summary, our results identify a receptor-induced alloster-
ic activator in NiV-G that is critical for triggering the pre-hair-
pin intermediate formation in F and eventual membrane
fusion. NiV-G activation involves a RBE-epitope at the base of
the globular head domain that likely works in conjunction with
the stalk domain in mediating the allosteric transfer of B2-in-
duced signals that propagate the NiV fusion cascade. Whether
this model is generalizable for other paramyxoviruses that use
protein-based receptors remains to be determined.
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